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vHTS 
virtual library of likely synthetically 
accessible lead-like compounds 
predicted  
cLE > 0.28 
selected 
putative 
inhibitors 
BACE-1 
Abstract 
There are numerous complementary approaches to facilitate the identification of 
novel inhibitors for biological targets, including high throughput screening and fragment-
based drug discovery. Computational tools are often employed to predict binding pose 
and affinity of the new inhibitors. In this thesis an integrated computational and 
experimental approach to identify novel inhibitors is described. The approach involves 
the design of a virtual library of likely synthetically accessible lead-like molecules, 
followed by virtual high throughput screening (vHTS) against target protein. To 
exemplify the approach, BACE-1 was selected as an example target protein. BACE-1 is 
responsible for the formation of amyloidal plaque in brains affected by Alzheimer’s 
disease and therefore is a potential target for the treatment of the disease.  
A virtual library of lead-like molecules was generated based on diversity-oriented 
synthesis methods established in our laboratory. The library underwent virtual high 
throughput screening (vHTS) against BACE-1 by using eHiTS and two families of 
putative inhibitors were identified with high predicted ligand efficiency (cLE). The in 
silico approach employed to identify novel putative BACE-1 inhibitors is schematically 
represented as follows. 
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A focused library based on the selected putative inhibitors was designed and 
synthesised, and biological activity was assessed via a fluorimetric assay. Structure- 
activity relationship (SAR) studies were conducted to rationalise the activity of the 
inhibitors and to confirm the validity of the integrated approach in identifying new 
inhibitors for biological targets. A novel series of BACE-1 inhibitors was identified and 
is herein described.   
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Chapter 1. Introduction 
This introductory Chapter is composed of two parts. The first part gives an 
overview of the drug discovery process (Section 1.1) and of methods to identify and 
generate lead molecules for biological targets (Section 1.2). The second part introduces 
the protein BACE-1, the biological target chosen for this project (Section 1.3) and gives 
an overview of known BACE-1 inhibitors (Section 1.4). Finally an outline of the project 
is provided (Section 1.5). 
1.1 Drug discovery process: from leads to drug candidates 
The discovery of drugs for biological targets is a long process, which starts by 
identifying initial molecules, called hits or leads, having affinity for a specific biological 
target. Lead molecules can be identified by a variety of screening methods (Section 
1.2); once a lead is identified, studies of its properties are performed in order to 
understand the role that different functional groups have in binding the target. Structure-
activity relationship (SAR) studies facilitate lead optimisation and ultimately a drug 
candidate is nominated. 
The physico-chemical properties of optimal oral drugs can be described by the 
Lipinski “rule of five”. This rule provides guidance of the ideal molecular weight (M.W. 
≤ 500) and  lipophilicity (logP
a
 ≤ 5), and of the number of H-bonding atoms (number of 
H-bond donors ≤ 5, number of H-bond acceptors ≤ 10)1 that a drug should have to allow 
for oral bioavailability, absorption and permeation. Since drug candidates are developed 
from leads, physico-chemical properties of leads have been defined as well. Good leads 
generally have molecular weight between 200 ≤ M.W. ≤ 350, lipophilicity value in the 
range of  ≤ logP ≤ +3,2 number of H-bonding donors ≤ 4, number of H-bond 
acceptors ≤ 8.3  
                                                 
aP is the partition coefficient which expresses the solubility of a unionised compound in 
two immiscible solvents, n-octanol and water. P= [solute]octanol/[solute]water. logP is used 
as a measurement of lipophilicity. 
2 
 
A clearer visual representation of lead development into drug candidates is 
provided by Nadin et al.
2 
(Figure 1). The chemical space of bioactive small molecules 
can be represented by lipophilicity and molecular weight. Typically, the drug discovery 
process results in a progression towards higher molecular weight and lipophilicity 
values. Drug candidates space is represented below M.W. ≤ 400 , logP ≤ 4, since it is 
often observed that molecules with these physico-chemical properties have more chance 
of becoming successful drugs.
4
 In Nadin's representation it is also shown that fragments, 
defined as small molecules having a molecular weight between 100 ≤ M.W. ≤ 300 and 
low lipophilicity,  ≤ logP ≤ 1.5, are a good starting point to develop leads. 
 
Figure 1. Chemical space of drug candidates, leads, and fragments. Representation 
of the chemical space explored during drug discovery process. clogP is a predicted 
measurement of logP estimated from a computed algorithm which sum logP values of 
small parts of a molecule.
5
 Adapted from Nadin et al.
 2
 
 A summary of physico-chemical properties of drug-like, lead-like and fragment-
like molecules is given in Table 1. It is worth mentioning that lead-likeness criteria were 
defined in a broader way (M.W. ≤ 460 and logP ≤ 46) before Nadin's definition in 2012. 
Nadin's chemical space definition can be considered an up-to-date guideline to develop 
and design optimal leads (Section 1.2.4).  
3 
 
Table 1. Guidelines of physico-chemical properties of drug-like, lead-like and 
fragment-like molecules 
a
Not defined 
b
nHA: number of heavy atoms, corresponding to number of non-hydrogen atoms. 
nHA is related to the molecular weight, therefore is not always defined. 
1.2 Approaches to identify lead compounds 
1.2.1 High throughput screening 
Approaches to identify leads can be categorised as: high throughput screening 
(HTS), fragment-based design and virtual high throughput screening (vHTS). HTS 
refers to screening of large compound libraries (up to 100.000 per day
9
) against a 
biological target by means of established and validated biochemical (e.g. ELISA
10
), 
biophysical (e.g. TR-FRET
11
) or biological assays (e.g. cell based
12
) which can measure 
compound binding affinity. HTS has been widely used by pharmaceutical companies 
since the mid-1990s.
9
 The screening is generally automated, molecules are assayed in a 
M concentration or lower, and up to 1536 compounds are screened in a run. It is useful 
to apply when there is no knowledge about the structure of a biological target, as any 
identified hits can give indication about relevant structure features. When information 
about the structure of likely active molecules is available, HTS is also applied to 
focused library subsets. This approach was successful for a range of biological targets, 
e.g. protein kinases, transferases, proteases and nuclear hormone receptors.
13
  
Drug-like molecules
1
 Lead-like molecules
2
 Fragment-like molecules
2
 
M.W. ≤ 500 200 ≤ M.W. ≤ 350 100 ≤ M.W. ≤ 300 
logP  ≤ 5  ≤ logP  ≤ +3  ≤ logP ≤ +1.5
n H-bond donors ≤ 5 n H-bond donors ≤ 43 n H-bond donors ≤ 37 
n H-bond acceptors ≤ 10 n H-bond acceptors ≤ 83 n H-bond acceptors ≤ 37 
n aromatic rings ≤ 58 n aromatic rings ≤ 38 - a 
-
 a
 16 ≤ nHAb ≤ 26 - a 
4 
 
1.2.2 Fragment-based design 
Fragment-based approaches were developed with the idea of identifying key 
fragment-sized molecules, able to bind discrete sites of a biological target, and to link 
them in order to build a lead molecule. These approaches have the potential to combine 
active fragments in many possible ways, building a variety of potentially active leads. 
Physico-chemical properties of fragments, have been defined according to the “rule of 
three”: M.W. ≤ 300, logP ≤ 3, number of H-bond donors and acceptors ≤ 3 (Table 1).7 
The “rule of three” is used as a good guideline to prepare libraries of fragments, which 
can be also chosen for their commercial availability and solubility at high 
concentrations (mM range). Methods of screening fragments include: directed binding 
assays (e.g. ELISA), NMR
14
, mass-spectrometry
15,16
 and X-ray.
17
 Once active 
fragments are identified, they can be linked with chemical spacers known from previous 
inhibitors;
18
 alternatively a technique of “in situ assembly” can be employed. This 
technique consists of adding reactive fragments in the presence of the biological target 
and analysing the higher affinity products obtained.
19
  
 
The process of growing fragments into leads is often assisted by computational 
docking programs, which contain virtual library of linkers. The so-called de novo 
generation software use the coordinates of a known binding pose of a fragment in a 
target binding site and connect this fragment to virtual linkers and other fragments 
directly in the target binding site. The resulting virtual leads are docked and ranked 
according to predicted binding affinity values
20
 or ligand efficiency, which expresses 
the affinity per heavy atom (see Section 1.2.3.1). Examples of de novo generation 
software are shown in Table 2.
21
 Due to the potential of combining fragments in 
different ways, fragment-based approaches enable efficient coverage of chemical space.  
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 Table 2. Examples of de novo generation software.
21
 
1.2.3 Virtual screening 
Virtual screening is used in drug discovery to predict binding affinity of virtual or 
known compounds against a specific biological target or to design variations of known 
active molecules. Virtual screening can help to identify putative leads; therefore the 
software predictions of lead binding affinity need to be proven by established assays. 
Virtual screening methods can be differentiated into structure-based and ligand-based 
methods.  
Structure-based virtual screening requires knowledge of the binding site of a 
biological target to predict binding poses of ligands and to estimate their binding 
affinity through scoring functions.
22
 The prediction of binding poses can be performed 
according to different docking programs; using stochastic or systematic methods.
23
 
Stochastic methods perform random simulations of ligand binding poses until 
Examples of software Characteristic 
LUDI 
Fragments are selected according to the hydrogen bond 
interactions formed in the protein binding site and to the 
hydrophobic pocket filling. Fragments are scored, linked together 
and collected in a library.  
The protein binding site is classified in areas of directional 
interactions: lipophilic-aliphatic, lipophilic-aromatic, hydrogen 
donor and hydrogen acceptor.   
The library of fragments is matched with the four binding site 
areas to identify a new potential ligand. 
GROW 
An initial fragment is placed in the protein binding site and is 
grown by peptide bond formation. 
The molecule obtained is scored according to a function of 
energies parameters: van der Waals, electrostatic, conformational 
and solvation. 
SPROUT 
Fragments are sorted according to shape and molecular properties.  
The target site is divided in different hydrogen-bonding, 
electrostatic and hydrophobic areas.  Fragments are docked in all 
the binding site areas according to their shape and are linked 
together.  
Atoms with the same hybridisation are interchanged in the 
fragment structures to optimise the interactions. Fragments are 
scored according to enthalpy and entropy factors to identify the 
potential ligand. 
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convergence criteria are met. In the Monte Carlo method, for example, a ligand is 
randomly placed in the binding site and its degree of thermal motion is gradually 
decreased, until a stable state with minimum energy is reached.
24
 Systematic methods 
decompose ligands into fragments and dock them independently in a protein binding 
site; then the final binding pose is built on the basis of those docking results. The 
reconstruction of a ligand structure from fragments is performed through incremental 
construction or conformational search algorithm (for more details, see Table 3).
23
 
The estimation of binding affinity for the predicted ligand binding poses is made 
using scoring functions. Scoring functions are based on mathematical models and can 
be categorised as force-field, empirical and knowledge based.
25
 Force-field scoring 
functions assess the free energy of binding by deriving the enthalphy of binding at gas 
phase as sum of van der Waals and electrostatic intramolecular interactions. 
Intramolecular strain energy (angle, torsional, steric strain), entropic and desolvation 
energies are also included. Empirical scoring functions estimate the binding affinity 
from a series of energy terms: van der Waals, ionic, hydrogen bond, hydrophobic 
interactions and surface complementarity. The knowledge-based scoring function uses 
databases of known inhibitor-protein complexes to compare distance between ligand 
and protein atom types and to derive a favourable interaction. The ligand binding energy 
is derived from a function of distribution of atom pair interactions. The mathematical 
models, on which scoring functions are based, do not always consider entropic or 
flexibility factors in the estimation of binding affinity. Scoring functions are therefore 
limited and implementations of their mathemal models are still challenging.
25
 
Ligand-based virtual screening aims to enrich active compounds. Libraries of 
(virtual or real) ligands are compared with an active compound of reference according 
to structural and pharmacophoric similarity. The similarity search algorithm can 
perform a structure comparison by superimposing each ligand with the compound of 
reference (small molecule alignment search), or by considering electrostatic and 
conformational properties (pharmacophore similarity search).
24
 As an outcome, ligands 
are ranked according to similarity to the active compounds.  
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Table 3. Summary of virtual screening method.
23
 
1.2.3.1 Criteria for ligand selection: ligand efficiency  
Ligand efficiency (LE)
27
 is widely employed in the literature to evaluate the 
binding quality of ligands of different sizes to a target protein. LE is defined as the free 
energy of binding, Go, of a ligand divided by its number of heavy atom, nHA 
(Equation 1). LE helps to identify ligands which bind to a target protein efficiently. 
Ligands with a large number of heavy atoms can show a high binding affinity, but they 
are less efficient than ligands showing the same binding affinity and having a smaller 
number of heavy atoms (Figure 2).
28
  
Stochastic method Characteristic 
Examples of 
software 
Monte Carlo 
Cycles of simulations of ligand poses in 
the protein binding site are applied. 
The initial thermal motion of a ligand is 
gradually decreased until reaching a 
minimum energy. 
Autodock, ICM 
Genetic algorithm 
Initial ligand states are defined according 
to conformation and orientations, and then 
they are modified by random gene-fashion 
crossover and mutation. 
The resulting new ligands are selected 
according to their fit.
26
 
DOCK, GOLD 
Systematic method Characteristic 
Examples of 
software 
Incremental 
construction algorithm 
Ligands are broken into fragments by 
cutting at rotating bond positions. 
Set of rigid fragments, called anchors, are 
docked against the binding site. 
Flexible fragments are matched to anchors 
and docked considering different torsion 
angles. 
DOCK 4.0, FlexX, 
Hammerhead 
Conformational search 
Ligands are broken into fragments and a 
set of rigid fragments are docked. 
Only fragment poses which correspond to 
the original ligand structure are kept and 
flexible chains are added to these specific 
rigid fragment poses. 
eHiTS, FLOG 
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Equation 1. Ligand efficiency definition. 
 
Figure 2. Representation of the ligand efficiency concept. Cartoon of a protein 
binding site occupied by two ligands with the same binding affinity but of different 
sizes. A) The ligand is filling all the cavities of the protein binding site by interacting 
with five different groups, two of them with low-quality binding (orange and brown 
colour elements). B) The ligand is filling all the cavities of the protein binding site by 
interacting with four groups, each giving high-quality binding. Adapted from Kitchen et 
al.
28
 
It is often reported in the literature
29, 30
 that when values of Ki and IC50 of ligands 
are available, they can be used in their logarithmic forms (log) to calculate LE, in place 
of Go, according to Equation 2.31 The difference between Go and log(Ki) is, in fact, a 
factor of 1.37, as shown in Equation 3.
32
 Therefore the LE' values calculated with 
log(Ki) would only differ from the LE values calculated with G
o
 by the same factor 
(Equation 4). 
     
       
   
  
         
   
 
Equation 2. Ligand efficiency calculated with log(Ki) and log(IC50)
b
.
31
  
                                                 
b 
In Equation 2 the difference between Ki and IC50 is taken in account
29 
A 
 
B 
 
less ligand efficient binding  more ligand efficient binding  
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Equation 3. Correlation between ΔGo and log(Ki) or log(IC50). 
              
Equation 4. Difference between LE and LE' 
The definitions of LE and LE', as expressed in the Equation 1 and 2, can also be 
applied to assess the quality of binding of the virtual ligands. Docking software predict 
the binding affinity of virtual ligands giving a score which expresses log(Ki); therefore 
this score can be used to calculate computed/ predicted ligand efficiency, cLE or cLE', 
according to Equation 5. In this report LE′ and cLE′ will be used to compare quality of 
binding of known BACE-1 inhibitors (Section 1.4) or predicted inhibitors (Section 
2.1.3) 
             
      
   
         
      
   
  
Equation 5. Computed ligand efficiency, cLE and cLE′. 
1.2.4 Diversity-oriented synthesis 
Combinatorial libraries of compounds of biological interest and large compound 
collections of pharmaceutical companies tend to lack diversity in shape and in structure, 
being mainly populated by flat compounds (2-D shape) which differ by their 
appendages, rather than their skeleton.
33
 An analysis of ten commercially available 
libraries, performed by Baell in 2012,
3
 showed that vendor libraries of ca. 400,000 
compounds contained only 6,000 lead-like molecules, which lack diversity. Since the 
biological activity of compounds depends on their structural features, compound 
libraries with a high degree of structural diversity increase the probability of interaction 
with different biological targets.
34
 Therefore a demand for developing more structurally 
diverse libraries of lead-like molecules has risen in drug discovery.  
It has been demonstrated that a convenient strategy to create a library of skeletally 
diverse compounds is to start form a range of different chemotypes, rather than 
10 
 
extending or varying the structure of a single chemotype.
35
 A successful synthetic 
approach towards diversity enriched libraries is that of diversity-oriented synthesis 
(DOS). The principle of DOS is to generate multiple scaffolds by performing parallel 
modification of starting materials to access a series of structurally diverse building 
blocks/chemotypes. These are able to undergo further diversification. A schematic 
representation of the DOS approach is given Figure 3. 
 
Figure 3. Diversity-oriented synthesis vs combinatorial library synthesis approach. 
A) A traditional approach in combinatorial library synthesis is based on variation of one 
chemotype, to obtain structure variations able to address a specific biological target. B) 
Diversity-oriented synthesis approach is based on a series of parallel modifications of 
an initial starting material to achieve a range of chemotypes leading to structurally 
diverse scaffolds. Adapted from Galloway et al.
33
  
A DOS strategy which uses a “reagent-based” approach was developed by Pizzarini 
et al. 
36
 (Scheme 1). The strategy employed one poly-functionalised starting material, 
the aminopropargylic alcohol 1, which was exposed to a series of different reagents to 
give three different chemotypes, compounds 2, 3 and 4, respectively via enyne 
metathesis, derivatisation with acetyl anhydride and intramolecular nucleophilic 
aromatic substitution. The resulting chemotypes contained different pairs of functional 
groups which were reacted intramolecularly under different conditions to give diverse 
cyclic scaffolds. For example, compound 3 was modified via enyne metathesis and the 
Pauson-Khand reaction,
37
 giving scaffolds 5 and 6; while compound 4 underwent two 
A 
diversity-oriented synthesis  
one 
chemotype 
traditional combinatorial library 
synthesis 
B 
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different cyclisation via Pauson-Khand reaction and enyne metathesis to lead to 
scaffolds 7 and 8. 
 
Scheme 1. Example of reagent-based DOS, applied to the poly-functionalised 
aminopropargylic alcohol 1. Synthetic pathway developed by Pizzirani et al.
36
 
Conditions: a) Hoveyda-Grubbs second-generation catalyst, ethylene, toluene, r.t.; b) 
acetic anhydride, Et3N, DMAP, CH2Cl2, 0 
o
C; c) NaH, THF, 10 oC; d) Hoveyda-
Grubbs second-generation catalyst, ethylene, toluene, 45 
o
C; e) and f) [Co(CO)8], 
triethylamine N-oxide, THF, r.t.; g) Hoveyda-Grubbs first-generation catalyst, CH2Cl2, 
r.t., then Pb(OAc)4. 
In our research group, DOS methodologies have been developed extensively to 
prepare lead-like molecules following a “substrate-based approach”.33 This approach 
uses a range of starting materials to couple under the same conditions, to form key 
12 
 
building blocks. Those building blocks contain functional groups, able to pair together 
and provide skeletally diverse molecules. This methodology was employed to prepare a 
variety of heterocyclic scaffolds based on piperazine, 1,4-diazepanes and 1,5 
diazocanes,
38
 and a series of alkaloid-like scaffolds.
39
 In the case of heterocyclic 
scaffolds, a series of commercially available aminoalcohols was protected and then 
reacted with a range of cyclic sulfamidates to give cyclisation precursors. These 
precursors underwent to cyclisation to lead to a variety of heterocyclic scaffolds 
(Scheme 2). 
 
Scheme 2. Example of substrate-based DOS to prepare lead-like heterocycles. 
Coupling of a range of N-nosyl amino alcohols with cyclosulfamidates led to the 
preparation of cyclisation precursors, able to cyclise to give diverse heterocyclic 
scaffolds. Ns: o-nitrophenylsulfonyl, Ns′: p-nitrophenylsulfonyl. Adapted from James et 
al.
38
 
For the preparation of alkaloid-like molecules, a range of unsaturated building 
blocks was synthesised by attachment of propagating and terminating appendages to 
initial starting materials. The resulting cyclisation precursors underwent metathesis 
cascade reactions to yield skeletally diverse scaffolds. The initial building blocks were 
attached to a fluorous-tagged linker which facilitated the purification of the final 
scaffolds via fluorous solid-phase extraction (Scheme 3). 
13 
 
Scheme 3. Example of substrate-based DOS, using propagating and terminating 
appendages to prepare cyclisation precursors. Compounds 9 and 10 were prepared 
via coupling of starting materials with propagating groups via Mitsunobu reaction, 
followed by deacetylation. The resulting substrates were coupled with terminating 
groups again via Mitsunobu reaction, followed by deacetylation. Mitsunobu reaction 
condition: starting material or substrate (1.0 eq.), propagating group or terminating 
group (4.0 eq.), PPh3 (4.0 eq.), DEAD (4.0 eq.), CH2Cl2, 0 
o
C–r.t.; deacetylation 
condition: NH3 in MeOH (0.025 M). Compounds 11 and 12 were synthesised via 
metathesis cascade. Conditions: a) Hoveyda-Grubbs second-generation catalyst, 
CH2Cl2, 50 
o
C then Et3N (86 eq.), P(CH2OH)3 (86 eq.) then silica. PhSH (1.2 eq.), 
K2CO3 (3.0 eq.), DMF; b) Hoveyda-Grubbs second-generation catalyst, methyl tert-
buthyl ether, 50 
o
C then Et3N (86 eq.), P(CH2OH)3 (86 eq.) then silica. PhSH (2.4 eq.), 
K2CO3 (6.0 eq.), DMF. 
F
DIPESO is a fluorous-tagged linker. Adapted from Maurya et 
al.
.39
 
1.2.5 Combining diversity oriented synthesis and virtual screening 
In this thesis a new approach to design novel bioactive lead molecules is described. 
To demonstrate the validity of the approach, it was applied to the BACE-1 protein. The 
approach combined in silico generation of a library of skeletally diverse lead-like 
14 
 
scaffolds, with virtual screening of this library against BACE-1. The generation of 
skeletally diverse lead-like scaffolds was obtained by designing a synthetic protocol 
based on DOS methodology. The aims in developing such an approach was, on one 
hand, to explore the chemical space of lead-like molecules by means of computer-aided 
design of DOS protocols; and on the other hand, to identify novel active leads, able to 
inhibit BACE-1, a target of pharmaceutical interest. Moreover, it was hoped to 
contribute in implementing lead discovery approaches, by combining the prediction of 
activity of lead-like scaffolds with information of their synthetic accessibility. An 
overview of the project is described in Section 1.5. In the following Section 1.3 the 
protein BACE-1 is introduced. 
1.3 BACE-1 
1.3.1 Involvement in Alzheimer’s disease 
BACE-1 is a transmembrane human aspartic protease, known as ‘β-site amyloid 
precursor protein cleaving enzyme’ (BACE), which is expressed in high levels in the 
brain, mostly by neurons, and also in the peripheral tissues and in the pancreas
14,15 
in 
low level. BACE-1 enzymatic activity is displayed only in the brain,
15
 where it is 
involved in the early stage of formations of β-amyloid plaques, insoluble accumulations 
of neurotoxic amino acidic fragments recognised as the major symptoms of Alzheimer’s 
disease. Alzheimer’s disease is a neurodegenerative disease which affects memory, 
cognitive functions and behaviour. The causes of Alzheimer’s disease are still unknown, 
but the molecular mechanism associated with the disease is believed to start with the 
“amyloid cascade”.40 The amyloid cascade is a process which leads to the formation of 
neurotoxic peptides of 40/42 amino acids, called β-amyloid peptides Aβ40 and Aβ42, 
from the amyloid precursor protein (APP). APP is a substrate for different proteases, but 
its cleavage by BACE-1 starts an amyloidogenic pathway.  
APP is cleaved by BACE-1 at the M-D bond contained in the sequence KMDAE, 
producing two fragments: an Aβ N-terminus soluble fragment, called APPsβ, and a C-
terminus fragment, called CTF99.
40
 The CTF99 fragment is then heterogeneously 
cleaved by γ-secretase, releasing neurotoxic peptides Aβ40 and Aβ42. In the metabolism 
15 
 
of APP another alternative and ‘non-amyloidogenic’ pathway is initiated by the zinc 
metalloproteinase α-secretase; this pathway prevails in most cell types (Figure 4).41  
 
Figure 4. Amyloidogenic and non-amyloidogenic pathway of APP substrate. The 
APP can undergo two alternative and competing metabolic pathways. The major and 
non-amyloidogenic pathway, on the left, is started by α-secretase and precludes the 
formation of Alzheimer’s Aβ peptide. The amyloidogenic pathway, on the right, is 
started by β secretase. Adapted from Cole et al.40 
Aβ40 and Aβ42 are insoluble peptides which aggregate to form β-amyloid plaques; 
they are formed in the brain cells, but they can be transported outside spreading their 
damaging effect.
42
 According to the amyloid cascade hypothesis, the formation of β-
amyloid plaques has two main consequences: the activation of an inflammatory 
response and the hyperphosphorylation of Tau protein. The inflammatory response 
relies principally on the activation of brain glial cells, which degenerate and produce 
oxygen free radicals causing damage and neurons death.
43
 The hyperphosphorylation of 
Tau protein induces pairing of helical filaments of the protein which accumulate, 
resulting in the so called toxic “neurofibrillary tangles”.44 
It has been demonstrated that BACE-1 inhibition reduces Aβ peptide levels in 
mouse brain and up-regulates the α-secretase non amyloidogenic pathway.45 While 
BACE-1 total inhibition caused development of cognitive dysfunctions in mice,
46
 since 
Amyloidogenic pathway Non amyloidogenic pathway 
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BACE-1 is necessary for specific hippocampal memory processes,
47
 its partial 
inactivation may not affect normal learning and memory processes. Therefore BACE-1 
has been considered a good therapeutic target for the disease. 
1.3.2  Structure and catalytic mechanism 
Due to its pharmaceutical interest, BACE-1 has been targeted and studied widely in 
the last three decades. There are more than 250 crystal structures of BACE-1 in 
complex with inhibitors,
48
 and BACE-1 structural features and catalytic mechanism 
have been disclosed. The main characteristics of BACE-1 are: a flexible region, located 
in front of the substrate binding cleft, and the presence of two conserved water 
molecules in its catalytic site. These characteristics are in common with other aspartic 
proteases, with which BACE-1 shows from 24 to 52% of sequence identity (e.g. 29% 
with cathepsin D, 52% with BACE-2, 24% with renin, 27% with pepsin).
49 
 
The BACE-1 flexible region, called “flap”, is a β hairpin structure composed of 14 
residues (from Lys65 to Glu79) and a sequence of 7 amino acids (from Ala101 to 
Lys107) connected by antiparallel H-bond interactions and forming three strands which 
cover the binding cleft.
50
 The role of this flexible region in other aspartyl proteases is 
unclear; while X-ray structures of numerous of BACE-1 complexes
51,52
 revealed
 
that 
this flexible region induces a conformational change in the protein, from an open and 
closed position, allowing the insertion of APP substrate in the catalytic site. The 
substrate-free BACE-1 structure (apo-structure) adopts an open conformation in which 
the flap is distant from the binding cleft and APP substrate can access into the active 
site. A closed conformation has been observed when BACE-1 is in complex with 
inhibitors and the flap residues move up to ca. 4.5 Å closer to the binding cleft
 
(Figure 
5).
50 
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Figure 5. Features and conformations of the flexible region of BACE-1, called 
“flap”. A) Apo-structure of BACE-1 (pdb code 1W50) with the flexible region, flap, 
highlighted in yellow. The flap is covering the binding cleft. B) Example of protein 
adopting open flap conformation (pdb code: 1W50). C) Example of closed flap 
conformation: BACE-1 is in complex with an inhibitor (pdb code 2XJT) and the flap 
surface is overlapping with the top surface of the protein, which limits the binding cleft. 
Visualised with Discovery Studio 3.0.  
B 
A 
C 
surface overlapping 
closed conformation 
open conformation 
binding cleft 
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In the flap region Tyr71 is involved in key H-bond interactions which determine the 
protein conformational change. In the open conformation, Tyr71 forms a H-bond (CO 
backbone) with Gly74 (NH backbone) of ca. 2.8 Å of length,
52
 in the closed 
conformation, Tyr71 can be oriented towards Trp76
52
 or towards Lys107
53
 and can form 
new H-bonds with the O atom of the OH group of Tyr71 side chain (Figure 6). 
 
Figure 6. Example of H-bond interactions formed in the flap regions of BACE-1. 
14 amino acids (from Lys65 to Glu79) and 7 amino acid sequences (from Ala101 to 
Lys107) connected by antiparallel H-bonds, which constitutes the flap region. A) H-
bonds formed in a flap open conformation; Tyr71 and Gly74 (yellow colour) form a 
characteristic H-bond between Tyr71 (CO backbone) and Gly74 (NH backbone) (pdb 
code 1W50). B) H-bonds formed in a flap closed conformation (pdb code 2XJT). A new 
H-bond is formed between Tyr71 (OH) and Lys107 (CO backbone). Visualised with 
Discovery Studio 3.0.  
A B 
open conformation closed conformation 
19 
 
As with other aspartyl proteases, BACE-1 contains two proximal aspartyl residues, 
Asp228 and Asp32, and two conserved water molecules in the catalytic site. One water 
molecule (Wat1) is located between Asp32 and Asp228 and seems to assist the catalytic 
process of the natural substrate. The second molecule (Wat2) is part of a conserved 
network of hydrogen-bonds which involves Ser35 (Figure 7). The proteolysis 
mechanism of BACE-1 is an acid-base catalysed mechanism mediated by Wat1 and by 
the Asp228/Asp32 pair (see Figure 8).
54
 
 
Figure 7. Water molecules located in the catalytic site of BACE-1. The two 
conserved water molecules, Wat1 and Wat2, form a network of H-bond (green) with the 
proteolytic Asp228 and Asp32, and with Ser35.  
 
Figure 8. Catalytic mechanism of BACE-1. The conserved water molecule Wat1, 
located between the two catalytic aspartates, takes part in the proteolytic mechanism of 
APP substrate. Asp32 is represented in its mono-protonated form, which is likely to be 
assumed at pH 4.5, at which BACE-1 is active.
55
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As shown in Figure 8, one catalytic aspartate, Asp32, seems to assume a 
monoprotonated state where the inner oxygen contains the proton.
55
 It has been reported 
that BACE-1 optimal activity is at pH 4.5.
52
 The binding of the inhibitor resulted to be 
pH dependent: at pH 5.0 the inhibitor binding seems to occur simultaneously with 
protein conformational switching, whilst at pH 4.5 proteolysis of the inhibitor occurs.  
1.3.3 Specificity for the APP substrate 
The specificity of BACE-1 for APP has been explained from studies of mutations 
of APP. The cleavage point of APP is the M596-D597 bond of the EVKMDAEF 
sequence. According to the standard nomenclature of proteases, these residues are 
labelled P4-P3-P2-P1*P1′-P2′-P3′-P4′ and the cleavage point is indicated by * (Figure 
9).  
 
Figure 9. Amino acids sequence of BACE-1 APP substrate, flanking the cleavage 
point. The cleavage point between M and D is in highlighted in red. The amino acids 
are represented according to the charge state likely assumed at pH 4.5, at which BACE-
1 is active. 
Mutations of KM NL at P2-P1, the so-called Swedish mutation, are associated 
with early onset of Alzheimer's disease.
56
 The sequence EVNL*DAEF of the Swedish 
mutant is very efficiently hydrolysed by BACE-1; while a mutation of M596 with V at 
P1 position reduces the cleavage.
57
 Sauder et al.
58
 explained this difference of substrate 
preference by modelling interactions formed by P1*P1′ residues of APP substrates with 
BACE-1 residues located in the catalytic site. The P1′ residue of APP can form a salt 
bridge with Arg235 of BACE-1; while hydrophobic contacts can be established by the 
P1 residue with Leu30 and Ile118 of BACE-1, located in hydrophobic pocket of the 
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protein, and with Tyr71 located in the flap region. These interactions could show 
BACE-1 specificity for a negative charge at P1′ and for a hydrophobic residue at P1. 
They also reveal a difference with most aspartyl proteases, which have a preference for 
hydrophobic residues at P1′ (Figure 10). 
 
Figure 10. BACE-1 region of interactions with P1 and P1′ residue of APP 
substrate. A hydrophobic region containing Leu30 and Ile118 interacts with P1 
lipophilic residue of APP, M, together with the lipophilic Tyr71, located in the flap. A 
positively charged region, containing Arg235, shows preference for interaction with 
negatively charged P1′ residue of APP, D. Visualised with Discovery Studio 3.0. 
The Swedish mutant substrate, containing Leu at P1, can maintain hydrophobic 
contacts with Leu30, Ile118 and Tyr71 of BACE-1. When the P1 residue of APP is 
mutated to V, one of the methyl groups of V can be oriented towards the catalytic 
Asp32 of BACE-1 and interferes with the catalytic activity; at the same time 
hydrophobic interactions with Leu30, Ile118 and Tyr71 would be suppressed. This 
could explain why BACE-1 hydrolyses the Swedish mutant substrate more efficiently.  
positively charged 
residue: P1′ interaction 
area 
 
hydrophobic pocket: 
P1 interaction area 
flap region 
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The BACE-1 specificity for APP is also determined by other interactions with APP 
residues P2, P3, P2′ and P3′. These residues seem to occupy specific pockets of BACE-
1, which are named according to the contacts made with APP residues (Figure 11). The 
study of pocket interactions was important in the development of BACE-1 inhibitors. 
 
Figure 11. BACE-1 pockets. BACE-1 pockets are separated by the flap region (in 
yellow) and are numbered according to the interactions made with residues P1, P2, P3 
and P1', P2', P3' of APP substrates. Visualised with Discovery Studio 3.0. 
1.4 Overview of BACE-1 inhibitors 
BACE-1 inhibitors can be separated into two major categories: peptidomimetic 
inhibitors and non-peptidomimetic inhibitors. The first attempts to design BACE-1 
inhibitors were based on structural modifications of the APP substrate which led to a 
series of peptides containing a transition state isostere modification in the substrate 
backbone. Further research was directed to the discovery of a series of potent and lower 
molecular weight peptidomimetic inhibitors (M.W. ~700), but the need to improve the 
inhibitor brain penetration forced the investigation towards a series of small non-
peptidomimetic inhibitors (M.W. <500). The design of these inhibitors has proven to be 
extremely difficult due to the large size of the active site of BACE-1 (> 10000Å).
59, 60
 
23 
 
1.4.1 The first peptidomimetic inhibitor: compound OM99-2 
The first peptidomimetic inhibitor, OM99-2, reported by Tang and co-workers
57
 
was based on an octapeptide sequence of EVNL*AAEF in which the L-A bond was 
substituted by a hydroxyethylene transition-state isostere (Figure 12). The design of the 
inhibitor was based on the substitution of the P1′ residue of the Swedish mutant 
EVNL*DAEF. The crystal structure of BACE-1 in complex with OM99-2 shows that 
the inhibitor forms a network of H-bonds in the active site, which involves the catalytic 
Asp32 and Asp228. OM99-2 is a nanomolar inhibitor of BACE-1 (Ki =1.6 nM).
61
  
 
Figure 12. Structure of the OM99-2 inhibitor. 2D structure and representation of H-
bonds formed between the OM99-2, first BACE-1 inhibitor,
57
 and BACE-1 residues in 
the catalytic site. The inhibitor structure is based on a reduced form of the Swedish 
mutant peptide, having only eight amino acids. A hydroxyethylene isostere group is 
contained at the centre of the sequence (highlighted in red) in replacement of the 
peptidic bond L-D, in position P1 and P1′. The amino acids are represented according to 
the likely charge state assumed at pH 4.5, at which BACE-1 is active. 
Improvement of the OM99-2 structure
 
led to the peptide analogue ELDL*AVEF. 
This inhibitor, OM00-3, forms three new H-bonds with NH and CO groups of the 
backbone of residue E and with the NH of the backbone of residue F in P3′ and P4′ 
position. Its Ki value is 0.3 nM (Figure. 13).
50
 In the BACE-1 complex formed with 
OM99-2 and with OM00-3 inhibitor, the water molecule Wat1, located between the two 
catalytic aspartates, is displaced by the inhibitor in the binding site.
62
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Figure. 13. Structure of the OM00-3 inhibitor. 2D structure and representation of H-
bonds formed between the OM00-3 inhibitor and BACE-1 residues in the catalytic site. 
The OM00-3 inhibitor contains an hydroxyethylene bond between P1-P1’ residue (in 
evidence in red). The E and F residues of the inhibitor are involved in new H-bonds 
with BACE-1. 
1.4.2 Inhibitors incorporating a transition state isostere as a central core  
Peptide analogues containing a transition state isostere were proven to be effective 
inhibitors of the BACE-1 enzyme. A key structural feature of these compounds is the 
hydrogen bonds formed between the secondary hydroxyl group with the Asp32 and 
Asp228 residues of BACE-1 in the catalytic site (as shown in Figures 12 and 13). A 
series of BACE-1 inhibitors containing this hydroxyl group has been reported;
63,64
 the 
structures are based on statine, tert-hydroxy motif,
65
 hydroxyethylene (HE),
51, 66
 
aminoethylene
67
 and hydroxyethylamine (HEA);
68
 units that are non-cleavable isosteres 
of the transition state (Figure 14).  
new interaction 
 
new interactions 
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Figure 14. Inhibitors incorporating a transition state isostere. A) Representation of 
the central core of transition state isostere-type inhibitors. The hydroxyl group or the 
primary amine is incorporated in replacement of a peptide bond. B) HE isostere 
inhibitor designed by Wångsell et al.
65 
C) Aminoethylene isostere inhibitor designed by 
Yang et al.
67
 D) HEA isostere inhibitor designed by Stachel et al.
68
 Red circles 
highlight the isostere central core of the inhibitors. 
The inhibitors presented in Figure 14 show a higher lipophilic character in 
comparison with the peptidomimetic inhibitors OM99-2 and OM00-3. The aromatic 
groups were introduced in the structure to fill BACE-1 hydrophobic pockets. In the case 
of the inhibitor 13, an interaction in the S1 pocket of BACE-1 was established by 
increasing the size of a lipophilic group at P1; while the S2 pocket was occupied by the 
sulfonyl groups, and the S2′ was filled with a benzylic group (Figure 15).65  
A 
A 
B 
C D 
IC50 = 3.1 nM 
IC50 = 26 nM IC50 = 11 nM 
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Figure 15. Example of interactions of the HE inhibitor 13 in BACE-1 pockets. 3D 
representation of the conformation assumed by BACE-1 in complex with the HE 
inhibitor 13. S1, S2 and S3 pockets of BACE-1 are occupied by the aryl group at P1, the 
sulfonyl group at S2 and the benzylic group at P3. Another benzyl group at P2' occupies 
S2' pocket of BACE-1. Adapted from Wångsell et al.
66
 (pdb code 3IXK). Visualised 
with Discovery Studio 3.0. 
1.4.3 Reducing inhibitor peptidic character, towards macrocyclic inhibitors 
Most of the peptide-like BACE-1 inhibitors showed a limited brain penetration due 
to their large molecular weight and their affinity for P-glycoprotein.
69
 Some structural 
adjustments were made to reduce molecular weight and peptide character, such as 
removing the P3-P4 amide segment and modifying the P2-P3 positions. Machauer et 
al.
70
 modified the structure of the inhibitor OM99-2 by: replacing Asn chain at P2 with 
a methyl group, methylating the N atom at P2-P3 bond, and ring closing the P1-P3 
extremities. A macrocyclic inhibitor was derived, compound 16, which displayed a sub-
micromolar activity, IC50= 0.15 M (Scheme 4).  
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Scheme 4. Example of a macrocyclic inhibitor derived from OM99-2 inhibitor 
structure. Gradual modifications of the inihibitor OM99-2, which led to the 
macrocyclic inhibitor 16. The length of the amino acid chain of OM99-2 was reduced 
by eliminating P3-P4 and P3'-P4' fragments and by methylation of N atom at P2-P3 
bond. Cyclisation of lateral chain in P1-P3 gave the macrocylce 16. The isostere central 
core (highlighted in red) was kept in the macrocycle structure. Adapted from Machauer 
et al.
70
  
Macrocyclic inhibitors demonstrated a low molecular weight, potential for high cell 
permeability and good proteolytic stability.
71
 Structural differences of these inhibitors 
relied on the lateral chain linked to the ring (which contains the isostere unit); on the 
number of atoms contained in the ring (generally between 15 and 17 membered) and on 
the rigidity of the ring. Examples are provided in Figure 16.
72,73 
 
2 
IC50 = 0.15 M 
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Figure 16. Other macrocyclic inhibitors. A) Inhibitor designed by Hanessian et al.
72
, 
containing a HE unit in the later chain (highlighted in red). B) Inhibitor designed by 
Lecher et al.
73
, containing a HEA unit in the later chain (highlighted in red) and a longer 
and more rigid ring structure. 
Further structural development brought to eliminate of the isostere core, as shown 
in the macrolactone inhibitor 19. Compound 19 contains a primary amine which forms 
key H-bond interactions with the catalytic Asp32 and Asp228.
74
 The macrolactone 19 
occupies S1, S2 and S3 pockets of BACE-1 (Figure 17). 
  
Figure 17. Macrolactone inhibitor 19. A) 2D structure and representation of the key 
H-bonds (green dotted line) formed by the inhibitor 19 with Asp32 and Asp228 of 
BACE-1. The inhibitor does not contain an isostere core; the primary amine is 
responsible for forming key H-bond interactions. B) 3D representation of the 
conformation assumed by BACE-1 in complex with the inhibitor 19: S1, S2 and S3 
pockets are filled by aromatic groups (pdb code 2QZK). Adapted by Moore et al.
74
 
Visualised with Discovery Studio 3.0. 
A B 
A B 
IC50 = 0.19 M IC50 = 17 M 
IC50 = 27 nM 
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1.4.4 Discovery of non-peptidomimetic inhibitors 
Since 2006, many BACE-1 non-peptidomimetic inhibitors were discovered by 
fragment-based screening and optimised by computer modelling and SAR studies. 
These inhibitors have different structures but they all contain a heterocyclic unit and a 
central primary amine, which forms key H-bond interactions with the Asp32 and 
Asp228 in the BACE-1 catalytic site. These inhibitors can be divided into: pyridinyl 
aminohydantoin,
75-77
 aminopyridine,
78, 79
 acylguanidine,
80, 81
 dihydroquinazoline,
82
 
aminoimidazole,
83
 and spiropyrrolidine
84
 inhibitors. X-ray structures of BACE-1 in 
complex with these inhibitors revealed that BACE-1 adopts an open or semi-closed flap 
conformation. The water molecule located between the two catalytic aspartates, Wat1, is 
displaced by the inhibitors. Examples of interactions formed by these heterocyclic 
inhibitors in the BACE-1 catalytic site are reported in Figures 18-21. Value of activity 
against BACE-1 and respective LE' are shown; values of activity against BACE-2, a 
homologue of BACE-1 with 52% of sequence similarity, are also shown when 
available. 
 
Figure 18. Pyridinyl aminohydantoin inhibitor 20. A) 2D structures and 
representation of key H-bond (green dotted line) formed by the inhibitor 20 with Asp32 
and Asp228 of BACE-1. B) 3D representation of the conformation assumed by BACE-1 
in complex with the inhibitor 20: S1, S3 pockets are filled by aromatic groups. The flap 
is open (pdb code 3IN4), adapted from Malamas et al.
75
 Visualised with Discovery 
Studio 3.0. 
A B 
open conformation 
BACE-1: IC50 = 40 nM, LE′ = 0.25 
BACE-2: IC50 = 26 M 
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Figure 19. Aminopyridine inhibitor 21. A) 2D structures and representation of key H-
bond (green dotted line) and  interactions (orange dotted line) formed by inhibitor 21 
with BACE-1 residues in the catalytic site. B) 3D representation of the conformation 
assumed by BACE-1 in complex with the inhibitor 21: S1, S3 pockets are filled by 
aromatic groups. The flap is semi-closed (pdb code 2OHU), adapted from Congreve et 
al.
78
 Visualised with Discovery Studio 3.0.  
 
Figure 20. Acylguanidine inhibitor 22 and dihydroquinazoline inhibitor 23. 2D 
structures and representation of key H-bond interactions (green dotted line) formed by 
inhibitors 22 and 23 in with BACE-1 residues in the catalytic site. A) Acylguanidine 
inhibitor 22 designed by Cole et al.
81
 B) Dihydroquinazole inhibitor 23 designed by 
Baxter et al.
82
  
B A 
A B 
semi-closed conformation 
BACE-1: IC50 = 0.7 nM, LE′ = 0.26 
BACE-1: IC50 = 0.6 M, LE′ = 0.21 
BACE-2: IC50 = 0.5 M 
BACE-1: Ki = 11 nM, LE′ = 0.21 
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Figure 21. Aminoimidazole inhibitor 24 and spiropyrrolidine inhibitor 25. 2D 
structures and representation of key H-bond (green dotted line) and  interactions 
(orange dotted line) formed by inhibitors 24 and 25 with BACE-1 residues in the 
catalytic site. A) Aminoimidazole 24 designed by Malamas et al.
83
 B) Spiropyrrolidine 
inhibitor 25 designed by Efremov et al.
84
 
1.4.5  An interesting spiropiperidine iminohydantoin inhibitor 
Among the series of non-peptidomimetic BACE-1 inhibitors identified by 
fragment-based drug design, there is the interesting spiropiperidine iminohydantoin 
inhibitor 26.
85
 The X-ray structure of the inhibitor 26 in complex with BACE-1 showed 
a particular feature of H-bond interactions. The water molecule located between the two 
catalytic aspartates, Wat1, is not displaced but forms a H-bond network with the N of 
the piperidine group of the inhibitor and with the BACE-1 catalytic aspartates. Another 
water molecule forms H-bonds with the secondary amine group of the inhibitor and 
with Gly34 and Asp228. This type of inhibition through water molecules is a new mode 
of inhibition (Figure 22). The inhibitor 26 also forms H-bonds with Phe108 and Thr72, 
located in the flap region, locking the protein in an open conformation.  
BACE-1: IC50 = 34 nM, LE′ = 0.23 
BACE-2: IC50 = 11 M 
BACE-1: IC50 = 12 M, LE′ = 0.18 
A B 
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Figure 22. Spiropiperidine iminohydantoin inhibitor 26. 2D (A) and 3D (B) 
representation of the binding pose of the inhibitor 26 in the BACE-1 catalytic site. H-
bond interactions are represented as green dotted line, water molecules are highlighted 
in red. The characteristic of the spiropiperidine inhibitor 26 is to inhibit BACE-1 
through a network of H-bonds with two bridge water molecules, one of which is the 
conserved water molecule Wat1. Adapted from Barrow et al.
85
 (pdb code 3FKT). 
Visualised with Discovery Studio 3.0.  
Inspired by this kind of water bridge inhibition mode, Brodney et al.
86
 designed a 
series of a spirocyclic sulfamide inhibitors. Among those, the inhibitor 27 assumes a 
binding pose similar to the previously shown inhibitor 26. Wat1 is involved in a H-bond 
with the N of the piperidine group of the inhibitor and forms a network of H-bonds with 
the catalytic aspartates of BACE-1. Another water molecule forms a H-bond with 
Asp228. The X-ray structure shows also another H-bond formed by the O-alkyl group 
of the aromatic substituent of the inhibitor with a third water molecule (Figure 23).  
A B 
B A 
BACE-1: IC50 =3.0 M, LE′ = 0.18 
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Figure 23. Spirocyclic sulfamide inhibitor 27. 2D (A) and 3D (B) representation of 
the binding pose of the inhibitor 27 in the BACE-1 catalytic site. H-bond interactions 
are represented as green dotted line, water molecules are highlighted in red. The 
inhibitor has a binding pose similar to inhibitor 26 (Figure 22). The conserved water 
molecule Wat1 is involved in a bridge network of H-bonds. Two other water molecules 
are present in the catalytic site region. The sulfamide ring is involved in a H-bond with 
the NH (backbone) of Gln73 in the flap region. Adapted from Brodney et al.
86
 (pdb 
code 4FM7). Visualised with Discovery Studio 3.0.  
1.4.6 Inhibitor designed through computational methods 
Virtual screening was also successful in discovering new structures for BACE-1 
inhibitors. In 2010 Xu et al.
87, 88
 identified two new BACE-1 inhibitors by screening in 
silico libraries of commercially available compounds with lead-like properties (Section 
1.1). One inhibitor was based on a pyrazole-derived central core and the other on a 
benzothiazole central core (Figure 24).  
B A 
BACE-1: IC50 =0.1 M, LE′ = 0.17 
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Figure 24. Inhibitors identified via virtual screening by Xu et al.
 87, 88
 A) Inhibitor 28 
contains a pyrazole-derived central core. B) Inhibitor 29 contains a benzothiazole 
central core.  
In 2013 Mok et al.
89
 employed a de novo generation software, SPROUT, to design 
a series of biphenylacetamide BACE-1 inhibitors. Among those, the inhibitor 30 
showed an IC50 of 33 M (Figure 25). In 2014 Viklund et al.
90
 generated novel cores for 
BACE-1 inhibitors based on de novo design of lead molecules and computational 
prediction of their affinity, permeability and synthetic feasibility. They derived and 
synthesized seven active cores, containing variation elements from known cores (Figure 
26). 
 
 
Figure 25. Inhibitors designed through de novo generation software. Inhibitor 
design by Mok et al.
89
 using SPROUT.  
BACE-1: IC50 = 0.5 M, LE′ = 0.17 BACE-1: IC50 = 0.1 M, LE′ = 0.19 
BACE-1: IC50 = 33 M, LE′ = 0.19 
BACE-2: IC50 = 100 M 
B A 
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Figure 26. Cores for BACE-1 inhibitors identified by de novo design. Seven cores 
designed by Viklund et al.
90
 
1.4.7  Challenges of BACE-1 inhibitor design, failure in clinical trials 
Despite the wide range of BACE-1 inhibitors designed, only few of them entered 
into clinical trials. To enter a phase I clinical trial BACE-1 inhibitors require good 
cellular potency (nM range) and selectivity for BACE-1 vs BACE-2 and vs cathepsin D 
(100-fold). Inhibitors designed by Eli Lily, AstraZeneca and Roche from 2009 onwards 
failed phase I studies due to the poor blood-brain barrier permeability. Currently only 
two inhibitors are in phase II and phase III trials, one is E2609 of Eisai (phase II) and 
the other is MK-8931 of Merck (phase III).  
Due to the failure of clinical studies, a new approach based on antibody therapies 
was proposed in 2011 to target BACE-1. A human antibody, able to target BACE-1 and 
to induce conformational changes on residues 157-170 of the protein, was developed  
by Atwal et al.
91
 Residues 157-170 of BACE-1 normally adopt α-helical structure when 
the protein binds APP substrate. In the antibody-BACE-1 complex these residues 
assume a random loop structure, which seems to prevent APP substrate to reach the 
catalytic site of the protein. The anti BACE-1 antibody therapy showed in mice high 
selectivity and effective reduction of β-amyloidal peptides. 
1.5 Project outline 
The project described herein was directed to develop a novel computational and 
experimental approach to design lead-like bioactive molecules by generating a virtual 
library of likely synthetic accessible lead-like compounds based on DOS strategy. To 
BACE-1: IC50 from 100 to 1 M 
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investigate the approach, BACE-1 protein was chosen as biological target, and the 
virtual library of lead-like compounds was screened in silico against BACE-1.  
A virtual library of likely synthetic accessible lead-like compounds was generated 
by following DOS methologies developed in the Nelson group. A protocol of synthesis 
was designed on the basis of known chemical reactions and commercially available 
reactants, and was built using Pipeline Pilot software. The virtual library was screened 
in silico against BACE-1 using eHits software. Putative BACE-1 inhibitors were 
identified from the virtual screening according to criteria of ligand efficiency (cLE′) and 
were selected for synthesis. Two synthetic routes were investigated to prepare a focused 
library of putative inhibitors. The biological activity of the focused library was assessed 
via a fluorimetric assay. 
This report is composed as follows. Chapter 2 describes computational tools 
(Pipeline Pilot and eHiTS) and strategy envisaged to design lead-like putative BACE-1 
inhibitors. Chapter 3 describes two synthetic routes towards a focused library of 
putative BACE-1 inhibitors. Chapter 4 presents results of the biological activity of 
putative BACE-1 inhibitors; describes further SAR studies and provides a discussion of 
the obtained results. 
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Chapter 2. Structure-based design of putative bioactive molecules for 
BACE-1 
The following Chapter describes a novel computational approach to identify new 
putative bioactive molecules for BACE-1. The approach involved the design of a virtual 
library of likely synthetically accessible lead-like compounds based on diversity-
oriented synthesis (DOS) and the virtual screening of this library against BACE-1. An 
overview of the approach, including a description of the computational tools employed 
for the enumeration of a virtual library (Pipeline Pilot) and for virtual screening 
(eHiTS), is presented in Section 2.1. Demonstration of the validity of the virtual 
screening method is given in Section 2.2. A detailed description of the performed 
computational process is shown in Section 2.3 and analysis of the identified putative 
inhibitors is presented in Section 2.4. 
2.1 Overview of the computational approach 
The proposed computational approach combined the in silico enumeration of likely 
synthetically accessible compounds using DOS and virtual high-throughput screening 
(vHTS). The approach was directed towards the identification of novel small cyclic 
BACE-1 inhibitors, able to interact with the catalytic aspartates, Asp32 and Asp228, 
and/or with two water molecules located in the catalytic site of BACE-1 (similarly to 
the inhibitor 26, Section 1.4.5).  
 
Two libraries of cyclic molecules were generated using Pipeline Pilot. The first 
library, library A, was optimised after analysing the results of an initial vHTS round 
against BACE-1. The optimisation of library A led to the generation of the more 
focused library B. From each library, lead-like molecules were selected according to 
specific structural and lipophilicity parameters: number of heavy atoms, 16 ≤ nHA ≤ 23 
for library A and 16 ≤ nHA ≤ 27 for library B; number of aromatic rings ≤ 2; value of 
the atomic-based prediction partition coefficient,
92
 0 ≤ AlogP
c
 
 ≤ 3.5. The number of 
saturated rings > 0 was also considered as a parameter for the selection of molecules in 
                                                 
c
AlogP is an algorithm estimation of the partition coefficient, P
octanol/water
, based on the 
contribution of different atoms according to their physicochemical properties. 
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order to verify that only cyclic molecules were generated from the enumeration of the 
two virtual libraries.  
 
The selected lead-like molecules underwent vHTS using two BACE-1 structures: 
one containing two water molecules in the catalytic site and the other one without water 
molecules. After the vHTS of library B, putative inhibitors were chosen for synthesis. 
The overall computational approach is shown in Figure 27. 
 
 
 
 
Figure 27. Summary of the computational approach which led to the identification 
of novel putative BACE-1 inhibitors. 1) The approach starts with the enumeration of a 
virtual library of likely synthetically accessible molecules, library A. The generated 
library was filtered according to lead-like parameters and the resulting molecules were 
screened in silico against the target protein BACE-1. Promising ligands were identified 
and analysed. 2) The initial library A was optimised and the more focused library B was 
obtained. Library B underwent the same computational process to identify putative 
inhibitors of BACE-1. 
2.1.1 Pipeline Pilot 
Pipeline Pilot
93, 94 
is a scientific informatics platform which can be used to generate 
virtual compound libraries. Pipeline Pilot allows the creation of configurable protocols 
to manage, order and analyse scientific data, and to enumerate combinatorial processes. 
Configurable protocols can be built by assembling specific components which store, 
identification 
of promising 
ligands 
enumeration of a first 
virtual library 
enumeration of a second 
focused virtual library 
selection 
selection 
vHTS 
vHTS 
selections of 
putative inhibitors 
for synthesis 
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manipulate, filter, and display data. The chemistry components in Pipeline Pilot are able 
to: perform virtual reactions, modify chemical structures, enumerate libraries, calculate 
different molecular properties, search molecules according to substructures and 
similarities, and cluster and filter compounds. An example of a configurable protocol 
designed in Pipeline Pilot to enumerate a virtual library of structurally diverse 
compounds is illustrated in Figure 28. 
 
Figure 28. Configurable protocol designed in Pipeline Pilot to enumerate a virtual 
library of structurally diverse compounds. The protocol was built with a series of 
components. Firstly starting materials and reactants are read in the form of a ChemDraw 
file (components “Reader” 1 and 2, on the left), then a series of virtual reactions are 
performed through chemistry components. The data are then processed (removing 
duplicates and generating a 3D conformation per molecule) and stored in the form of 
SD file. The resulting molecules are then visualised as HTML and Excel File 
(components on the right). 
starting 
material 
input 
virtual reactions/chemical 
components 
data 
processing  
output and 
visualisation 
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2.1.2 eHiTS 
eHiTS
23
 (electronics High Throughput Screening) is one of the many docking 
programs (Section 1.2.3) employed in the virtual screening of molecules. eHiTS 
contains a systematic structure search algorithm to predict the binding pose of a ligand 
in a protein target site,
23
 and an empirical scoring function to estimate binding affinity. 
The structure search algorithm in eHiTS identifies rigid fragments and flexible chains 
contained in the ligand structure, and docks rigid fragments separately in any available 
location of the protein binding site. The docked poses of the fragments which are in 
proximity to each other are considered “pose sets” and are combined together through a 
graph matching algorithm. The ligand flexible chains are connected to the “pose sets”, 
without changing their original conformation, and the overall structure of the ligand is 
then reconstructed. The reconstructed ligand structure is then optimised by considering 
low energy rotamers or by resolving steric clashes. The predicted ligand pose is scored 
according to an empirical scoring function.  
 
The scoring function detects interactions between surface points of a ligand’s rigid 
fragments and of a protein binding site to determine the initial score. Surface points are 
classified according to chemical properties and are divided into 23 different types: 
metals, H-bond donors, weak H-bond donors, lone pairs, π-electrons, halogens, 
positively charged hydrogens, etc. An estimation of the binding affinity of a ligand is 
derived from a statistic sum of the ligand surface point types and it is expressed as a 
negative value on a logarithmic scale.
23
 The estimated ligand binding affinity can be 
correlated with the ligand inhibition constant for the target protein, Ki, as follows: an 
eHiTS score of7.0 would correspond to an estimated 107 M inhibitor.  
 
Protonation states of the ligand and the protein binding site are important factors in 
predicting the ligand binding pose and its affinity. eHiTS scores all possible protonation 
states of the ligand and the protein in one run and selects the best protonation state for 
each single interaction. eHiTS can screen thousands of molecules in one run, enabling 
virtual high throughput screening. 
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2.1.3 Ligand selection 
As shown in Figure 1 (Section 2.1), promising ligands were selected from virtual 
screening of library A and putative inhibitors were selected from virtual screening of 
library B. The criteria of selection of promising ligands and putative inhibitors were 
based on values of cLE' (Section 1.2.3.1) and molecular weight: cLE' ≥ 0.27 or 0.28 and 
200 ≤ M.W. ≤ 460. The cLE' was calculated from the eHiTS score according to 
Equation 6. The limiting value of cLE′ was chosen according to the distribution of data, 
in order to focus on the best 1-2% of cLE′. 
       
            
   
 
Equation 6. Computed ligand efficiency calculated from eHiTS scores. 
The range of molecular weight and lipophilicity chosen to select promising ligands 
and putative BACE-1 inhibitors (200 ≤ M.W. ≤ 460 and 0 ≤ AlogP ≤ 3.5) respects the 
lead-likeness criteria suggested by Monge et al.
6
 (M.W. ≤ 460 and logP ≤ 4). According 
to the chemical space definition of Nadin et al.
2
 (Section 1.1), instead, this range 
includes mostly lead-like compounds and a small part of drug like-compounds (Figure 
29). The selection of promising ligands and putative inhibitors selection was performed 
by using a specific protocol designed in Pipeline Pilot (Figure 30). 
 
Figure 29. Chemical space explored in the identification of putative bioactive 
molecules. The blue area shows the chemical space explored in the proposed approach 
to identify bioactive molecules. According to the representation of chemical space of 
Nadin et al.,
2
 this area includes mostly lead-like and part of drug -like molecules. 
area of 
exploration 
42 
 
 
Figure 30. Protocol designed in Pipeline Pilot to select virtual ligands identified by vHTS against BACE-1. The results files of any vHTS rounds, 
containing eHiTS scores, are used to calculate cLE'. The results are filtered according to cLE' and M.W. values, and are visualised in a scatter plot of 
AlogP vs cLE'. 
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2.2 Testing the applicability of eHiTS to BACE-1 
The docking method employed by eHiTS was validated before being applied to the 
virtual screening of libraries A and B. To verify the applicability of eHiTS to BACE-1 
and to confirm the validity of eHiTS in predicting ligand binding poses, a docking test 
was performed. The test consisted of reproducing the binding pose of a known inhibitor 
in the catalytic site of BACE-1 using eHiTS. The known co-crystal structure of the 
spiropiperidine iminohydantoin inhibitor 26 bound to BACE-1,
85
 referred as 3FKT
a
 
hereafter, was chosen for the docking test (Figure 31). The compound 26, a 3 μM 
inhibitor, inhibits BACE-1 via a hydrogen bonding network with the conserved water 
molecule Wat1, located between the catalytic aspartates, and another water molecule 
contained in the protein catalytic site (Section 1.4.5).  
 
Figure 31. 2D representation of the inhibitor 26 in complex with BACE-1. The H-
bond network formed in the catalytic site of BACE-1 is represented in green dotted lines.  
                                                 
a
3FKT corresponds to the PDB access number of the complex formed between the  
inhibitor 26 and BACE-1.   
BACE-1: IC50 =3.0 M, LE′ = 0.18 
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To reproduce the mode of interaction of the inhibitor 26 with BACE-1, a 
compatible structure had to be derived from 3FKT. The coordinates corresponding to 
the inhibitor 26, as well as the coordinates corresponding to all water molecules, except 
for the two in proximity to the catalytic aspartates, were removed. The resulting 
structure is shown in Figure 32. 
 
Figure 32. Derived BACE-1 structure for docking test. A) Original X-ray co-crystal 
structure of the 3FKT (1.90 Å). B) Derived BACE-1 structure used for docking test. 
The coordinates of the ligand and the water molecules, except for the ones in proximity 
to the catalytic aspartates, were removed. Structures visualised with Discovery Studio 
3.0. 
25 different three-dimensional conformations of the inhibitor 26 were generated
a
,
95
 
and docked against BACE-1. The resulting binding poses were analysed and sorted 
according to their eHiTS score. The top five binding poses predicted by eHiTS are 
reported in Table 4.   
                                                 
a
The three-dimensional conformations of the inhibitor 26 were generated using Corina
95 
water 
 
original co-crystal structure 3FKT  
derived BACE-1 structure for 
docking test 
A 
 
B 
 
45 
 
Table 4. Top scoring poses of inhibitor 26 predicted by eHiTS software.  
a
Binding poses visualised with Discovery Studio 3.0 
  
Entry eHiTS predicted pose eHiTS score 
Predicted (grey) vs 
experimental (blue) pose
a
 
1 
 
7.05 
           
2 
 
7.03 
 
3 
 
6.89 
 
4 
 
6.88 
 
5 
 
6.82 
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The predicted binding pose ranked as second, according to its eHiTS score, was in 
good agreement with the pose of the inhibitor 26 (Table 4, entry 2). The root mean 
square deviation (RMSD) of heavy atom position between this predicted binding pose 
and the co-crystal structure pose of the inhibitor 26 was of 1.36 Å; in line with the 
accepted limited value of Å ≤ 2.0 for reliable prediction.96 This predicted binding pose 
forms one H-bond between the piperidine-N atom of the inhibitor 26 and Wat1 in the 
catalytic site of BACE-1 (Figure 33).  
 
Figure 33. Superimposed binding poses of the spiropiperidine iminohydantoin 
inhibitor 26 in the catalytic site of BACE-1. Predicted (grey) and experimental (blue) 
binding poses of the inhibitor 26 in complex with BACE-1.
a.
 The green dotted lines 
show the network of H-bond interactions for the experimental binding pose, red circles 
indicate the water molecules. The inhibitor binding pose predicted by eHiTS forms a H-
bond with Wat1 (dark green dotted line), while the inhibitor 26 in complex with BACE-
1 forms other three main H-bonds: one with another water molecule in proximity of 
Asp228, one with Phe108 and another one with NH (backbone) of Gln73. Visualised 
with Discovery Studio 3.0.  
                                                 
a 
PDB access number 3FKT
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The H-bond between the secondary amino group of the inhibitor and the water 
molecule in proximity of Asp228, observed in 3FKT (Figure 31), was not detected. 
Other two H-bonds with BACE-1 residues, Gln73 and Phe108, located in the flap 
region (Section 1.3.2) were also missed. Nevertheless, the orientation of the inhibitor 26 
in the catalytic site of BACE-1 was correctly reproduced and the reliability of eHiTS 
was therefore demonstrated. 
2.3 Design of a virtual library of likely synthetically accessible lead-like 
compounds 
A virtual library of likely synthetically accessible lead-like molecules was 
enumerated using Pipeline Pilot. In each case, it was envisaged that a scaffold might be 
assembled from an initial coupling of two main building blocks and the resulting 
intermediate could be varied by a sequence of established reactions. The virtual 
synthesis of each scaffold was performed in parallel from a range of different building 
blocks and a library of structurally diverse scaffolds was generated according to the 
DOS principle (Section 1.2.4).  
 
In order to ensure synthetic accessibility as far as possible, a toolbox of previously 
established reactions and a pool of commercially available reagents were applied to the 
protocol. The protocol started with a series of virtual coupling reactions between 
nucleophile and electrophile building blocks (e.g. nucleophilic opening of cyclic 
sulfamidates,
97
 Ir-catalysed asymmetric amination of an allylic carbonate
98
), and then 
proceeded with virtual derivatisation reactions on the resulting intermediates with 
isocyanates or aryl bromide reagents. The resulting compounds underwent one or two 
virtual cyclisation reactions (e.g. metathesis,
99
 Pd-catalysed aminoarylation
100
) followed 
by virtual removal of protecting groups. A series of virtual skeletally diverse molecules 
was obtained and further modified by virtual derivatisation reactions. The list of virtual 
reactions and building blocks employed to enumerate the library, library A, is reported 
in Appendices 1.1 and 1.3. 
 
The resulting compounds were filtered according to lead-like parameters (Section 
2.1) and a library of ca. 85,000 likely synthetically accessible compounds, library A, 
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was obtained. Examples of cyclic compounds obtained from the enumeration of library 
A are represented in Figure 34. 
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Figure 34. Protocol of virtual synthesis employed to enumerate virtual library A. 
Examples of virtual products obtained at each stage are shown. 
N
o
 aromatic ring ≥ 2 
N
o
 saturated ring ≥ 0 
0.0 ≤ AlogP ≤ 3.5 
16 ≤ nHA ≤ 23 
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2.3.1 Identification of promising ligands  
Library A was docked against BACE-1 in order to identify putative ligands. A first 
vHTS was conducted using a randomly-selected sample of 10% of the molecules,
a
 in 
order to identify representative classes of molecules contained in the library. The 
resulting eHiTS scores were used to calculate the cLE'. The most promising putative 
ligands were chosen on the basis of cLE' value, cLE' ≥ 0.27.
b
 The structures of those 
ligands were analysed and clustered into eight main substructures (Figure 35).  
 
Figure 35. Eight main substructures of the most promising virtual ligands of 
library A. The substructures were identified by vHTS a randomly-selected sample of 
10% of library A against BACE-1. 
All the compounds in library A that contained one of the above substructures were 
selected. The resulting 29,084 molecules were docked against BACE-1. The 131 most 
promising compounds, with cLE' ≥ 0.28,b were analysed: 68% of the compounds 
contained the substructure e, 35% the substructure c and 7% the substructures d and h. 
Examples of those compounds and their distribution according to lipophilicity (AlogP) 
and cLE', values are reported in Figure 36. 
                                                 
a
The three-dimensional conformations of the representative 10% sample of library A were 
generated using Corina
95
 (one three-dimensional conformation for each molecule). 
b
The limiting value of cLE' was chosen according to the distribution of data, in order to focus on 
the best 1% of cLE'. 
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Figure 36. Promising putative BACE-1 ligands with cLE' ≥ 0.28 contained in 
library A. Each symbol represents a single ligand described by AlogP and cLE′. 
Representative ligands are coloured according to their substructure defined in Figure 35. 
131 ligands were identified following vHTS of 29,084 molecules. The substructures c 
and e contained mainly 2 or 3 saturated or aromatic rings, while the substructure d and 
h contained 1 or 2 saturated or aromatic rings. Graph reproduced with Dotmatics 
Vortex. 
2.3.2 Optimisation of library A and identification of two families of putative 
BACE-1 inhibitors 
The protocol used for the generation of library A was modified in order to create a 
more focused virtual library of putative BACE-1 inhibitors. A further series of virtual 
derivatisation reactions, performed with a variety of secondary amines, was added at the 
end of the protocol and a broader variety of virtual derivatisation reagents (aryl bromide 
and isocyanates) was used. The list of virtual derivatisation reactions and of the reagents 
employed is provided in Appendices 1.2 and 1.3.  
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Five million molecules were generated and filtered according to the established 
lead-like parameters (Section 2.1) and a virtual library of ca. 55,000 molecules was 
derived; library B. The overall protocol for the generation of the virtual library B is 
illustrated in Figure 37. It was observed that molecules generated from library B 
showed more substituted structures than members of library A (Figure 38).  
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Figure 37. Protocol of virtual synthesis employed to enumerate virtual library B. 
Examples of virtual products obtained at each stage are shown. The protocol of virtual 
synthesis of library A was implemented with additional virtual derivatisation reactions 
(below the dotted line) to give more substituted structures (16 ≤ nHA ≤ 27). 
N
o
 aromatic ring ≥ 2 
N
o
 saturated ring ≥ 0 
0.0 ≤ AlogP ≤ 3.5 
16 ≤ nHA ≤ 27 
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Figure 38. Comparison of virtual molecules obtained by in silico enumeration of 
libraries A and B. The molecules contained in library B showed a more substituted 
structures than in library A, and number of heavy atoms was 16 ≤ nHA ≤ 27.  
Library B was docked against BACE-1
a
 and the eHiTS scores were used to 
calculate cLE'. A larger proportion of molecules had cLE' ≥ 0.28, compared to library A 
(ca. 900 vs 131); confirming that more promising virtual ligands were present in the 
focused library B. Two main families of putative inhibitors were identified amongst all 
the virtual ligands with cLE' ≥ 0.28. The amino tetrahydropyridine family, containing 
the substructure e (Figure 35), represented 37% of all the ligands; the imidazolidinone 
family, containing the substructure c (Figure 35), represented 63% of all the ligands. 
Their distribution according to AlogP and cLE' values are reported in Figure 39. 
                                                 
a
Three-dimensional conformations were generated using Corina
95
(one three-dimensional 
conformation for each molecule). 
16 ≤ nHA ≤ 23 
 
more substituted structures  
16 ≤ nHA ≤ 27 
 
Virtual library A 
output 
 
Virtual library B 
output 
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Figure 39. Putative BACE-1 inhibitors, cLE′ ≥ 0.28 identified from library B. Each 
symbol represents a single ligand described by AlogP and cLE′. Representative ligands 
are coloured according to their substructure defined in Figure 35. 900 ligands were 
identified following vHTS of ca. 55,000 molecules. The amino tetrahydropyridine 
family of putative inhibitors (substructure e) contained mainly 1 or 2 saturated or 
aromatic rings, while the imidazolidinone family of putative inhibitors (substructure c) 
contained mainly 2 to 4 saturated or aromatic rings. Graph reproduced with Dotmatics 
Vortex. 
2.4 Analysis of the predicted binding poses of the putative inhibitors 
The predicted binding poses of the two identified families of putative inhibitors for 
BACE-1 were analysed. For both families the key predicted interactions with the 
catalytic site of BACE-1 were H-bond interactions formed through the primary amine 
contained in the putative inhibitor structures. The predicted H-bond interactions were 
directed towards the water molecules and/or the catalytic aspartates, Asp32 and Asp228. 
The primary amine is predicted to be protonated at the pH at which BACE-1 is active 
55 
 
(pH 4.5). Other predicted H-bond interactions were formed with Lys107 and Phe108 
contained in the flap region of BACE-1 or with Arg235. Examples of the predicted 
binding poses of the two main families of putative inhibitors are shown in Figure 40. 
When docking was conducted without including the water molecules in the 
catalytic site of BACE-1, the H-bond interactions between the putative inhibitor's 
protonated primary amine, NH3
+
, and the catalytic aspartate residues, Asp32 and 
Asp228, were still predicted (illustrations given in the Appendix 2.1). The binding pose 
prediction was therefore consistent, orienting the putative inhibitors in the catalytic site 
of BACE-1 in the same direction, either in presence or in absence of the water 
molecules. 
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Figure 40. Predicted binding pose of representative members of the identified 
families of BACE-1 putative inhibitors. A) and C) 2D structure of the 
imidazolidinone putative inhibitor 31 (A) and of the amino tetrahydropyridine putative 
inhibitor 32 (C) in their protonated state. B) and D) 3D image of the predicted binding 
pose of the inhibitors 31 (B) and 32 (D). The predicted H-bond interactions are shown 
with green dotted lines, -cation interactions are shown in orange line, and red circles 
indicate water molecules. The water molecules, Asp228 and Asp32 form H-bonds with 
the protonated primary amine, NH3
+
, of the putative inhibitor 31 (B) and 32 (D). 
Arg235 forms a -cation interaction with one pyridine ring of the putative inhibitor 31 
(B). Lys107 and Phe108, both located in the flap region form H-bond with the other 
protonated primary amine, NH3
+
, of the putative inhibitor 32 (D). Visualised with 
Discovery studio 3.0. 
A B 
C D 
eHiTS score = 7.12 
cLE′ = 0.29 
 
eHiTS score = 7.78 
cLE′ = 0.35 
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2.4.1 Validation of the predicted binding poses with additional docking 
software 
A representative set (eight molecules) of the two identified families of putative 
BACE-1 inhibitors was studied using the Maestro suite (Schroedinger).
101
 The lengths 
of the predicted H-bonds formed in the catalytic site of BACE-1 were measured. The 
predicted length range was of 2.4-2.9 Å
 
for H-bonds formed with Asp32 and Asp228, 
and 2.2-2.5 Å for H-bonds formed with the water molecules. These lengths were in 
agreement with the range of 2.5-3.2 Å reported in the literature for H-bonds formed in 
the catalytic site of BACE-1.
77, 86 
Representative examples are provided in Appendix 
2.2. 
The predicted binding poses of the representative putative inhibitors were analysed 
using Macromodel, a specific component within Maestro, in order to assess their 
conformational energy. Macromodel was used to minimise the conformational energy 
of raw eHiTS binding poses inside the catalytic site of BACE-1. Macromodel applied a 
force field method to calculate the putative energy of a ligand, using an iterative 
function of distances and angles between atoms and keeping the coordinates of the 
protein unchanged. Representative examples of energy-minimised binding poses of the 
putative inhibitors are represented in Figure 41. The root-mean square deviation 
(RMSD) of heavy atom positions between raw and minimised conformations was in the 
range of 1.8 ≤ Å ≤ 1.3, in line with the accepted limited value of Å ≤ 2.0 for reliable 
prediction.
96
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Figure 41. Evolution of raw binding poses upon conformational energy 
minimisation for selected putative inhibitors. A) and C) 2D structure representation 
of the imidazolidinone and the amino tetrahydropyridine putative inhibitors 33 and 34. 
B) and D) Superimposed structures of the energy-minimised (grey) and raw (green) 
binding poses for the putative inhibitors 33 and 34. 
The binding poses obtained after the minimisation of their conformational energy 
were compared with the raw eHiTS binding poses using SPROUT. SPROUT is a 
fragment-based ligand design program that identifies protein binding regions, 
favourable protein hydrogen bonding and hydrophobic sites.
102, 103
 In SPROUT, the 
ALIGATOR module (Algorithms for LIGAnd Testing and Ordering of Results) 
contains a scoring function which can help investigating the ligand binding poses 
generated by other in silico docking software (e.g. eHiTS). The scoring function of 
SPROUT has a logarithmic scale and hydrophobic interactions represent the main score 
parameter. The scores have a negative value and represent the predicted log(Ki) of the 
ligand for the protein.
a
 The binding poses of the eight representative putative inhibitors, 
predicted by eHiTS and Maestro, were scored using SPROUT.  
                                                 
a
A score of7.0 would correspond to an estimated 107 M inhibitor. 
A B 
C D 
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The resulting SPROUT scores for selected putative inhibitors are illustrated in 
Table 5 and in Table 6. As a general outcome, the SPROUT scores of binding poses 
with minimised conformational energy were similar to the raw ones (Table 5 and 6, 
column 3). Only one exception was observed (Table 5, entry 1). This similarity in the 
SPROUT scores for raw and energy minimised binding poses showed that the binding 
poses predicted by eHiTS were reliable.  
 
It was noticed that the SPROUT scores were higher by 3.5 logarithm units than the 
eHiTS scores (Table 5 and 6 column 3 and 4); thus predicting 10
4
 M inhibitors. These 
differences could be attributed to the different scoring functions employed by the two 
docking programs: H-bonding and -cation interactions are weighted more in eHiTS, 
while lipophilic interactions and cavity filling are weighted more in SPROUT. Despite 
the scores differences, the interactions predicted by eHiTS were confirmed by 
SPROUT. A summary of the predicted non-covalent interactions formed by 
representative ligands of the two promising families in the catalytic site of BACE-1 is 
given in Table 5 and 6. 
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Table 5. eHiTS and SPROUT scores and predicted non-covalent interactions of selected imidazolidinone putative inhibitors in BACE-1. 
a
Raw eHiTS binding poses scored by SPROUT; 
b 
energy-minimised binding poses (Macromodel/Maestro) scored by SPROUT;
c
calculated with eHits score  
Entry 2D representation of predicted non-covalent interactions 
Score Main H-bond interactions 
Other 
interactions SPROUT
a
 
(SPROUT)
b
 
eHiTS cLE'
c
 Wat1 
Other 
water 
Asp228 Asp32 
1 
 
3.99 
(5.06) 
      
Thr329       
(H-bond 
interaction) 
 
Arg235 
-cation 
interaction) 
2 
 
3.90 
(4.02) 
      
Arg235 
-cation 
interaction) 
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Table 6. eHiTS and SPROUT scores and predicted interactions of selected amino tetrahydropyridine putative inhibitors in BACE-1. 
a
Raw eHiTS binding poses scored by SPROUT; 
b
 energy-minimised binding poses (Macromodel/Maestro) scored by SPROUT;
 c
calculated with eHits score 
Entry 2D representation of predicted non-covalent interactions 
Score Main H-bond interactions 
Others 
interactions SPROUT
a
 
(SPROUT)
b
 
 
eHiTS 
 
cLE' Wat1 
Other 
water 
Asp228 Asp32 
1 
 
4.58 
(4.50) 
      
Thr232       
(H-bond 
interaction) 
2 
 
3.37 
(3.30) 
      
Thr231       
(H-bond 
interaction) 
 
Arg235       
-cation 
interaction) 
   62 
 
2.4.2 Design of a focused library of putative inhibitors 
The two families of putative inhibitors identified by vHTS showed similar 
interactions with the catalytic site of BACE-1. The selection of one family over the 
other for synthesis was determined by their respective chemical structural features. An 
evaluation of their structural novelty, potential for diversification, and chemical stability 
were made.  
To assess the novelty of the putative BACE-1 inhibitors, structures were compared 
with the ones of known BACE-1 inhibitors. Elements of novelty were found in both 
putative inhibitor scaffolds. The imidazolidinone scaffold (Table 7 entry 1) differed 
from the spiropiperidine imihydantoin inhibitor 26 and from the 2-aminoimidazole-4-
one inhibitors
77
 in the position of the amino group and the number of substituent groups 
around the cyclic urea ring. The amino tetrahydropyridine scaffold entry (Table 7, entry 
2) differed from known aminopyridine inhibitors
78, 104, 105
 for the position in the N atom, 
and the number of double bonds in the ring; and from a tetrahydropyridine inhibitor
106
 
for the position and type of substituent groups on the ring. As a consequence, both 
putative inhibitor scaffolds were considered novel chemotypes for BACE-1. 
Table 7. Comparison of structure features of putative BACE-1 inhibitors with 
known BACE-1 inhibitors. 
a
The central core of the molecules is shown; 
b
Only one example in the literature
106
  
Entry 
Putative BACE-1 
inhibitors
a
 
Known BACE-1 inhibitors
a
 
1 
   
2 
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In terms of potential for diversification, the imidazolidinone scaffold represented 
the most diverse family of putative BACE-1 inhibitors. In this scaffold the central core 
can be diversified at three different positions, allowing for a broad investigation of 
binding effect of substituent groups. In the case of the amino tetrahydropyridine 
scaffolds, only two positions of diversification can be considered (Figure 42).  
 
Figure 42. Positions of diversification in the structures of the two families of 
putative inhibitors. 
Regarding chemical stability, it was noticed that the amino tetrahydropyridine 
scaffold can be subjected to tautomerisation into the , unsaturated ketone, giving a 
reactive Michael acceptor. From those considerations, the more potentially diverse and 
stable family of imidazolidinone compounds was chosen for synthesis. A focused 
library of these compounds was designed (Figure 43). Binding pose predictions, 
hydrophilicity, and variation of geometry and length of the substituent groups were 
considered in the library design.  
 
Figure 43. Focused library of putative BACE-1 inhibitors. 
2.5 Summary 
The design of a library of putative BACE-1 inhibitors was presented in this 
Chapter. The design approach consisted of enumerating a virtual library of lead-like 
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compounds and screening those compounds in silico against BACE-1. The virtual 
library enumeration was based on diversity oriented synthesis, to generate skeletally 
diverse molecules from an initial pool of building blocks. The protocol employed for 
the virtual library enumeration included established chemical reactions and 
commercially available reactants to ensure synthetic accessibility as far as possible.  
The virtual screening of the library was performed using eHiTS. The eHiTS 
screening method was validated and the predicted binding poses of the putative BACE-
1 inhibitors were also analysed using Maestro Macromodel and SPROUT. The non-
covalent interactions predicted by eHiTS were confirmed. Two families of putative 
BACE-1 inhibitors were identified, both containing elements of novelty in comparison 
to known BACE-1 inhibitors. One family was chosen over the other for synthesis, on 
the basis of potential points of diversification and chemical stability. A focused library 
of imidazolidinone putative inhibitors was then designed; the synthesis of these 
compounds is discussed in Chapter 3. 
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Chapter 3. Synthesis of a library of imidazolidinones 
The following Chapter describes the synthetic routes to a library of BACE-1 
putative inhibitors based on the imidazolidinone structure. Two different potential 
synthetic routes are presented, both including a cyclisation reaction on a series of N-
allyl urea substrates to lead to the imidazolidinone scaffold (Section 3.1). The first 
synthetic route is based upon a Pd-catalysed aminoarylation and is described in Section 
3.2; the second synthetic route is based upon an iodine-mediated cyclisation and is 
described in Section 3.3. 
3.1 Identification of two possible synthetic routes  
A variety of imidazolidinones was identified as putative inhibitors for the BACE-1 
by virtual high throughput screening. A generic representation of the putative inhibitors 
is given by structure 35 (Scheme 5).  Two possible synthetic routes were envisaged for 
the imidazolidinone 35. The synthetic route A was suggested by the protocol of virtual 
reactions employed for the enumeration of virtual libraries A and B (Section 2.3); while 
the synthetic route B was envisaged from literature precedence. The two routes lead to 
two different starting materials: the allylic amines 38 and 41.  
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Scheme 5. Retrosynthetic analysis of target imidazolidinones. The groups R
1
, R
2 
and 
Ar were chosen according to the virtual library hits (see Figure 43, Section 2.4.2). 
Following route A, the target imidazolidinone 35 might be obtained by functional 
group interconversions (FGIs) of cyclic precursor 36, itself be prepared by Pd-catalysed 
aminoarylation of the N-allyl urea 37. The N-allyl urea 37 might be synthesised from 
the allylic amine 38. According to route B, two FGIs of imidazolidinone 35 might lead 
to the precursor 39. Compound 39 might be formed via iodine-mediated cyclisation of 
the N-allyl urea 40, derived from the allylic amine 41. The investigation of the viability 
of these two routes is described in Sections 3.2 and 3.3.  
3.2 Synthetic route to the target imidazolidinones based upon a Pd-
catalysed aminoarylation 
The synthesis of a first imidazolidinone was planned on the basis of literature 
examples of a Pd-catalysed aminoarylation. Wolfe et al. reported the use of the 
phenylurea 42 as substrate for the aminoarylation (Scheme 6).
107 
Here the formation of 
the new C-N bond provided the cyclic urea system and a 2-naphthalenyl was 
concomitantly introduced. 
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Scheme 6. Example of a Pd-catalysed aminoraylation 
Wolfe et al. also applied the Pd-catalysed aminoarylation to a series of N-allyl 
phenylureas containing an alkyl group at the allylic position (Scheme 7, A). Following 
these examples, the reaction scope was extended and adapted to our synthetic purpose. 
A variety of N-allyl phenylureas containing different functional group substitutions at 
the allylic position was chosen for synthesis, keeping the target imidazolidinone 44 in 
mind (Scheme 7, B). 
 
Scheme 7. Other substrates for Pd-catalysed aminoarylations. A) Substituted N-allyl 
ureas employed in the literature. B) Designed N-allylureas to investigate Pd-catalysed 
aminoarylation in order to achieve the final amine 44. 
3.2.1 Synthesis of substrates for the Pd-catalysed aminoarylation  
A first substrate for the Pd-catalysed aminoarylation, compound 45, was 
synthesised starting from the allylic carbonate building block 46 (Scheme 8). The allylic 
A 
B 
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carbonate 46 was prepared in four steps from 2-aminoethanol following a literature 
procedure (Scheme 9).
108
 
 
Scheme 8. Allylcarbonate 46, precursor of compound 45, substrate for Pd-
catalysed aminoarylation. 
 
Scheme 9. Synthesis of the allylic carbonate 46. 
2-Aminoethanol was treated with di-tert-butyl dicarbonate under solvent free 
conditions to form the carbamate 47. The carbamate 47 then underwent an one pot 
Parikh–Doering oxidation109/Wittig reaction110 by treatment with sulfur trioxide 
pyridine, triethylamine and dimethylsulfoxide (DMSO) in CH2Cl2, followed by addition 
of the triphenylphosphorane Ph3PCHCO2Et. The resulting unsaturated ester 48 was 
obtained with >98:<2 E:Z selectivity. The reduction of the ester 48 to the corresponding 
alcohol 49 was achieved by treatment with diisobutylaluminium hydride (DIBAL) and 
borontrifluoride diethyletherate in CH2Cl2 at 78 
o
C. Finally, treatment of the alcohol 
49 with methylchloroformate and pyridine in CH2Cl2 gave the allylic carbonate 46. 
The allylic carbonate 46 was then employed in the synthesis of the allylic amine 50, 
precursor of the substrate for the Pd-catalysed aminoarylation. The conversion of the 
allylic carbonate 46 into the allylic amine 50 was achieved via an Ir-catalysed allylic 
amination (Table 8).
98
 The allylic carbonate 46 was treated with aniline in DMSO or 
THF as solvent in presence of 2 mol% of each of the precatalyst [Ir(dbcot)Cl]2,
111,112
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phosphoramidite chiral ligands (S,S aS)-51 and (R,R aR)- 52
113
 and n-butyl amine.
a
 The 
active catalyst was formed in situ.
114
 The reaction was performed using a 1:1 mixture of 
the two chiral ligands (S,S aS)-51 and (R,R aR)-52 in order to obtain the product as a 
racemate. The reaction was attempted in DMSO and THF;
115
 similar yields were 
obtained in both solvents (Table 8) and, as a general trend, the yield improved with the 
scale  of the reaction (entry 1 and 3 and entry 2, 4).  
Table 8. Synthesis of the allylic amine 50. 
 
                                                 
a
The dbcot ligand, the precatalyst [Ir(dbcot)Cl]2 and the phoshoramidite ligands (S,S 
aS)-51 and (R,R aR)-52 were prepared according to literature procedures. 
Entry Scale 46 (mmol) Solvent Yield (%) 
1 0.50 DMSO 49 
2 0.50 THF 43 
3 0.75 DMSO 61 
4 1.2 THF 69 
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The allylic amine 50 was ultimately converted into the N-allyl urea 45. The 
formation of the N-allyl urea 45 required the treatment of 50 with an excess of 
ethylisocyanate in CH2Cl2, stirring at reflux for 2 days (Scheme 10). The urea 45 was 
prepared in 58% yield. 
 
Scheme 10. Synthesis of the N-allyl urea 45. 
To prepare other substituted N-allyl ureas, an alternative concise approach was 
subsequently adopted. The synthesis of the N-allyl urea 54 was accomplished in two 
steps consisting of a Petasis multicomponent reaction,
116
 followed by an urea formation 
(Scheme 11). The allylic amine 53 was isolated as a racemate after combining 
glycoaldehyde dimer, vinyl boronic acid pinacol ester and aniline in H2O–THF. A range 
of conditions was investigated (Table 9) and ultimately the best yield was obtained at 30 
o
C over 4 days. The conversion of the allylic amine 53 into the respective urea 54 was 
performed by treatment with an excess of ethylisocyanate in CH2Cl2 in 80% yield. 
 
Scheme 11. Preparation of the substituted N-allyl urea 54. 
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Table 9. Reaction conditions employed in the preparation of the allylic amine 53. 
Three additional substrates for the Pd-catalysed aminoarylation were prepared from 
the N-allyl urea 54. The N-allyl urea 54 was converted into the NsBoc-protected amine 
55, the MOM-protected alcohol 56 and the azide 57 (Scheme 12).  
 
Scheme 12. Conversion of the N-allyl urea 54 into the N-allyl ureas 55, 56 and 57.  
The NsBoc protected amine 55 was prepared under Fukuyama–Mitsunobu117 
conditions in 53% yield, by treating the N-allyl urea 54 with NsNHBoc, 
triphenylphosphine and DEAD. The protected alcohol 56 was obtained in a 41% yield 
stirring the alcohol 54 with methyl chloromethyl ether (MOMCl) and N,N-
diisopropylethylamine (DIPEA) base in CH2Cl2. The formation of the azide 57 was 
achieved from compound 54 using 1,8-diazadicyclo[5.4.0]undec-7-ene (DBU) and 
diphenylphosphoryl azide (DPPA).
118
 Initially the reaction was conducted in DMF 
stirring from 1 to 3 days obtaining up to 34% yield (entry 1 and 2, Table 10). When 
toluene was employed as solvent, the yield improved to 63% (entry 3, Table 10). 
Entry Scale PhNH2 (mmol) Time (days) Temperature ( °C) Yield (%) 
1 1.5 2 50 18 
2 2.0 3 50 30 
3 20 4 30 45 
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Table 10. Study of the formation of the azide 57 from the alcohol 54. 
 
3.2.2 Investigation of the Pd-catalysed aminoarylation  
The Pd-catalysed aminoarylation reaction was initially reproduced using the known 
substrate 42
1
 and then it was investigated using the prepared N-allyl urea substrates 45, 
54, 55, 56 and 57. In each case, the relevant substrate was treated with 2-
bromonaphthalene and NaO
t
Bu in the presence of a 5 mol% of Pd2(dba)3 complex and 
10 mol% of phosphine ligand Xantphos in toluene, stirring the resulting mixture at 
reflux for 2-3 days (Table 11).  
Entry DBU, DPPA (eq.) solvent Time (days) Yield (%)a 
1 3.0 DMF 1 21 
2 6.0 DMF 3 34 
3 3.0 toluene 3 63 
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Table 11. Results of the Pd-catalysed aminoarylations performed on different N-
allyl ureas.  
 
 
a
Ar = 2-naphthyl; 
b
All the substrates were reacted for 3 days, only in the case of entry 2 the reaction 
lasted 2 days; 
c
The starting material was recovered in 15% yield. 
  
Entry
 b
 
N-allyl 
urea 
R 
ArBr
a
 
(eq.) 
NaO
t
Bu 
(eq.) 
product yield (%) 
1 42 H 2.0 1.8 
 
48 
2 45 CH2NHBoc 1.5 2.5 
 
4 
3 54 CH2OH 2.0 1.8 
   
10
c 
4 55 CH2NsNBoc 2.0 1.8 
   
13 
5 56 CH2OMOM 2.0 1.8 
 
35 
6 57 CH2N3 3.0 1.8 
 
5 
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From the N-allyl ureas 42, 56 and 57, the expected imidazolidinones 43, 60 and 61 
were obtained (entry 1, 5 and 6). In the case of the N-Boc substrate 45, the N-arylated 
imidazolidinone 58 was isolated in 4% yield (entry 2). In this reaction, an excess of base 
was employed since no product was recovered by using one equivalent of NaO
t
Bu. 
From the N-allyl urea 55, containing Nosyl-N-Boc amino group, a product of the 
competing Heck reaction,
119 
compound 59, was obtained in 13% yield (entry 4). The 
starting material and the amine precursor, compound 53, were recovered from the 
reaction of the N-allyl urea 54 (entry 3). A mechanistic rationalisation of these reactions 
is provided in Sections 3.2.2.2 and 3.2.2.3. 
3.2.2.1 Determination of the stereochemistal outcome of the Pd-catalysed 
aminoarylation  
The 500 MHz 
1
H-NMR spectrum of the imidazolidinone 43 was studied to help 
assign the relative configuration of the other imidazolidinone products. A nOe 
experiment of the imidazolidinone 43 was performed (Figure 44). A nOe enhancement 
(6%) of the proton 5-HA was recorded when the proton 4-H was irradiated and vice 
versa, while no nOe enhancement was recorded between proton 4-H and 5-HB. 
Therefore a syn relationship was assigned between the proton 4-H and 5-HA. 
 
Figure 44. Results of the nOe experiment on the imidazolidinone 43. No nOe was 
observed between proton 4-H and 5-HB. 
The relative configuration of the imidazolidinones 58, 60 and 61 was assigned on 
the basis of the magnitude of the coupling constant, J, of the diagnostic proton signals in 
the urea ring system, protons 4-H and 5-H. The protons 4-H and 5-HA of the 
imidazolidinone 43 in syn relationship showed a J value of 8.9 Hz, while the protons 4-
H and 5-HB in anti relationship showed a J value of 6.0 Hz. Proton 4-H in the 
imidazolidinones 58, 60 and 61 all showed a J value between 3.0-4.0 Hz, therefore the 
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relative configuration assigned was trans. The magnitude of the observed coupling 
constants was in accordance with the Karplus relation.
120
 A summary of the J values of 
all the synthesised imidazolidinones is provided in the Appendix 3 (Table 24). 
3.2.2.2 Rationalisation of the stereochemical outcome of the Pd-catalysed 
aminoarylation 
The stereochemical outcome of the Pd-catalysed aminoarylation may be 
rationalised using the mechanism reported by Wolfe et al (Scheme 13).
107
 The Pd-
phosphine complex, formed in situ, is proposed to undergo oxidative addition to 2-
bromonaphthalene to start the catalytic cycle of the reaction. Once the urea substrate is 
deprotonated by NaO
t
Bu, an Ar-Pd-amido complex 62 is formed, followed by syn 
insertion across the alkene. From the resulting cyclic urea species 63, the formation of 
the aryl-C bond occurs via a reductive elimination leading to the product and to the 
regeneration of the Pd
(0)
 catalyst. 
 
Scheme 13. Catalytic cycle of the Wolfe reaction. Adapted from Wolfe et al.
1
 
According to the mechanism, the stereo-determining step is the olefin syn addition 
across the alkene which leads to the intermediate 63. The substituent R at the allylic 
postion in the imidazolidinones 58, 60 and 61 determines the facial selectivity of the 
reaction. The N-Pd bond would attack the olefin from the opposite side to the R group, 
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through the favoured conformation 64, favouring the formation of the trans 
imidazolidinones (Scheme 14). 
 
Scheme 14. Rationalisation of the stereochemical outcome of the Pd-
aminoarylation. 
3.2.2.3 Proposed mechanism for the formation of the N-arylated imidazolidinone 
27 
A mechanism for the formation of the N-arylated imidazolidinone 58, obtained 
from the N-allyl urea 45, is here proposed (Scheme 15). Under the high temperature of 
the reaction the Boc group was removed
121,122
 either before or after the product 
formation, therefore, in the Scheme 15 the R group can represent either the Boc group 
or a proton. 
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Scheme 15. Proposed mechanism for the formation of the imidazolidinone 58. 
According to the mechanism proposed, after the formation of the Pd-amido 
complex 67 from the allyurea 66 and the Pd active species 65, the syn addition of the 
olefin would occur. The resulting cyclic intermediate 68 would undergo a hydrogen 
transfer and a concomitant Pd exchange, between the amino group and the carbon 
attached to the Pd, to give a new Pd-N complex 69. The species 69 would undergo a 
reductive elimination to provide the compound 58 and regenerate the catalyst. 
3.2.3 Practicability of the route based upon the Pd-catalysed aminoarylation 
The investigation of the Pd-catalysed aminoarylation on different N-allyl ureas 
showed that the protected alcohol 56 was tolerated under the reaction conditions, giving 
the imidazolidinone 60 in 35% yield. A possible synthetic pathway towards the 
synthesis of the final imidazolidinone 44, starting from the precursor 60 was envisaged 
(Scheme 16).  
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Scheme 16. Envisaged synthetic steps towards the preparation of the target 
imidazolidinone 44. 
The synthesis of the final imidazolidinone 44 would consist of three steps: 
deprotection of the alcohol group, subsequent displacement with azide and final 
reduction to the amino group. The envisaged synthetic pathway would have to be 
applied to each desired compound, making the synthetic route longer and not 
necessarily practical. Moreover, the Pd-catalysed aminoarylation is not known with 
heteroaromatic-containing ureas and the insertion of a heteroaryl group is limited to the 
2-pyridyl group.
1
 Contextually the preparation of the heteroaromatic N-allyl urea 
substrates would need to be planned differently. In Section 3.2.2, the alcohol 53, 
precursor of the N-allyl urea 54, was prepared using the Petasis reaction from aniline, 
but the use of amines containing a heteroaromatic group is not known for the Petasis 
reaction.
116,123 
Due to these considerations, the synthetic route based upon the Pd-
catalysed aminoarylation was not pursued. A potentially more viable synthetic route 
based upon an iodine-mediated cyclisation was investigated (Section 3.3).  
3.3 Synthetic route to the target imidazolidinones based upon an 
iodine-mediated cyclisation reaction  
An alternative synthesis of the target imidazolidinones was investigated according 
to the envisaged retrosynthetic route B (Section 3.1). In this synthesis, the key urea ring 
system would be prepared through an iodine-mediated cyclisation of the N-allyl urea 
substrate. The synthesis was first explored using benzylallylamine, expanding the scope 
of a literature procedure (Section 3.3.1),
124
 and
 
then was extended to the specific N-allyl 
urea substrates (Section 3.3.3).   
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3.3.1 Exploration of synthetic route from benzylallylic amine   
The synthesis of imidazolidinones via an iodine-mediated cyclisation of N-allylurea 
was firstly reported by Moody et al. in 2010.
124 
The reaction, performed on three 
different N-allylurea substrates, gave yields between 67 and 83% (Scheme 17). In order 
to expand the scope of the iodine-medicated cyclisation for our synthetic purpose, the 
preparation of the imidazolidinone 73 was initially attempted (Scheme 18).  
 
Scheme 17. Literature example of iodine-mediated cyclisation of N-allylureas. 
 
Scheme 18. Study of the iodine-mediated cyclisation on benzylallylamine. 
Benzylallylamine 70 was prepared in 47% yield by treating benzyl bromide with an 
excess of allylamine and potassium carbonate. The N-allyl urea 71 was then obtained in 
95% yield by treatment of the benzylallylic amine 70 with phenylisocyanate in CH2Cl2. 
The imidazolidinone 73 was synthesised by treatment of the urea 71 with trimethylsilyl 
trifluoromethanesulfonate and triethylamine in CH2Cl2 and then with iodine in THF. 
The cyclic urea 73 was isolated in 53% yield. Presumably, the reaction proceeds via an 
O-silyl imidate species 72. 
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Subsequently, the synthetic steps for the transformation of the imidazolidinone 73 
into the amine 75 were undertaken (Scheme 19). The iodide 73 was treated with sodium 
azide in DMF to give the azide 74 in a 37% yield. The azide 74 was used without 
further purification in the following reduction. The imidazolidinone 75 was obtained in 
81% yield following a Staudinger reaction, using triphenylphosphine in THF–H2O 
(11:1) with stirring at r.t. for 18 h.
125
 
 
Scheme 19. Conversion of the imidazolidinone 73 into the amine 75. 
3.3.2 Synthesis of the target imidazolidinones  
This synthetic route was then extended to a series of N-allyl urea substrates 
containing a substituent at the allylic position. The choice of the heteroaromatic and 
alkyl groups to incorporate in the N-allyl ureas was determined by the commercial 
availability of the reactants. As a consequence, the initial design of a focused library of 
imidazolidinones (Figure 43, Section 2.4.2) was readapted, taking in consideration 
computational predictions of binding affinity of the new substituent groups against 
BACE-1. The resulting diverse N-allyl ureas selected for the synthesis are illustrated in 
Figure 45. An N-allyl urea substrate without substitution at the allylic position was also 
included in the series.  
 
Figure 45. Structure of the designed N-allyurea substrates for the iodine-mediated 
cyclisation reaction. 
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3.3.2.1 Synthesis of substrates for the iodine-mediated cyclisation 
The use of the building blocks 76 and 77, containing respectively a benzyl and 
isoxazole group at the allylic position, was envisaged for the preparation of the designed 
substituted N-allyl ureas (Scheme 20). The substituted allylic amine 76 was prepared in 
two steps following a literature precedence.
126
 Then, the same reaction conditions were 
applied to prepare the amine 77 (Scheme 21). 
 
 
Scheme 20. Allylic amines building block 76 and 77 for N-allyl ureas. 
 
Scheme 21. Synthesis of the substituted allylic amines 76 and 77, building blocks 
for a variety of N-allyl ureas. 
Benzophenone was condensed with allylamine in presence of titatium isopropoxide 
in toluene at 80 
o
C to give the resulting imine 78 in 98% yield. Deprotonation of the 
imine 78 by n-butyl lithium, followed by addition of the relevant electrophile 
(chloroisoxazole 79 or benzyl chloride), led to formation of the substituted imine 
intermediate which was hydrolysed to give the substituted allylic amine 76 and 77 in 
50% and 49% yield respectively. 
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Reductive amination was employed to prepare a series of secondary amines from 
compounds 76 and 77 and from allylamine (Table 12). In the majority of cases, the 
relevant aldehyde was reacted with the relevant amine in MeOH at r.t. and the resulting 
imine was reduced with sodium borohydride. The products did not require purification. 
The secondary amines 80-83 were obtained in 98%, 45%, 65% and 43% yield 
respectively (entry 1-4). The secondary amine 84 (entry 5) was prepared by treating the 
allylic amine 76 with acetone and magnesium sulfate in EtOH at r.t. and the resulting 
imine was reduced with sodium borohydride to yield the amine 84 in 61% yield.  
Table 12. Synthesis of the secondary amines 80-84, precursors of the N-allyl urea 
substrates for the iodine-mediated cyclisation reaction.  
 
Entry aldehyde product R R1
 
Yield 
(%) 
1 
O
CHO
 
80 
ON  
O
 
98 
2 CHOCl
 
81 
ON  
 
45 
3  82 
 
 
65
 
4 CHOCl
 
83 H 
 
43 
5 
O
 
84 
ON  
 
61
a 
              a
Reaction conditions: 1)Acetone (4 eq.), MgSO4, EtOH, r.t., 2 days; 2)NaBH4 (3.0 eq.),     
          0 
o
C-r.t., 1 day 
 
 
The secondary amines 80-84 were converted into a range of N-allyl ureas (85-92) 
by refluxing with the relevant isocyanate in CH2Cl2 for 1 or 2 days (Table 13). The N-
allyl ureas 85, 88, 89, 90 and 91 (entry 1, 4, 5, 6, 7) were obtained in similar yield, 
CHOCl
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between 77-87%; lower yields, between 58-70%, were achieved with the N-allyl ureas 
86, 87 and 92 (entry 2, 3 and 8). 
Table 13. Preparation of a variety of N-allyl ureas from the amine 85-92. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                             a
Reaction time extended to 2 days 
 
3.3.2.2 Synthesis of a focused library of imidazolidinones 
The iodine-mediated cyclisation and the final steps of the synthesis of the target 
imidazolidinones were initially investigated using the N-allyl urea 85 and then were 
applied to the N-allyl ureas 86 and 87 (Scheme 22). The relevant N-allyl urea was first 
Entry Product R R1 R2 
Yield 
(%) 
1 85 
ON  
O
 O
N  
77 
2
a 86 
ON  
O
 
O
O  
70
  
3 87 
ON  
 
O
N  
58
 
4 88 H 
 
O
N  
82 
5 89 
ON  
 
 87 
6 90 
ON  
 N
 
80
 
7 91 
 
 
O
N  
81 
8
a 92 
ON  
  
68 
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treated with trimethylsilyl trifluoromethanesulfonate and triethylamine in CH2Cl2 at r.t. 
and then with iodine in THF. Due to concerns about the stability of these products, the 
crude products were used in the next step without further purification. The displacement 
of the iodide with sodium azide was achieved by stirring in DMF at r.t. overnight. The 
azide product was obtained with trans relative configuration. The final imidazolidinones 
were obtained by reducing the relative azides under Staudinger
125
 conditions, by treating 
the relevant azide with trimethylphosphine in THF-H2O (11:1). 
 
Scheme 22. Final steps of synthesis of a focused library of imidazolidinones. 
The azide compounds prepared from the N-allyl urea 85, 86 and 87 contained traces 
of triethylamine salt and in some cases the final imidazolidinones contained traces of 
trimethylphosphium oxide. Therefore the iodine-mediated cyclisation on the next N-
allyl urea substrates, 88-92, was performed using DBU base instead of triethylamine, 
and triphenylphosphine was employed in the azide reduction instead of 
trimethyphosphine. The imidazolidinone 96, prepared from the N-allyl urea 86, gave the 
lactam 97 after purification (Figure 46). The results of the synthesis are summarised in 
Table 14. 
 
Figure 46. Imidazolidinone 96 and lactam 97. The lactam 97 was recovered after 
purification by ion exchange column of compound 96.  
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Table 14. Summary of synthesis of a focused library of imidazolidinones. 
 
a
Yield of purified product over two steps; 
b
DBU was employed in place of Et3N; 
c
PPh3 was used in place 
of PMe3; 
d
A trace of triethylamine salt was present; 
e
Trimethylphosphonium oxides was contained in 
10%; 
f
The imidazolidinone 99 was purified by HPLC; 
g
Reaction not attempted; 
h
The products 104, 106 
and 107 were purified by column chromatograpy; 
i
Insufficient material for full characterisation. 
 
Entry 
N-allyl 
urea 
R R1 R2 
Azide 
formation 
yield (%) 
[trans:cis]
a 
Final 
product 
yield (%) 
1 85 
ON  
O
 O
N  
93, 16
d
           
[> 98: < 2] 
trans
d 
94, 18
 
trans
d 
2 86 
 
O
 
 
95, 20           
[> 98: < 2] 
trans 
lactam 97 
 
8
e 
3 87 
  
O
N  
98, 20           
[> 98: < 2] 
trans 
99, 9
f 
4
b 88 H 
 
O
N  
100, 18           
[> 98: < 2] 
trans 
101, 7 
5
b 89 
  
 
102, 7               
[> 98: < 2] 
trans 
-
g 
6
b,c 90 
   
103, 18           
[> 98: < 2]
 
trans 
104, 27
h 
7
b,c 91 
 
 
O
N  
105  
telescoped 
106, 2.5 
over three 
steps
h 
[> 98: < 2]  
trans
 
 
 
8
b,c 92 
ON  
  
107, 13
i
             
[> 98: < 2] 
trans 
<1 mg
h,i 
obtained 
O
O
N
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In general, the yields of the preparation of the azides and amines from the 
substituted N-allyl ureas were surprisingly lower compared to that obtained during the 
synthesis of the imidazolidinone 75 (Section 3.3.1). Presumably the poor yields 
obtained in the synthesis of the azide were affected by the outcome of the iodine-
mediated cyclisation. The iodine-mediated cyclisations were monitored by LCMS and 
TLC and were not quenched until the N-allyl urea starting material was completely 
consumed, but the 500 MHz 
1
H-NMR analysis of the reaction mixture of the iodide or 
of the azide crude revealed the presence of the N-allyl urea precursors in 20-35%. This 
could be explained by the hydrolysis of the O-silyl imidate species, which could lead to 
the N-allyl urea precursors, preventing the formation of the iodide compounds.  
The final amines were also obtained in low yields. The purification of the amines 
through analytical methods, HPLC and mass directed chromatography, gave yields 
between 8-18% (entry 1-4). Better yields, ~28%, were obtained when the amines were 
purified via column chromatography (entry 6-7). Despite the low yields, the synthetic 
route based upon the iodine-mediated cyclisation allowed the preparation of a focused 
library of imidazolidinones to test against the biological target, BACE-1.  
3.3.2.3 Determination of the relative configuration of products 
By analogy to the analysis reported in Section 3.2.2.1, the relative configuration of 
the imidazolidinones in Table 7 was assigned on the basis of J values of the diagnostic 
proton 4-H/5-H. Firstly the protons of the imidazoldinone 75 were assigned by a nOe 
experiment. A nOe enhancement (1.6%) of the proton 5-HA was recorded when the 
proton 4-H was irradiated and vice versa, while no nOe enhancement was showed 
between proton 4-H and 5-HB (Figure 47). Therefore a syn relationship was assigned 
between the proton 4-H and 5-HA. 
 
Figure 47. Results of the nOe experiment on the imidazolidinone 75. No nOe 
enhancement was observed between protons 4-H and 5-HB. 
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The imidazolidinone 75 had a J value of 9.0 Hz between the syn-related protons 4-
H/5-HA, while the J value between the anti-related protons 4-H/5-HB was 5.1 Hz.
124
 The 
protons 4-H/5-H of all the imidazolinone products had J values in the range of 3.5-6.0 
Hz, as a consequence, the relative configuration of those compounds was assigned as 
trans. A summary of the diagnostic J values of all the synthesised imidazolidinones is 
provided in the Appendix 3 (Table 24). 
3.3.2.4 Rationalisation of the stereochemical outcome of the urea ring formation  
The stereochemical outcome of the synthesised imidazolidinones is controlled by 
the formation of the respective cyclic iodine precursors from the N-allyl urea substrates; 
therefore the mechanism of the iodine-mediated cyclisation can provide a rationalisation 
of the stereochemical outcome. The substituted N-allyl urea substrates were first treated 
with triethylamine and trimethylsilyl trifluoromethanesulfonate to presumably form the 
O-silyl imidate species 108 (Scheme 23).  
 
Scheme 23. Rationalisation of the stereochemical outcome of the iodine-mediated 
cyclisation. 
Treatment with iodine is believed to trigger iodonium ion formation, species 109. 
The formation of the iodonium ion species is considered reversible;
127
 therefore the 
stereochemistry of the reaction is likely determined by the intramolecular nucleophilic 
attack of the nitrogen of the urea system onto the iodonium ion. The attack would 
favour the formation of a five-membered ring and the new formed C-I bond would be 
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oriented to the opposite side in respect to the methyl-aryl substituent, avoiding clashing 
interactions. The resulting compound 110 would have trans geometry. 
3.4 Summary 
Two synthetic routes towards the imidazolidinone compounds, putative inhibitors 
of BACE-1, were described in this Chapter. The first one was based upon the Pd-
catalysed aminoarylation on N-allyl ureas, containing different functional groups at the 
allylic position: NHBoc, NsBocN, OH, N3, OMOM. The second one was based upon 
the iodine-mediated cyclisation of N-allyl ureas containing different aromatic group at 
the allylic position.  
The investigation of the Pd-catalysed aminoarylation showed that the N-allyl urea 
56, containing the MOM protected alcohol at the allylic position, was a suitable 
substrate for the reaction, giving the imidazolidinone 60 in 34% yield. Further studies to 
convert the imidazolidinone 60 into the target one, compound 44, containing a primary 
amino group, or to prepare a range of MOM substituted N-allyl ureas, containing 
different heteroaromatic and alkylic group at N atoms, were not carried on.  
The route based upon the iodine-mediate cyclisation was applied to eight different 
N-allyl urea substrates and led to the synthesis of a small family of six target 
imidazolidinones and seven azide precursors. Surprisingly, the yields of the iodine-
mediated cyclisation and of the final two steps of synthesis were low. The biological 
activity of those compounds will be discussed in Chapter 4.  
An analysis of the relative configuration of the imidazolidinones, prepared through 
both synthetic routes, was also described in the Chapter. A summary of the diagnostic J 
value of those compounds is reported in Appendix 3, Table 24. Mechanisms to 
rationalise the stereochemical outcomes of the Pd-catalysed aminoarylation and the 
iodine-mediated cyclisation were also discussed.  
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Chapter 4. Biological activity evaluation of BACE-1 imidazolidinone 
putative inhibitors  
The following Chapter presents results of the biological activity of the synthesised 
imidazolidinone compounds against BACE-1. The biological activity evaluation was 
performed through an in vitro assay based on fluorescence quenching (Section 4.1). 
Initially, measurements of biological activity at single concentration were performed; 
subsequentially dose responses were carried out for selected molecules (Section 4.2). 
After a discussion of the biological results, new structural analogues of active inhibitors 
were synthesised and tested against BACE-1 (Section 4.3). Studies of biological 
selectivity were also performed by assessing the biological activity of selected inhibitors 
against BACE-2, a homologue of BACE-1 (Section 4.4). 
4.1 Assay for biological activity evaluation against BACE-1 
The biological activity of the synthesised imidazolidinone compounds against 
BACE-1 was assessed using an in vitro fluorescent competitive inhibition assay. The 
assay uses a Swedish mutant of BACE-1 natural substrate containing a fluorescent tag, 
FAM, and a quencher, TAMRA, at its two extremities (Figure 49). The distance 
between the fluorescent tag and quencher is such that, under UV light excitation, the 
fluorescence of the donor is quenched.  
 
Figure 48. Swedish mutant of BACE-1 natural substrate containing a fluorescent 
tag and a quencher at its extremities. The peptide sequence of the Swedish mutant at 
the centre of the figure is represented by amino acid symbols. 
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When BACE-1 cleaves the substrate, the fluorescent tag is separated from the 
quencher and a fluorescence signal is emitted. In presence of a BACE-1 inhibitor, the 
substrate cleavage is partially or totally inhibited; as a consequence, the fluorescence 
signal emission is also reduced or suppressed. The difference between the signal 
observed in absence and in presence of a BACE-1 inhibitor is used to assess the 
inhibition. A schematic illustration of the fluorescence quenching assay is provided in 
Figure 49.  
 
Figure 49. Fluorescent quenching assay illustration. A) BACE-1 cleaves the 
substrate, the fluorescent tag, FAM, is separated from the quencher, TAMRA, and it 
emits a fluorescence signals. B) An inhibitor competes with the substrate in interacting 
with BACE-1, therefore the substrate cleavage is partially inhibited and a reduced 
fluorescent emission is observed. 
4.2 Biological activity measurements 
The biological activity of imidazolidinone putative inhibitors was measured at the 
initial concentration of 100 M in DMSO. The commercially-available 
inhibitorsecretase IV (10 M in DMSO) was used in the assay as a positive control; 
DMSO-only (5-10%) was used as a negative control. Details regarding the protocol of 
the fluorescent quenching assay are provided in Section 5.4. The designed 
imidazolidinone compounds 94, 97, 99, 101, 104 and 106, their azide precursors and an 
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iodo precursor, 111,
a 
were assayed. The lipophilic imidazolidinone 43, 60, 73, 74 and 
75, which were not included in the putative inhibitor design but were prepared to 
establish the synthetic route of target compounds, were also assayed. The 
imidazolidinones showing ≥ 25% inhibition were also assayed for a dose response to 
determine their IC50. The ligand efficiency, LE' was calculated from the IC50 values (see 
Equation 2, Section 1.2.3.1, page 8). The results of these in vitro assays are summarised 
in Table 15 and Table 16. In cases in which was not possible to determine the full dose 
response, due to solubility or stability issues, the concentration of the putative inhibitor 
at 50% of inhibition was reported. Examples of dose response curves are illustrated in 
Figure 50 further data are reported in Appendix 4.1.  
                                                 
a
 Intermediate of the synthesis of the imidazolidinone 99. 
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Table 15.  Biological activity of amino and azido imidazolidinones against BACE-1. 
Entry Compound Inhibition at 100 μM (%) IC50 (μM) LE' 
a 
1 
 
33 ± 11 250 ± 4 0.12 
2 
   
39 ± 2 720 ± 20 0.10 
3 
 
17 ± 2 - b - b 
4 
 
13 ± 4 -b -b 
5 
 
9 ± 5 - b - b 
6 
       
12 ± 4 - b - b 
7 
      
6 ± 1 -b - b 
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Entry Compound Inhibition at 100 μM (%) IC50 (μM) LE' 
a 
8 
     
28 ± 5 750 ± 20 c  -d 
9 
             
30 ± 3 590 ± 20 0.10 
10 
          
10 ± 2 - b -b
 
11 
               
8 ± 5 - b -b 
12 
            
no inhibition observed -b -b 
13 
            
7 ± 2 - b -b 
a
LE' calculated as –log(IC50)/nHA (see Equation 2, Section 1.2.3.1); 
b
Not determined; 
c
Concentration at 50% inhibition, 
d
Not calculated, IC50 value not available  
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Table 16. Biological activity of lipophilic imidazolidinones against BACE-1. 
Entry Compound Inhibition at 100 μM (%) IC50 (μM) LE' 
a 
1 
 
34 ± 12 260 ± 20 0.17 
2 
 
28 ± 1 805 ± 13c -d 
3 
 
15 ± 7 - b - b 
4 
    
16 ± 1 - b - b 
5 
 
27 ± 5 260 ± 5c -d
 
a
LE' calculated as –log(IC50)/nHA (see Equation 2, Section 1.2.3.1); 
b
Not determined; 
c
Concentration at 50% inhibition, 
d
Not calculated, IC50 value not available 
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Figure 50. Dose response curves of imidazolidinone 99 and 75 against BACE-1. 
Data fitted with a sigmoidal dose response model using Origin Pro 8.6. 
IC50 = 260 ± 20 M 
IC50 = 250 ± 4 M 
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4.2.1 Analysis of structure-activity relationship 
The biological results obtained with the designed series of imidazolidinones, 
summarised in Table 15, showed that the imidazolidinone 99 (entry 1, IC50 =250 M) is 
the most active compound of the series and contains the best combination of substituent 
groups around the cyclic urea ring. In this compound, the two dimethyl isoxazole 
groups seem to be important for the activity observed. Replacing the dimethyl isoxazole 
at the N-3 with a pyridyl ring (entry 3, compound 104) resulted in an inhibition value at 
single concentration below the 25% threshold (17%). Replacing the dimethyl isoxazole 
at C-5 with a phenyl group (entry 2, compound 106) decreases the activity of 3-fold 
(IC50 = 720 M), and removing the dimethyl isoxazole at C-5 (entry 7, compound 101) 
causes a drastic fall of activity (6% inhibition at 100 M).  
A comparison of the azides 98 (entry 8, IC50 = 750 M) with the amines 99 (entry 
1) shows that the azide group could be a viable surrogate of the primary amine, 
maintaining a moderate activity. This was shown also by the azide 103 (entry 9, IC50 = 
590 M) to compare with the amine 106 (entry 2, IC50 = 720 M). The presence of an 
iodide group (entry 4, compound 111) or of a more constrain cyclic amidic bond (entry 
6, compound 97) reduces significantly the activity (ca. 13% inhibition at 100 M).  
The importance of the dimethyl isoxazole groups at the N-3 and at C-5 was 
observed also in the azide compounds (entry 8-13). The substitution of the dimethyl 
isoxazole at the N-3 (entry 10, compound 102) and the removal of the dimethyl 
isoxazole at the C-5 (entry 13, compound 100) bring the activity below the 25% 
threshold (ca. 10% inhibition at 100 M) in comparison with compound 98 (entry 8). 
Regarding the p-chlorobenzyl substituent, it appears to be preferred in comparison to 
the furan ring or the isopropyl group, as shown by the difference of activity between 
compound 99 (entry 1) and compounds 94 (entry 5, ca. 10% inhibition at 100 M); and 
between compound 102 (entry 10, ca. 10% inhibition at 100 M) and compound 107 
(entry 12, no inhibition observed).  
Among the lipophilic series of imidazolidinones, Table 2, the compound 75 (entry 
1) resulted surprisingly active (IC50 = 260 M), showing an activity similar to the 
designed imidazolidinone 99 in Table 1 (entry 1). The azide analogue (entry 2) of the 
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imidazolidinone 74 demonstrated a lower level of activity (concentration at 50% 
inhibition = 805 M), and the iodide analogue 73 (entry 3) did not show any activity 
(15% inhibition at 100 M); confirming the trend of the imidazolidinones 99, 98, 111 in 
Table 1 (entry 1, 4, 7). It was interesting to note that the compound 60 (entry 5), 
containing a MOM protected alcohol group instead of the primary amine and a bulkier 
aromatic lipophilic substituent at the C-5, was active (27% inhibition at 100 M). 
Unfortunately due to solubility issues, it was not possible to obtain the full dose 
response curve. As expected, the monosubstituted analogue 43 (entry 4) did not display 
any activity (15% inhibition at 100 M). 
In terms of ligand efficiency, the active compounds 99, 106 and 103 (Table 15, 
entry 1, 2 and 9) had similar ligand efficiency values (LE' = 99: 0.12, 106 and 103: 
0.10). The lipophilic compound 75 (Table 16, entry 1) was the most ligand efficient, LE' 
= 0.17; as generally occurred with lipophilic compounds
b
.
32
 The ligand efficiency values 
were generally lower than the predicted ones (cLE' = 99: 0.23, 106: 0.21, 103: 0.20 and 
75: 0.26) and the activity values as well (eHiTS prediction of 10
7
 M inhibitors). 
The structures of the most active compounds were analysed in order to rationalise 
the activity results. As mentioned, the biological results revealed that in the case of the 
imidazolidinone 99 the two dimethyl isoxazole substituents seemed to be fundamental 
for activity (Figure 51). This might suggest that the two dimethyl isoxazoles could be 
involved either in key interactions in BACE-1 catalytic site or that their geometry could 
be more efficient in filling BACE-1 pockets, in comparison to phenyl or pyridine 
groups.  
                                                 
b
Lipophilic compounds generally show higher ligand efficiency but less specific 
interactions with a biological target.  
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Figure 51. Structure activity relationship relevant to the imidazolidinone 99. 
In order to shed light on this outcome, an analysis of the predicted binding poses of 
the imidazolidinones 99 was performed. According to the binding pose predicted by 
eHiTS, the dimethyl isoxazole attached to N-3 of the urea central core could be involved 
in a H-bond with Wat1, positioned between the two catalytic aspartates; while the 
primary amine could act as an H-bond donor and form a H-bond with Glu124 located in 
the flexible region of the protein, called flap (Section 1.3.2). At the same time the 
carbonyl group of the urea could act as a H-bond acceptor and be involved in an H-bond 
with Thr231 (Figure 52, panel A). In terms of protein surface interactions, the dimethyl 
isoxazole group at C-5 is predicted to being accommodated in the S3 pocket of BACE-1 
(Section 1.3.3); the p-chlorobenzyl group is predicted to occupy the S2 pocket, and the 
H-bond with Glu124 is predicted to lock the protein in a semi-closed conformation 
(Figure 52, panel B).  
IC50 = 250 ± 4 M not active not active IC50 = 720 ± 20 M 
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Figure 52. Predicted binding pose of the imidazolidinone 99 in BACE-1. A) 
Representation of the predicted H-bonds (green dotted lines) formed with aminoacidic 
residues in the catalytic site. The primary amine is predicted to form a H-bond with 
Glu124, located in the flexible region of BACE-1, while the O atom of the isoxazole at 
N-3 is predicted to form an H-bond with Wat1. B) Representation of the predicted 
surface interaction. The imidazolidinone 99 is predicted to fill S3 and S2 pockets of 
BACE-1 respectively with the dimethyl isoxazole at C-5 and with the p-chlorobenzyl 
group. Images correspond to the 4S, 5S enantiomer of the imidazolidinone 99, 
visualised by Discovery Studio 3.0.  
A 
B 
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The predicted binding pose of the imidazolidinone 99 seems to help rationalising 
the role of the isoxazoles. Keeping in mind limitations of computational prediction, it 
can still be stated that a dimethyl isoxazole group could interact with the conserved 
water molecule in BACE-1 catalytic site, forming H-bonds with its N or O atoms. 
Furthermore, it is known that heteroaromatic and aromatic groups can often be 
accommodated in BACE-1 pockets (See examples in Section 1.4.4); therefore it is 
plausible that the dimethyl isoxazole group can assume a similar role, and that the two 
methyl groups can contribute to occupy the pockets more extensively in comparison to 
pyridine and phenyl group (Figure 53). 
 
 
Figure 53. Comparison of surface interactions between the imidazolidinone 99 and 
imidazolidinone 105 in BACE-1 catalytic site. A) Representation of surface 
interaction of the imidazolidinone 99 containing the dimethyl isoxazole group. B) 
Representation of surface interaction of the imidazolidinone 99, containing the phenyl 
group. The more extended surface of the dimethylisoxazole ring (A) occupies S3 pocket 
and partially S1 pocket, while the phenyl group (B) occupies only a part of S3 pocket. 
Visualised with Discovery Studio 3.0. 
Regarding the lipophilic monosubstituted imidazolidinone 75 (Table 16, entry 1), it 
was interesting to note that the main structure difference with the inactive analogue 101 
(Table 15, entry 7) was the N-aryl substituent group (Figure 54). This difference might 
suggest that, in this case, the isoxazole group is not involved in critical binding 
interactions. Other type of interactions, such as lipophlic one, might determine the 
activity of the monosubstituted imidazolidinone 75, which might assume a different 
binding pose in BACE-1 catalytic site, in respect to the imidazolidinone 99. 
A B 
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Figure 54. Comparison of two monosubstituted imidazolidinone analogues. The 
active imidazolidinone 75 differs from the not active imidazolidinone 101 mainly for 
the substituent group at N-3. This seems to suggest that lipophilic interactions have an 
important role for the activity of the imidazolidinone 75.  
 Moreover, a comparison between the monosubtituted imidazolidinones 75 and the 
more lipophilic bisubstituted imidazolidinone 60 (Table 16, entry 5), both containing a 
phenyl group, revealed that lipophilic aromatic groups at the “right side” of the urea 
core might play an important role for the activity (Figure 55). In order to investigate 
those lipophilic interactions and to understand the role of the OMOM group, the 
synthesis of a series of analogues of those molecules was designed and prepared 
(Section 4.3). 
 
 Figure 55. Comparison of the imidazolidinone 75 with the lipopophilic compound 
60. 
4.3 Design of structural analogues of active compounds 
A small library of analogues of lipophilic imidazolidinones was designed varying 
the structure of compounds 75 and 60. The analogues were designed in order to identify 
an alternative group to the primary amine and to evaluate the importance of the 
lipophilic interactions (Figure 56). 
IC50 = 260 ± 20 M not active 
IC50 = 260 ± 20 M [M]50% inhibition = 260 ± 5 M 
“right side" “right side" 
lipophilic group 
at C-5  
lipophilic group 
at the N-1 
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Figure 56. Analogues of lipophilic imidazolidinones selected for synthesis. 
4.3.1 Synthesis of monosubstituted analogues 
The alcohol 112 was prepared in two steps from the iodide 73 via displacement of 
iodide with acetate (Scheme 24). The iodide 73 was treated with silver acetate in acetic 
acid to give the intermediate 116 which was used without further purification. The 
intermediate 116 was converted into the alcohol 112 by treatment with potassium 
carbonate in MeOH. The alcohol 112 was obtained in 44% yield over two steps. 
Scheme 24. Synthesis of the alcohol 112. 
The synthesis of the imidazolidinone 113 was attempted using the established 
iodine-mediated cyclisation (Section 3.3.1). Commercially-available methyl allylamine 
was treated with phenylisocyanate in CH2Cl2 to give the urea 117, which was used 
without further purification. The urea 117 was first treated with trimethylsilyl 
trifluoromethanesulfonate and triethylamine in CH2Cl2 at room temperature, and then 
with iodine in THF. The resulting iodide intermediate 118 was mixed with sodium azide 
in DMF at room temperature overnight, giving the azide 119 in 14% yield over three 
steps. Treatment of the azide 119 with triphenylphospine and water in THF did not give 
the expected product (Scheme 25). 
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Scheme 25. Synthetic route towards the preparation of the amine 113. 
4.3.2 Synthesis of bisubstituted analogues 
The imidazolidinone 114 was prepared from the precursor 60 (Section 3.2.2) in one 
step, via deprotection of the MOM group. The compound 60 was treated with few drops 
of hydrochloric acid in MeOH stirring at r.t., giving the alcohol 114 in 42% yield 
(Scheme 26).  
 
Scheme 26. Preparation of the alcohol 114. 
The imidazolidinone 115 was prepared from the amine building block 120 (Scheme 
27). The amine building block 120 was synthesised in 54% yield from the imine 78, 
using a similar methodology to the amines 76 and 77 (Scheme 21, Section 3.3.2.1), by 
treatment with n-butyl lithium and 2-(chloromethyl)naphthalene, followed by base 
hydrolysis. The amine 120 was then treated with acetylchloride and triethylamine in 
CH2Cl2, to give the acetamide 121. The acetamide 121 was reduced to give the ethyl 
allylamine 122 in 88% yield by treatment with lithium aluminium hydride in THF. The 
urea 123 was prepared from the allylamine 122 and phenyl isocyanate in CH2Cl2 in 
47% yield and was employed in the iodine-mediated cyclisation to give imidazolidinone 
124. The urea 123 was treated with trimethylsilyl trifluoromethanesulfonate and 
triethylamine in CH2Cl2 at r.t. and then with iodine in THF. The resulting iodine 
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intermediate was treated with sodium azide in DMF at r.t. overnight to give the azide 
125, which was used without further purification. The azide 125 was treated with 
triphenylphospine and water in THF to give the final imidazolidinone 115 in 25% yield 
over three steps. 
Scheme 27. Synthesis of the imidazolidinone 115. 
4.3.3 Biological evaluation of a second generation of analogues 
The synthesised analogues of lipophilic imidazolidinones, compounds 112, 114 and 
115, and the azide compound 119 were tested against BACE-1 through the established 
in vitro assay. The results are summarised in Table 17. In cases in which it was not 
possible to obtain the full dose response curve, due to solubility issues, the 
concentration at 50% of inhibition observed was reported. 
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Table 17. Biological activity of analogues of lipophilic imidazolidinones against 
BACE-1. 
Entry Compound Inhibition at 100 μM (%) IC50 (μM) LE' 
a 
1 
 
10 ± 1 -b -b 
2 
 
no inhibition observed -b -b 
3 
 
41 ± 12 1170 ± 83c -d 
4 
 
25 ± 3 724 ± 12 0.12 
a
LE' calculated as –log(IC50)/nHA, (see Equation 2, Section 1.2.3.1); 
b
Not determined; 
c
Value of 
concentration at 50% inhibition, 
d
Not calculated, IC50 value not available 
The biological results showed that the alcohol group is not a suitable surrogate of 
the primary amine; since the monosubstituted analogues 112 (entry 1, 10% inhibition at 
100 M) and the bisubstituted analogues 114 (entry 3, concentration at 50% inhibition = 
1170 M) demonstrated lower activity than the respective amino compounds 75 (Table 
16, entry 1, IC50 = 260 M) and 115 (Table 3, entry 4, IC50 = 724M). The benzyl 
group at the N-1 of the urea central core seems to be critical for the activity of the 
monosubstituted series of imidazolidinones. Replacement of the benzyl group with a 
methyl group (compound 119, entry 2) suppressed any activity in comparison with the 
more lipophilic azide 74, (Table 16, entry 2, 28% inhibition at 100 M). These results 
seem to indicate that, in this series of compounds, lipophilic groups at both side of the 
urea central core play a significant role in inhibiting BACE-1. 
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Regarding the series of bisusbtituted imidazolidinones, the analogue 114, 
containing the alcohol group at C-4 (entry 3) displayed activity at single concentration 
above the threshold; but, once again, it was not possible to determine the full dose 
response due to solubility issues. A comparison of the concentrations at 50% inhibition 
revealed that the analogue 114 (entry 3) is ca. 5-fold less active than the analogue 60 
containing the MOM group (Table 16, entry 5, concentration at 50% inhibition = 260 
M). The imidazolidinone 115, containing the amino group (entry 4), displayed modest 
activity: ca. 2.8-fold less than the monosubstituted compound 75 (Table 16, entry 1, 
IC50 =260 M). This might suggest that the best position to incorporate a lipophilic 
group is at N-1, at the “right side” of the urea central core. 
Illustrations of the predicted binding poses of the imidazolidinone 75 are provided 
in Figure 57. The imidazolidinone 75 is predicted to be involved in H-bond and -cation 
interactions with Arg235, located at the top of BACE-1 catalytic site. The H-bond is 
formed through the carbonyl group, while the -cation interactions are formed through 
both benzyl and phenyl group. These interactions seem to direct the primary amine 
towards the water molecules, allowing the formation of H-bonds (Figure 57, panel A). 
In terms of protein surface interactions, the phenyl group is predicted to occupy the S1′ 
pocket of BACE-1, while the benzyl group is predicted to be oriented towards the inner 
without occupying any pocket (Figure 57, panel B).  
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Figure 57. Predicted binding pose of the imidazolidinone 75. A) Representation of 
the predicted H-bonds (green dotted-lines) and -cation interactions (orange dotted 
lines) in BACE-1 catalytic site. B) Representation of the predicted surface interactions: 
the benzylic group is not oriented towards the available pockets (right), the phenyl 
group is accommodated into S1′ pocket (left). Figures represented for the R enantiomer 
of the imidazolidinone 75. Visualised with Discovery Studio 3.0.  
A 
B 
No cavities filled S1′ cavity filled by phenyl group 
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The predicted binding pose of the imidazolidinone 75 might suggest a possible 
explanation about the importance of the aromatic groups for the activity against BACE-
1. When both benzyl and phenyl group are attached to the two N of the urea core, they 
could be oriented in the same direction in BACE-1 catalytic site and be involved in 
common binding interactions (e.g. -sigma, - or -cations interactions or pocket 
filling); which might act as an “anchor point” to direct the rest of the molecule towards 
the catalytic aspartates or Wat1, where the primary amine can form H-bonds. When the 
benzyl group is replaced with an alkyl group (in the case of the imidazolidinone 113, 
Table 17, entry 2) or when a bulkier aromatic group is incorporated in another position 
around the cyclic urea central core (in the case of the imidazolidinone 60, Table 16, 
entry 5), such as a common interaction cannot occur and the imidazolidinone scaffold 
might assume a less effective binding pose. 
4.4 Assessing inhibitor selectivity for BACE-1 
BACE-2 is an homolog of BACE-1, with 75% homology and 45% gene coding 
sequence identity.
128
 BACE-2 is expressed in low level in brain and competes with 
BACE-1 for the same substrate, acting as an antagonist for BACE-1, similar to -
secretase
129
 (Section 1.3.1). The role of BACE-2 in Alzheimer’s disease is not fully 
understood yet, but seems to be marginal in comparison to BACE-1.
130
 BACE-1 
inhibitors are generally tested against BACE-2 in order to determine their selectivity for 
BACE-1. Therefore the two identified BACE-1 inhibitors, the imidazolidinone 99 and 
75, were assayed in vitro against BACE-2 protein to determine their selectivity for 
either protein. 
4.4.1 Biological activity measurements 
The described in vitro fluorescent competitive inhibition assay (Section 4.1) was 
employed to determine the activity of the imidazolidinone 99 and 75 against BACE-2. 
The biological activity was initially measured at 100 M (5-10% of DMSO in buffer); 
then a dose response assay was performed. As for BACE-1, the commercially-available 
inhibitorsecretase IV (100 M in DMSO) was employed as a positive control 
DMSO-only (5-10%) was employed as a negative control. Details regarding the 
execution of the fluorescent quenching assay for BACE-2 are provided in Section 5.4.1. 
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The results of the in vitro assays are summarised in Table 18; dose response curves are 
illustrated in Figure 58 and Figure 59. 
Table 18. Biological activity of imidazolidinones 99 and 75 against BACE-2. 
Entry Compound Inhibition at 100 μM (%) IC50 (μM) 
1 
      
10 ± 3 -a 
2 
      
8 ± 4 647 ± 20 
aNot determined, dose-response not observed. 
 
 
Figure 58. Comparison of activity of the imidazolidinone 99 against BACE-1 and 
BACE-2. Data fitted with a sigmoidal dose response model using Origin Pro 8.6. 
BACE-1: IC50 = 250 ± 4 M 
BACE-2: not active 
 
 
  110  
   
 
Figure 59. Comparison of the dose response curves of the imidazolidinone 75 
against BACE-1 and BACE-2. Data fitted with a sigmoidal dose response model using 
Origin Pro 8.6. 
The imidazolidinone 99 and 75 displayed a similar value of inhibition against 
BACE-2 at single concentration, ca. 10%; but the dose response revealed different 
outcome. The imidazolidinone 75 showed an activity of ca. 647 M, only 2.5-fold less 
active than against BACE-1, suggesting that the activity may stem from non-specific 
interactions. Regarding the imidazolidinone 99, although the IC50 could not be 
determined with BACE-2, the compound showed at least 10-fold selective for BACE-1. 
4.5 Summary 
This Chapter described the evaluation of biological activity of a focused library of 
imidazolidinone putative inhibitors of BACE-1, and of a series of lipophilic analogues. 
The compounds were assayed at a single concentration (100 M) and IC50 values of the 
promising inhibitors were also determined. The best BACE-1 inhibitors, amongst the 
imidazolididones assayed, were compounds 75 and 99, showing an IC50 value of ca. 
250 M.  
BACE-1: IC50 = 260 ± 20 M 
BACE-2: IC50 = 647 ± 20 M 
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The inhibitor 99, belonging to the designed focused library of compounds, showed 
the following key structure features: an hydrophilic dimethyl isoxazole ring at N-3 of 
the urea system, a p-chlorobenzyl group at N-1, another dimethyl isoxazole ring at the 
C-4 position and a primary amine at the C-5 position (Figure 60, panel A). The 
lipophilic imidazolidinone 99, which did not belong to the designed focused library of 
putative inhibitors, contained lipophilic substituents (benzyl and phenyl) at both the N 
atoms of the urea system and a primary amine at the C-4 position (Figure 60, panel B).  
 
Figure 60. Structures of the identified imidazolidinone BACE-1 inhibitors. A) 
Designed imidazolidinone 99, IC50 = 250 M, dimethyl isoxazole groups seem to be 
critical for activity. B) Lipophilic imidazolidinone 75, IC50  = 260 M, aromatic groups 
at the N atoms seem to be critical for activity.  
The designed imidazolidinone 99 demonstrated a good selectivity for BACE-1 vs 
the homolog BACE-2, being at least 10-fold less active against BACE-2. The lipophilic 
imidazolidinone 75, instead, was only 2.5-fold more active against BACE-1 than 
against BACE-2, suggesting that it might bind BACE-1 through non-specific lipophilic 
interactions. Given the good selectivity of the imidazolidinone 99, it can be considered a 
good novel lead molecule to be developed into a more potent BACE-1 inhibitor.  
A B 
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4.6 Conclusion and future directions 
In this thesis a novel approach to design inhibitors was described and validated. The 
approach started with a computational design of a virtual library of skeletally diverse 
virtual lead-like compounds, which was screened in silico against a target protein, 
BACE-1. From the virtual screening, identified putative inhibitors were selected for 
synthesis and tested in vitro through a fluorimetric assay.  
A virtual library of skeletally diverse lead-like compounds was generated on the 
basis of the diversity oriented synthesis approach (DOS) developed within the Nelson 
group. The approach used a virtual protocol of synthesis, in which an initial pool of 
virtual electrophile and nucleophile building blocks underwent a combinatorial virtual 
coupling, followed by a series of virtual chemical reactions: derivatisation, cyclisation 
and further derivatisation (Section 2.3, Figures 34 and 37). The virtual chemical 
reactions employed were previously established experimentally, and only commercially 
available reactants were included in the virtual library enumeration, in order to ensure 
synthetic accessibility as far as possible. A virtual library of ca. 55,000 cyclic lead-like 
molecules was generated. The virtual library was screened against BACE-1 using 
eHiTS software. 
Two families of putative inhibitors of BACE-1 were identified after the vHTS with 
eHiTS: the amino tetrahydropyridine and the imidazolidinone family. Both families 
contained elements of novelty with respect to known BACE-1 inhibitors. The most 
potentially diverse family of imidazolidinone was selected for synthesis (Section 2.4.2). 
A focused library of this family was designed. The key features of the structure of 
imidazolidinones were a primary amine and a series of heteroaromatic or alkyl 
substituent positioned around the cyclic urea central core (Figure 61). According to the 
computational prediction of binding poses of this family, the primary amine would form 
key H-bond interactions with the catalytic Asp32 and Asp228 in BACE-1 catalytic site; 
while heteroaromatic group could fill pockets in BACE-1. 
  113  
   
 
Figure 61. Features of the designed library of imidazolidinones putative inhibitors 
of BACE-1. 
Two synthetic routes were envisaged for the synthesis of the imidazolidinone 
putative inhibitors of BACE-1, both based on a key cyclisation reaction of N-allyl ureas, 
to obtain the cyclic central core of the imidazolidinones. The first synthetic route was 
suggested by the virtual protocol of synthesis employed to enumerate a virtual library of 
lead-like compounds. The route was based upon the Pd-catalysed aminoarylation on N-
allyl ureas containing different functional groups at the allylic position. The second 
synthetic route was based upon the iodine-mediated cyclisation of N-allyl ureas 
containing different aromatic groups at the allylic position (see Scheme 5, Section 3.1, 
page 66).  
The investigation of the Pd-catalysed aminoarylation led to the identification of the 
imidazolidinone 60 (Figure 62), containing the MOM protected alcohol at the 4-CH2 
position, as a precursor of the final imidazolidinone, containing a primary amine at the 
same position. To apply this route to the designed imidazolidinones (Figure 61), further 
investigations regarding the synthesis of specific N-allyl urea substrates, containing 
heteroaromatic groups, were required. At the same time, chemical reactions to convert 
the MOM protected alcohol into a primary amine needed to be explored. As a 
consequence the route was abandoned.  
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Figure 62. Imidazolidinone 60, synthesised through the Pd-catalysed 
aminoarylation. The imidazolidinone 60 was identified as a possible precursor of a 
final imidazolidinone, containing a primary amine at 4-CH2 position. 
The second synthetic route, based upon the iodine-mediated cyclisation, was 
applied to eight different N-allyl urea substrates and led to the synthesis of a small 
library of six target imidazolidinones (Figure 63) and seven azide precursors. 
Surprisingly, the yields of the iodine-mediated cyclisation and of the final two steps of 
synthesis were low. The six target imidazolidinones, the azide precursors and a series of 
lipophilic imidazolidinones (synthesised during the exploration of the two synthetic 
routes) were assayed against BACE-1 through an established in vitro fluorimetric assay. 
 
Figure 63. Focused library of six imidazolidinones, putative inhibitors of BACE-1. 
Two compounds showed inhibitory capacity against BACE-1, with IC50 value of 
ca. 250 M (Figure 60, Section 4.5). The imidazolidinone 99, belonging to the designed 
library of putative inhibitors, showed a good selectivity (10-fold) for BACE-1 over its 
homologue BACE-2. The imidazolidinone 75, belonging to the series of lipophilic 
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compounds, was surprisingly active, but it did not show good selectivity for BACE-1 
over BACE-2; being only 2.5-fold more active against BACE-1. These results 
suggested that the imidazolidinone 99 is likely to interact through promiscuous 
interactions, while the designed imidazolidinone 75 is likely to form specific 
interactions in BACE-1 catalytic site. 
In conclusion, the biological results validated the computational approach 
employed to design a focused library of BACE-1 inhibitors. A novel imidazolidinone 
inhibitor, compound 99, exhibited a M inhibitory capacity, 3-fold lower than the one 
predicted by the eHiTS, nevertheless it showed a good selectivity for BACE-1 over 
BACE-2. Therefore, it can be considered a good lead to be developed in a more potent 
BACE-1 inhibitor. Suggestions towards the optimisation of 99 are herein indicated. 
A common strategy employed to develop initial leads of M activity into potent 
BACE-1 inhibitor is to increase the length of alkyl substituents or adding lipophilic 
groups.
49
 These modifications generally aim to occupy BACE-1 pockets. Following this 
strategy, similar modifications can be suggested to further develop the imidazolidinone 
99. Keeping the two dimethyl isoxazoles in the structure, critical for the activity, and the 
p-chloro benzyl group, which is preferred above a furan ring of an alkyl group (Section 
4.2), the imidazolidinone 99 could be modified at the primary amine. The primary 
amine could be converted into an amide, by reaction with amino acids containing 
aromatic groups. Alternatively it could be modified by simple arylation (Figure 64). The 
aromatic group and the amino acid chains could occupy S2' or S1' BACE-1 pockets, 
which are predicted not to be occupied by the imidazolidinone 99 (Section 4.2.1, Figure 
52).  
  116  
   
 
Figure 64. BACE-1 M inhibitor as lead molecule to develop into more potent 
inhibitors. A) Pyrrolidine compound discovered by Stachel et al.
131
 in 2012, and 
developed in a spiropyrrolidine inhibitor of 0.03 uM. B) Imidazolidinone inhibitor 99, 
to be develop in a more potent inhibitors by addition of alkyl or aromatic groups.  
The described computational approach had two main limitations: the difficulty of 
predicting both synthetic accessibility and inhibitory activity of the designed molecules. 
Regarding the synthetic accessibility, the protocol of synthesis designed in Pipeline 
Pilot was based on Pd-catalysed aminoarylation and was not successful. The 
investigation of the Pd-catalysed aminoarylation showed that functional groups such as 
azide, NHBoc, NsNBoc are not compatible with the reaction conditions. N-Allylurea 
substrates containing those functional groups at the allylic position did not give the 
expected product, or gave it in very low yield (Section 3.2.2, Table 11). Therefore a new 
synthetic route based on the iodine-mediated cyclisation was employed to prepare a 
focused library of imidazolidinones. Unfortunately, apart from few exceptions 
(compound 104, Section 3.3.2.2, Table14, entry 6, and compound 115, Section 4.3.2, 
Scheme 27), the yield of the iodine–mediated cyclisation were poor. In order to improve 
the value of virtual libraries of structurally diverse compounds, designed in silico 
according to our computational approach, it is necessary to refine them as the scope of 
the reactions included in the protocol of synthesis is defined. In our group, Richard 
Doveston has recently exemplified the synthesis of structurally diverse lead-like 
A 
B 
IC50 = 240 M 
 
 
IC50 = 0.07 M 
 
 
IC50 = 0.03 uM 
 
 
IC50 = 250 M 
 
 
R = amino acidic chain (e.g. Phe, Trp, Tyr, His)  
 
 
  117  
   
scaffolds using a robust toolkit of reactions. This toolkit of reactions would be a good 
basis for the design a virtual library of compounds, having a greater of successful results 
in synthesis. 
Regarding the prediction of inhibitory activity of novel molecules against biological 
target, the employed eHiTS software overestimated the potency of the imidazolidinone 
library. The predicted potency of compounds was of 10
-7
 M, while the measured 
potency was of ca. 10
-4
 M. eHiTS was reliable in reproducing the binding pose of the 
known inhibitor 26 (Section 1.4.4 and 2.2) and in predicting its activity (predicted 
activity of 10
-7
 M, real activity 3 M) therefore it seemed to be a good choice to 
perform the vHTS of virtual libraries. As eHiTS requires a reference inhibitor to 
identify protein binding site and to orient new ligands in the protein, it is possible that 
scores of ligand binding poses, which are oriented similarly to the inhibitor of reference 
in the binding site, can be overestimated. It is worth mentioning that SPROUT 
prediction of potency for the imidazolidinone library was more accurate, 10
-4
 M. 
SPROUT scoring function differs from eHiTS scoring functions; in SPROUT pocket 
filling and lipophilic interactions weighted more than H-bond interactions. Therefore it 
is possible that given the characteristic of BACE-1 target, with six pockets available to 
be filled (Section 1.3.3), SPROUT could be more appropriate to predict a more reliable 
score.  
The literature confirmed that prediction of activity of library of compounds against 
specific biological targets is still challenging. It has been reported that many docking 
software are able to reproduce correctly X-ray poses of an inhibitors in a biological 
target, but a reliable prediction of the free energy of binding is still very difficult.
132,133
 
Factors such as protein flexibility and solvent are not always predictable. In this project, 
vHTS was performed in the presence and absence of two water molecules, located in 
the proximity of the catalytic Asp32 and Asp228 residues, and in both cases similar 
docking predictions were obtained. The similarity of outcomes, for displaceable water 
molecules, occurred often with most biological targets.
134
 As general advice, the use of 
more than one docking software can be advantageous in achieving a good prediction of 
potency, and verifying predicted ligand binding poses through
 
X-ray and H
1
 NMR could 
be a good source of information to assess the quality of docking. 
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Despite the discussed limitations of the investigated approach, a novel lead 
molecule with M potency against BACE-1, compound 99, has been successfully 
identified. The importance of the dimethyl isoxazole groups for the compound activity 
is an interesting factor, which has not yet been acknowledged in the literature. Moreover 
the approach opens a new pathway towards ligand identification, which differs from the 
currently used approach of fragment based-drug design or high throughput screening. 
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Chapter 5. Experimental  
5.1 General experimental 
All non-aqueous reactions were performed under an atmosphere of nitrogen unless 
otherwise stated. Water sensitive reactions were performed in oven dried glassware, 
cooled under nitrogen before use, or flame dried, and cooled under vacuum if stated. 
Solvents were removed under reduced pressure using a Büchi rotary evaporator and a 
Vacuubrand PC2001 Vario diaphragm pump, or a Genevac HT-4 evaporation system. 
 
 Tetrahydrofuran, dichloromethane, toluene, ethanol and acetonitrile were dried and 
purified by means of a PureSolv MD solvent purification system (Innovative 
Technology Inc.). Anhydrous N,N-dimethylformamide and 1,4-dioxane was obtained in 
Oxford sure/seal™ bottles from Sigma–Aldrich. All other solvents used were of 
chromatography or analytical grade. Ether refers to diethyl ether and petrol refers to 
petroleum spirit (b.p. 40-60 °C). Commercially available starting materials were 
obtained from Sigma–Aldrich, Fluka, Lancaster, Alfa Aesar or Acros Organics and used 
without further purification unless stated. 
Thin layer chromatography was carried out on aluminium backed silica (Merck silica 
gel 60 F254) plates supplied by Merck. Visualisation of the plates was achieved using 
an ultraviolet lamp (λmax = 254 nm), KMnO4, anisaldehyde or ninhydrin.  Flash column 
chromatography was carried out using silica (35-70 m particles)135 with crude reaction 
mixtures loaded in dichloromethane (CH2Cl2) or the initial solvent system, or pre-
absorbed onto silica. Where specified, flash column chromatography was carried using 
Isolera flash purification system of Biotage SNAP cartridge Kp-Sil instrument (Isolera 
four, version 1.3.3). SNAP cartridge columns of 25 g were used for 1.0-1.5 g of crude 
and SNAP cartridge column 50 g for 3-4 g of crude.  
Mass-directed HPLC purifications were run on an Agilent 1260 Infinity Preparative 
HPLC system equipped with a Waters XBridge™ Prep C18 19 × 100 mm column, 5 μm 
particle size, on an acetonitrile or methanol/water gradient (5-95% acetonitrile or 
methanol over 8 minutes) and an Agilent 6120 Quadrupole system equipped with a 
quadrupole MS detector, using electrospray (ES) ionisation. Semipreparative HPLC 
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purifications were run on a Gynkotec system equipped with a Phenomenex® 
Hyperclone ODS-C18 250 × 10 mm column, 5 m particle size, on an acetonitrile/water 
gradient (5-95% acetonitrile, 0.1% TFA, over 30 minutes).  
All optical rotations were carried out at room temperature on a Perkin-Elmer AA-
1000 with a path length of 1 dm; concentrations are g/100 mL, the optical rotations are 
given in 10
-1
 deg cm
2
 g
-1
 and units are omitted for clarity. Infrared spectra were 
recorded on a Perkin-Elmer One FT-IR spectrometer, the wavelengths (max) are given 
in cm
-1
 and units are omitted for clarity.  
Proton and carbon NMR data were combined on an Avance 500, Bruker DPX500 
and DPX300 spectrometer. All shifts were recorded against and internal standard of 
tetramethylsilane (TMS). Solvents (CDCl3, DMSO-d6 and MeOH-d4) used for NMR 
experiments were obtained from Sigma-Aldrich. Splitting patterns in this report have 
been recorded in an abbreviated manner; app. (apparent), s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet). NMR data was recorded in the following format; 
ppm (number of protons, splitting pattern, coupling constant (Hz), proton ID). Signal 
assignments were made with the aid of COSY, DEPT 90 and 135, HMQC and HMBC. 
NMR spectra were recorded at 300 K, unless stated. 
Low resolution mass spectra data were recorded on a system comprising an Aligent 
1200 series LC system comprising and a Bruker HCT Ultra ion trap mass spectrometer 
using electrospray (ES) ionisation.The system used two solvent systems; MeCN/H2O + 
0.1% formic acid with a Phenomenex Luna C18 50 × 2 mm 5 micron column or 
MeCN/H2O with a Phenomenex Luna C18 50 × 2 mm 5 micron column. 
Nominal and accurate mass spectrometry was routinely performed by Mrs Tanya 
Marinko-Covell on a Waters-Micromass GCT spectrometer using electron impact (EI) 
or on a Bruker Daltronics micrOTOF using ES ionisation. Accurate mass spectrometry 
was also carried out using ES ionization with a Bruker Maxis Impact spectrometer. For 
each compound, data of the most abundant isotope are reported. 
In the experimental procedures for compounds, Session 5.3, novel compounds are 
indicated in italics according to the handbook for postgraduate research students of the 
University of Leeds.References of the preparation are indicated after the name of the 
compounds.  
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5.2 General experimental procedure 
A. General procedure for the preparation of the chiral phosporamidites (S,S aS)-
51 and (R,R aR)-52.
113
 
Triethylamine (4.0 mL, 28.0 mmol) was added slowly to a solution of phosphorus 
trichloride (0.6 mL, 7.0 mmol) in CH2Cl2 (15 mL) at 0 °C, then a solution of the 
relevant amine (bis[(R)-1-phenethyl]amine or bis[(S)-1-phenethyl]amine) (1.6 mL, 7.0 
mmol) in CH2Cl2 (25 mL) was added by dropping funnel over 1 h at 0 °C. The reaction 
mixture was allowed to warm to r.t. and stirred for 18 h, then a solution of the relevant 
naphthol [(R)-BINOL or (S)-BINOL)] (2.0 g, 7.0 mmol) in CH2Cl2 (25 mL) was added 
followed by triethylamine (3.0 mL, 21.6 mmol) by dropping funnel over 1 h at 0 °C. 
The reaction mixture was allowed to warm to r.t., stirred for 5 h and quenched with cold 
water (30 mL) at 0 °C. The phases were separated, the aqueous phase was extracted 
with CH2Cl2 (3 × 25 mL), the combined organic phases were dried (MgSO4) and 
concentrated under reduced pressure to give a crude product. 
B.  General procedure for the preparation of the ureas 42, 45, 54, 71, 85-92 and 
123.
100
 
The relevant isocyanate (2.0-10 eq.) was added slowly to a solution of the relevant 
amine (from 0.4 to 15.0 mmol) in CH2Cl2 (0.20 M) and the reaction mixture was heated 
under reflux and stirred. The reaction was monitored by TLC and LC/MS and, when 
judged complete, the mixture was concentrated under reduced pressure to give a crude 
product. 
C. General procedure for the Pd-catalysed aminoarylation of the N-allyl ureas, to 
give the imidazolidinones 43, 58, 60 and 61.
100
 
Pd2(dba)3 (5 mol%), Xantphos (10 mol%), NaO
t
Bu (1.8 eq.), 2-bromonaphthalen 
(1.5-3.0 eq.) were loaded in a flame-dried round bottom flask and the reaction vessel 
was purged with nitrogen and degassed (four times). The N-allylphenyl urea substrate 
(from 0.2 to 1.35 mmol) and toluene (4.0 mL/mmol of the urea substrate) were added 
and the resulting mixture was stirred at 110 °C for 2-3 days. The reaction was 
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monitored by TLC and LC/MS and, when judged complete, the reaction mixture was 
cooled to r.t. Then a saturated aqueous solution of ammonium chloride (5.0 mL/mmol 
of the urea substrate) was added and the mixture was extracted with EtOAc (3 × 4.0 
mL/mmol of the urea substrate). The combined organic phases were dried (Na2SO4) and 
concentrated under reduced pressure to give a crude product. 
D. General procedure for the preparation of substituted allylic amines 76, 77 and 
120.
126
 
n-Butyl lithium (1.0 eq.) was added dropwise to a solution of the diphenyl 
methylene propenamine 78 (from 18.1  to 29.0 mmol) in THF (0.9 M) at –50 °C and the 
resulting mixture was stirred at – 50 °C for 1 h. The relevant electrophile (1.0 eq.) was 
added portionwise as a solution of THF (6.0 M), the mixture was stirred at –50 °C for 1 
h and quenched with EtOH (0.7-1.2 mL). An aqueous solution of KHSO4 (20% w/v, 1.2 
mL/mmol of the propenamine) was added and the mixture was stirred overnight 
allowing the temperature to warm to r.t. Two phases were formed; the aqueous phase 
was separated, washed with methyl tert-butyl ether (25-35 mL) and CH2Cl2 (2 × 25 
mL), basified at 0 °C with an aqueous solution of NaOH (50% w/v) until pH 10 then 
extracted with CH2Cl2 (2 × 25 mL). The combined organic phases were washed with 
brine (2 × 25 mL), dried (Na2SO4) and concentrated under reduced pressure to give a 
crude product. 
E. General procedure for the reductive amination of substituted allylic amines, to 
give compounds 80, 81 and 83.
136
 
The relevant aldehyde (1.2-2.4 eq.) was added to a solution of the relevant amine 
(from 1.2 to 8.0 mmol) in MeOH (0.20 M) and the resulting mixture was stirred at r.t. or 
heated under reflux for 6-24 h. NaBH4 (3.0-5.0 eq.) was added at 0 
o
C and the mixture 
was stirred at r.t. overnight. The solvent was removed under reduced pressure and the 
crude material was dissolved in EtOAc (~10-20 ml), washed with H2O (2 x 10 mL) and 
brine (2 x 10 mL), dried (MgSO4) and concentrated under reduced pressure to give a 
crude product. 
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F.  General procedure for the preparation of the azides 74, 93, 95, 98, 100, 102, 
103, 105 and 107
124,137
 from allyl ureas. 
 
The iodo intermediates were prepared from the relevant allyl ureas according to the 
procedure of Moody et al.
124
 Triethylamine or DBU (2.0 eq.) and 
trimethylsilyltrifluoromethansulfonate (2.0 eq.) were added to a solution of the relevant 
allyl urea (0.3-1.5 mmol) in CH2Cl2
 
(0.20 M) and the resulting mixture was stirred for 1 
h at r.t., then concentrated under reduced pressure. The crude material was dissolved in 
THF (0.15 M), I2 (2.0 eq.) was added and the resulting mixture was stirred at r.t. or 
heated under reflux overnight. Then the reaction mixture was poured into an aqueous 
solution of Na2S2O3 (20% w/v) and extracted with EtOAc (3 × 7-20 mL). The combined 
organic phases were dried (MgSO4) and concentrated under reduced pressure to give the 
relevant iodo intermediate as a crude product which was used without further 
purification. 
The azide compounds were prepared from the relevant iodo intermediates 
according to the procedure of Knapp et al.
137
 Sodium azide (4.0-6.0 eq.) was added to a 
solution of the relevant iodo intermediate in DMF (0.1 M) at 0 
o
C; the resulting mixture 
was stirred under reflux overnight, allowed to cool at r.t., poured in EtOAc (7-20 mL) 
and washed with H2O (3 x 5.0-15 mL) and brine (2 x 5-15 mL). The organic phase was 
dried (MgSO4) and concentrated under reduced pressure to give a crude product. 
G. General procedure for the reduction of azides, to give the amines 75, 94, 97, 99, 
101, 104, 106 and 115.
138
 
Trimethylphosphine or triphenylphosphine (1.5 eq.) was added to a solution of the 
relevant azide in THF (0.1 M), H2O was added (1/10 of THF volume) and the resulting 
mixture was stirred under reflux for 2-3 days; then concentrated under reduced pressure 
to give a crude product. 
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5.3  Experimental procedures for compounds 
tert-Butyl(2-hydroxyethyl)carbamate
 
47
139
 
 
The title compound was prepared according to the general method of Jia et al.
139
 
Di-tert-butyl dicarbonate (14.5 g, 66.4 mmol) was added slowly at 0 °C to ethanolamine 
(4.0 mL, 66.4 mmol) and the resulting mixture was stirred at r.t. for 1 h. Water (40 mL) 
and EtOAc (40 mL) were added to the reaction mixture and the phases were separated. 
The aqueous phase was extracted with EtOAc (3 × 20 mL) and the combined organic 
phases were washed with brine (20 mL), dried (MgSO4) and concentrated under 
reduced pressure to yield the title protected amine 47 as a colourless oil (10.4 g, 97%), 
which was used without further purification. RF: 0.6 (10:1 CH2Cl2–MeOH); νmax/cm
-1
 
(film) 3358, 2978, 2934, 1693, 1530, 1367, 1280, 1172, 1070, 867; δH (500 MHz; 
CDCl3) 4.96 (1H, br s, NH), 3.70 (2H, q, J  4.8, 2-H2), 3.29 (2H, q, J  4.8, 1-H2), 2.47 
(1H, br s, OH), 1.45 (9H, s, 
tBu); δC (75 MHz, CDCl3) δ 157.2 (CONH), 79.9 (C(
t
Bu)), 
62.9 (C-2), 43.4 (C-1), 28.5 (
t
Bu): m/z (ES) 184.1 (100%, [M+Na]
+
). Characterisation 
data were consistent with those reported in literature.
139
 
 
(E)- Ethyl 4-(tert-butoxycarbonylamino)but-2-enoate 48
140
 
 
The title compound was prepared according to the general method of Crisóstomo  
et al.
140
 Dimethyl sulfoxide (26.0 mL), triethylamine (26.5 mL) and 
(ethoxycarbonylmethylene) triphenylphosphorane (22.0 g, 63.2 mmol) were added to a 
solution of the carbamate 47 (5.1 g, 31.6 mmol) in CH2Cl2 (210 mL). The reaction 
mixture was stirred until all reactants were solubilised, SO3∙Py complex (15.1 g, 91.8 
mmol) was added at 0 °C and the reaction mixture was stirred at r.t. for 36 h. An 
aqueous solution of HCl (1.00 M) was added until pH ~ 2 and the phases were 
separated. The aqueous phase was extracted with CH2Cl2 (3 × 30 mL) and the combined 
organic phases were washed with saturated solution of brine (3 × 50 mL), dried 
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(MgSO4) and concentrated under reduced pressure. The crude product was purified by 
chromatographic column (80:20 petrol–EtOAc), to give the unsaturated ester 48 (1.10 g, 
56%; E:Z >98:< 2) as pale yellow oil. RF: 0.6 (60:40 petrol–EtOAc); νmax/cm
-1
 (film) 
3361, 2980, 2933, 1721, 1662,1523, 1367, 1174, 1042, 867; δH (500 MHz; CDCl3) 6.88 
(1H, dt, J 15.7 and 6.1, 3-H), 5.91 (1H, d, J 15.7, 2-H), 4.65 (1H, br. s, NH), 4.19 (2H, 
q, J 7.1, ethyl 1-H2), 3.92 (2H, app. br s, 4-H2), 1.45 (9H, s, 
t
Bu), 1.28 (3H, t, J 7.1, 
ethyl 2-H3); δC (75 MHz; CDCl3) 166.1 (CO2Et), 155.5 (CONH), 144.7 (C-3), 121.6 (C-
2), 80.0 (C(
t
Bu)), 60.5 (ethyl C-1), 41.5 (C-4), 24.5 (
t
Bu), 14.3 (ethyl C-2); m/z (ES) 
252.1 (100%, [M+Na]
+
). Characterisation data were consistent with those reported in 
literature.
140
  
 
 (E)-tert-Butyl(4-hydroxybut-2-en-1-yl)carbamate 49
111
 
 
The title compound was prepared according to the general method of Moriwake et 
al.
111
 The unsaturated ester 48 (3.1 g, 13.6 mmol) was dissolved in dry CH2Cl2 (31 mL) 
at −78 °C and trifluoride etherate (1.9 mL, 4.1 mmol) was added. The reaction mixture 
was stirred at −78 °C for 30 min, then diisobutylaluminium hydride in hexane (41 mL, 
41.0 mmol, 1.0 M) was added slowly and the reaction mixture was stirred at −78 °C for 
90 min. The reaction mixture was quenched with an aqueous saturated solution of 
NH4Cl (30 mL) and filtered on Celite
®
 eluting with EtOAc. The phases were separated, 
the aqueous phase was extracted with EtOAc (3 x 7.0 mL), the combined organic 
phases were washed with brine (3 x 7.0 mL), dried (MgSO4) and concentrated under 
reduced pressure to give a crude product which was purified by column chromatography 
(50:50 petrol–EtOAc) to yield the alcohol 49 as a yellow oil (0.98 g, 38%). RF: 0.5 
(30:70 petrol–EtOAc); νmax/cm
-1
 (film) 3350, 2978, 2930, 1693, 1526, 1366, 1252, 
1171, 970; δH (500 MHz; CDCl3) 5.78 (1H, dt, J 15.7 and 5.0, 2-H), 5.72 (1H, dt, J 15.7 
and 5.1, 3-H), 4.59 (1H, br s, NH), 4.13 (2H, d, J 5.1, 4-H2), 3.75 (2H, app.br.s, 1-H2), 
1.44 (9H, s, 
t
Bu); δC (75 MHz; CDCl3) 155.9 (CONH), 130.8 (C-2), 129.0 (C-3), 79.6.1 
(C(
t
Bu)), 63.1 (C-4), 42.0 (C-1), 28.7 (
t
Bu); m/z (ES) 210.1 (100%, [M+Na]
+
). 
Characterisation data were consistent with those reported in literature.
111
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 (E)-tert-Butyl(4-methoxycarbonyl)oxy)but-2-en-1-yl)carbamate 46
141
 
 
The title compound was prepared according to the general method of Gramm et 
al.
141
 Methyl chloroformate (0.55 mL, 7.2 mmol) and pyridine (0.58 mL, 7.2 mmol) 
were added and to a solution of the alcohol 49 (1.0 g, 5.55 mmol) in CH2Cl2 (14 mL) at 
0 °C. The reaction mixture was stirred for 1 h at 0 °C, allowed to warm up to r.t. and 
stirred overnight. An aqueous solution of NH4Cl (1.0 M, 10 mL) was added, the phases 
were separated, the aqueous phase was extracted with CH2Cl2 (3 × 3.0 mL). The 
combined organic phases were dried (MgSO4) and concentrated under reduced pressure 
to give a yellow oil that was purified by flash chromatography (99:1 CH2Cl2–MeOH) to 
give the carbamate 46 as a pale yellow oil (0.88 g, 65%). RF: 0.6 (97:3 CH2Cl2–MeOH); 
νmax/cm
-1
 (film) 3351, 1750, 1696, 1236, 1168, 944, 792; δH (500 MHz; CDCl3) 5.82 
(1H, dt, J 15.3 and 4.8, 2-H), 5.72 (1H, dt, J 15.3 and 5.9, 3-H), 4.60 (2H, dd, J 5.9 and 
0.7, 4-H2), 4.56 (1H, br.s, NH), 3.78 (3H, s, OMe), 3.56 (2H, app.br.s, 1-H2), 1.44 (9H, 
s, 
tBu); δC (75 MHz; CDCl3) 156.1 (CO2Me), 155.6 (CONH), 132.5 (C-2), 124.9 (C-3), 
84.5 (C(
t
Bu)), 67.7 (C-4), 54.9 (OCH3), 41.5 (C-1), 28.5 (
t
Bu); m/z  (ES) 268.1 (100%, 
[M+Na]
+
). Characterisation data were consistent with those reported in literature.
141
  
 
tert-Butyl 2-(phenylamino)but-3-enylcarbamate 50
115
 
 
THF (2.5 mL) and n-butyl amine (4.8 μL, 50 mol) were added to the 
[Ir(dbcot)Cl]2 complex (20.4 mg, 25 μmol), phosphoramidites S,S aS-51 (13.1 mg, 25 
μmol) and R,R aR-52 (13.1 mg, 25 μmol). The reaction mixture was stirred at 50 °C for 
45 minutes, then the allyl carbonate 46 (0.30 g, 1.2 mmol) and aniline (167 μl, 1.8 
mmol) were added and the resulting mixture was stirred at 55°C for 18 h. The solvent 
was removed under reduced pressure and the crude product was purified by flash 
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chromatography (80:20 petrol–EtOAc) to give the title allyl phenylamine 50 as a 
colourless amorphous solid (0.22 g, 69%). RF: 0.7 (66:33 petrol–EtOAc); νmax/cm
-1
 
(film) 3388, 3321, 1667, 1603, 1517, 1498, 1165, 919; δH (500 MHz; CDCl3) 7.15 (2H, 
dd, J 8.5 and 7.3, phenyl 3- and 5-H), 6.70 (1H, app. t, J  7.3, phenyl 4-H), 6.61 (2H, dd, 
J 8.5 and 0.9, phenyl 2- and 6-H), 5.77 (1H, ddd, J 17.2, 10.5 and 5.3, 3-H), 5.31 (1H, d, 
J 17.2, 4-HA), 5.22 (1H, d, J 10.5, 4-HB), 4.80 (1H, s, NHBoc), 4.18 (1H, s, NHPh), 
3.95 (1H, app. dt, J 7.7 and 5.3, 2-H), 3.40-3.22 (1H, m, 1-HA), 3.29 (1H, ddd, J 13.8, 
7.7 and 6.1, 1-HB), 1.45 (9H, s, 
tBu); δC (75 MHz; CDCl3) 157.7 (CONH), 137.2 
(phenyl C-1), 129.4 (phenyl C-3-and C-5), 117.7 (phenyl C-4), 117.1 (C-3), 117.0 (C-
4), 113.5 (phenyl C-2 and C-6), 79.9 (C(
t
Bu)), 57.3 (C-2), 45.1 (C-1), 28.5 (
t
Bu); m/z 
(ES) 263.17 (100%, [M+H]
+
), HRMS Found: 263.1743 (C15H22N2O2, requires [M+H] 
263.1754).  
 
Dibenzo[a,e]cyclooctatetraene (dbcot)
142
 
 
The title compound was prepared from α,α’-dibromo-o-xylene according to the 
general method of Wuld et al.
142
 Under an atmosphere of argon, lithium (granular dry, 
high in sodium) (0.79 g, 113.5 mmol) was added to THF (24 mL). α,α’-dibromo-o-
xylene (5.0 g, 18.4 mmol) was dissolved in THF (7.5 mL) by sonication and added  
portionwise to the lithium solution at 0 °C, to give a grey suspension that was allowed 
to warm to r.t. and then sonicated for 3 h. The solution was separated from the residual 
lithium via syringe and the solvent removed under reduced pressure to give a pale 
yellow oil that was dissolved in EtOAc. Florisil (17.7 g) was added, the solvent was 
removed under reduced pressure and the resulting mixture was purified eluiting through 
a silica plug (95:5 cyclohexane–EtOAc) to give the 5, 6, 11, 12-
tetrahydrodibenzo[a,e]cycloctadiene 126, (1.54 g, 40%) as a colourless amorphous 
solid. RF: 0.6 (80:20 cyclohexane–ether); νmax/cm
-1
 (film) 3060, 3015, 2933, 2869, 2246, 
1490, 1450, 1159, 1047; 909; 720; 690; δH (500 MHz; CDCl3) 7.27-7.24 (8H, m, Ar 
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CH), 7.01-6.97, 3.06 (8H, s, 4 x CH2); δC (75 MHz; CDCl3)
c 
140.2 (C-13, C-14, C-15- 
and C-16), 129.8 (C-2, C-3, C-8 and C-9), 126.2 (C-1, C-4, C-7 and C-8), 35.4 (C-5, C-
6, C-11- and C-12); m/z (EI) 208.1 (100%, [M+H]
+
). Characterisation data were 
consistent with those reported in literature.
142
 
N-Bromosuccinimide (2.96 g, 14.9 mmol), recrystallised (water), was added to a 
solution of 126 (1.54 mg, 7.4 mmol) in CCl4 (52 mL) and the resulting mixture was 
stirred at 90 °C for 24 h under air. The reaction was allowed to reach r.t. and filtered; 
the solvent was removed under reduced pressure and the crude material was washed 
with water and sonicated. The water removed by azeotropical drying with toluene to 
give 5, 11-dibromo-5, 6, 11, 12-tetrahydrodibenzo[a,e]cycloctene 127, as an orange 
amorphous solid (2.4 g, 85%). RF = 0.5 (80:20 cyclohexane–ether); νmax/cm
-1
 (film) 
3063, 2928, 1715, 1601, 1489, 1450, 1146, 908; δH (500 MHz; CDCl3) 7.22-6.84 (8H, 
m, 8 x Ar CH), 5.34 (2H, dd, J 11.2 and 8.5, CHBr), 4.30 (2H, dd, J 14.2 and 11.3, 
CHAHB), 3.66 (2H, dd, J 14.3 and 8.5, CHAHB); δC (75 MHz; CDCl3)
d 
138.4 (C-13 and 
C-16), 136.4 (C-14 and C-15), 130.9 (C-4 and C-10), 130.8 (C-1 and C-7), 129.1 (C-3 
and C-9), 127.9 (C-2 and C-8), 52.9 (C-5 and C-11), 43.7 (C-6 and C-12); m/z (EI) 
285.0 (30%, [M−Br]+), 79.9 (30%, [Br]+). Characterisation data were consistent with 
those reported in literature.
142
 
A solution of the dibromide 127 (2.4 g, 6.8 mmol) in THF (67 mL) was added at 0 
°C to a suspension of 
t
BuOK (12.2 g, 109.3 mmol) in THF (150 mL). The reaction 
mixture was allowed to warm to r.t., stirred for 18 h and quenched with water (50 mL) 
at 0 °C. The phases were separated, the aqueous phase was extracted with chloroform (3 
× 35 mL), the combined organic phases were dried (MgSO4) and concentrated under 
reduced pressure to give a brown solid that was re-dissolved in CHCl3. Florisil (7.0 g) 
was added, the solvent was removed under reduced pressure and the crude product was 
purified by flash chromatography with Biotage instrument (gradient elution petrol–
                                                 
c
 Numbering according to the literature:   
d Numbering according to the literature:   
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EtOAc 100:0 → 95:5 in 10 column volumes) to give the dbcot as a colourless needle 
solid (0.34 g, 25%). RF: 0.3 (petrol–Et2O); m.p. 107-109 [lit. 109 
o 
C];
143
 νmax/cm
-1
 (film) 
3047, 3008, 1950, 1922, 1476, 1446, 1208, 1093, 1041, 976; δH (500 MHz; CDCl3) 7.17 
(4H, dd, J 5.7 and 3.4, 1-, 4-, 7- and 10-H), 7.07 (4H, dd, J 5.6 and 3.4, 2-, 3-, 8- and 9-
H), 6.77 (4H, s, 5-, 6-, 11- and 12-H)
e
; δC (75 MHz; CDCl3) 137.2 (C-13, C-14, C-15 
and C-16), 133.4 (C-5, C-6, C-11 and C-12), 129.3 (C-2, C-3, C-8 and C-9), 126.9 (C-1, 
C-4, C-7 and C-10); m/z (EI) 204.1 (100%, [M+H]
+
). HRMS Found: 204.0939 (C16H12, 
M+H requires 204.0950. Characterisation data were consistent with those reported in 
literature.
142
 
 
Chloro(dibenzo[a,e]cyclooctatraene)iridium(I)dimer, [Ir(dbcot)Cl2]
112
 
 
The title compound was prepared according to the general method of Crabtee et 
al.
112
 A solution of the dbcot (118 mg, 0.57 mmol) in CH2Cl2 (4.5 mL) was added by 
dropping funnel to solution of the [Ir(cod)Cl]2 complex in CH2Cl2 (3.5 mL) and  stirred 
for 20 minutes. The reaction mixture changed from red to yellow colour, the solvent 
was reduced to ca. 3.0 mL under flow of N2 and cyclohexane (8.0 mL) was added 
slowly. The precipitated was filtered and dried under reduced pressure to give the 
Iridium complex [Ir(dbcot)Cl2] as a yellow amorphous solid (136 mg, 28%). νmax/cm
-1
 
(film) 3066, 3020, 2978, 1488, 1462, 1384, 1218, 1003, 916, 829, 747; δH (500 MHz; 
CDCl3); 6.99 (4H, dd, J 5.6 and 3.3, 1-, 4-, 7- and 10-H), 6.85 (4H, dd, J 5.7 and 3.2, 2-, 
3-, 8- and 9-H), 5.32 (8H, s, 5-, 6-, 11- and 12-H); δC (75 MHz; CDCl3) 145.8 (C-5, C-
6, C-11 and C-12), 126.8 (C-2, C-3, C-8 and C-9), 126.2 (C-1, C-4, C-7 and C-10), 63.9 
(C-13, C-14, C-15 and C-16); m/z (EI) 864.0 (100%, [M+H]
+
). Characterisation data 
were consistent with those reported in literature.
112
  
                                                 
e 
Numbering according to the literature:  
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 (S,S aS)-O,O’-[1,1’-binaphthyl-2,2’-diyl-N,N’-bis[1-phenethyl]phosphoramidite 
51
113,144
 
 
The title compound 51 was prepared in 75% yield according to the general method 
of Mikhel et al.
113
 described in general procedure A. The crude product was purified 
by flash chromatography (95:5 petrol–EtOAc) to give a colourless needle solid. RF: 0.7 
(80:20, petrol-EtOAc); m.p. 85-87 
o
C [lit. 88-89 
o
C
145]; [α]D
25
: +16.5º (c. 1, CHCl3) [lit. 
[α]D
22
 +202 (c.0.79, CHCl3)
146]; νmax/cm
-1
 (film) 3059, 2970, 1591, 1463, 1373, 1327, 
1230, 1070, 946, 817; δH (500 MHz; CDCl3) 8.00 (1H, d, J 8.8 Ar CH), 7.92 (1H, dd, J 
8.8 Ar CH), 7.81 (1H, d, J 8.4 and 1.2 Ar CH), 7.73 (1H, dd, J 8.7 Ar CH), 7.57 (1H, d, 
J 8.7 and 0.9 Ar CH), 7.44-7.32 (4H, m, Ar CH), 7.30-7.15 (13H, m, Ar CH) , 4.42 (2H, 
dq, J 11.0 and 7.0 NCH), 1.68 (6H, d, J 7.1, CH3); δC (75 MHz; CDCl3) 150.9, 150.8 
(Ar C), 150.1, 143.5 (Ar CH), 133.3 (2 x Ar C), 133.2 (2 x Ar C), 131.8, 130.8, 130.7, 
130.0, 128.7, 128.5 (Ar CH), 128.4 (2 x Ar CH), 128.1 (2 x Ar CH), 127.7, 127.5 (Ar 
CH), 127.1 (Ar CH), 126.5, 126.3, 125.2, 124.7, 122.9 (Ar CH), 122.8, 122.7 (Ar CH), 
121.6, 121.5 (Ar C), 55.0, 54.9 (NCH), 23.5, 23.3 (CH3);  2 X Ar C not observed; m/z 
(ES)
 
540.21 (100%, [M+H]
+
). HRMS Found: 540.2087 (C36H30NO2P M+H requires 
540.2085). Characterisation data were consistent with those reported in literature.
144  
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 (R,R aR)-O,O’-[1,1’-binaphthyl-2,2’-diyl-N,N’-bis[1-phenethyl]phosphoramidite, 
52
113
 
 
The title compound 52 was prepared in 57% yield according to the general method 
of Mikhel et al.
113
 described in general procedure A. The crude product was purified 
by flash chromatography with Biotage instrument (gradient elution petrol–EtOAc 100:0 
in 2 column volumes → 80:20 in 6 column volumes, dry loading of crude in 7.0 g of 
Florisil, loaded in 50 g SNAP cartridge column) to give a colourless needle solid. RF: 
0.7 (80:20, petrol-EtOAc); m.p. 84-86 
o
C [lit. 88-89 
o
C
145
]; [α]D
25: −13.1º (c 1.0, 
CHCl3); νmax/cm
-1
 (film) 3058, 2969, 1590, 1463, 1327, 1230, 1117, 1070, 948; δH (500 
MHz; CDCl3) 8.00 (1H, d, J 8.8, Ar CH), 7.92 (1H, d, J 8.2, Ar CH), 7.81 (1H, dd, J 8.4 
and 0.4, Ar CH), 7.73 (1H, d, J 8.8, Ar CH), 7.58-7.56 (1H, m, Ar CH), 7.44-7.31 (4H, 
m, Ar CH), 7.29-7.13 (13H, m, Ar CH), 4.42 (2H, dq, J 10.8 and 7.0, NCH), 1.69 (6H, 
d, J 7.1, CH3); δC (75 MHz; CDCl3) 151.2, 151.1 (Ar C), 150.4, 143.7 (Ar CH), 133.6, 
133.5 (Ar C), 133.4 (2 x Ar C), 132.0, 131.1, 131.0, 130.2, 128.9, 128.8, 128.7, 128.6 
(Ar CH), 128.4 (2 x Ar CH), 127.9, 127.8, 127.3, 126.7, 126.5, 125.4, 125.0 (Ar CH), 
124.9, 124.8 (Ar C), 123.2, 123.1, 123.0 (Ar CH), 121.9, 121.8 (Ar C), 55.2, 55.1 
(NCH), 23.7, 23.6 (CH3); m/z (ES)
 
540.21 (100%, [M+H]
+
). HRMS Found: 540.2087 
(C36H30NO2P M+H requires 540.2089). Characterisation data were consistent with those 
reported in literature.
113
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tert-Butyl 2-(3-ethyl-1-phenylureido)but-3-enylcarbamate 45
100
 
 
 
The title compound 45 was prepared from allyl amine 50 (0.26 g, 1.0 mmol) and 
ethylisocyanate (0.6 mL, 5.0 mmol) in CH2Cl2 at 35 °C, according to general 
procedure B.
100 
The crude product was purified by flash chromatography (petrol–
EtOAc 66:33) to give a pale amorphous solid (58% yield). RF: 0.2 (66:33, petrol-
EtOAc); νmax/cm
-1 
(film) 3344, 2975, 2930, 1710, 1650, 1514, 1274, 1173, 927, 709; δH 
(500 MHz; CDCl3) 7.41 (2H, app. t, J 7.4, phenyl 2- and 6-H), 7.36 (1H, app.t, J 7.4 
phenyl 4-H), 7.18 (2H, d, J 7.4 phenyl 3- and 5-H), 5.71 (1H, ddd, J 17.4, 10.2 and 7.5, 
3-H), 5.17 (1H, dt, J 17.4 and 1.1, 4-HA) 5.13 (d, J 10.2, 4-HB), 5.00 (1H, app.tdd, J 7.5, 
6.8 and 0.5, 2-H), 4.02 (1H, br. s, NHEt), 3.50-3.38 (1H, m, 1-HA), 3.34-3.10 (3H, m, 1-
HB and ethyl 1-H2), 1.43 (9H, s, 
t
Bu), 1.01 (3H, t, J 7.19, ethyl 2-H3);  δC (75 MHz; 
CDCl3) 162.2 (NCONH) 157.9 (COOtBu), 137.7 (phenyl C-1), 135.6 (C-3), 130.9 
(phenyl C-2 and C-6), 130.3 (phenyl C-3 and C-5), 128.8 (phenyl C-4), 118.6 (C-4), 
80.2 (C(
t
Bu)3), 58.8 (C-2), 43.5 (ethyl C-1), 35.9 (C-1), 28.8 (
t
Bu), 15.9 (ethyl C-2); m/z 
(ES) 356.19 (100%, MNa
+
); HRMS Found: 356.1945 (C18H27N3O3 M+Na requires 
356.1951).  
 
2-(Phenylamino)but-3-en-1-ol 53
123
 
 
Vinylboronic acid pinacol ester (3.3 mL, 20.0 mmol) was added to a solution of  
glycoaldehyde dimer (1.20 g, 10.0 mmol) in water (100 mL) and the resulting mixture 
was stirred at 50
 
°C for 45 minutes, then allowed to warm to 30 °C. A solution of aniline 
(1.8 mL, 20.0 mmol) in THF (25 mL) was added and the resulting mixture was stirred 
for 4 days at 30 °C. An aqueous solution of HCl (1.0 M) was added until pH 1 and the 
mixture was extracted with CH2Cl2 (3 × 50 mL); then the combined aqueous phases 
were basified with an aqueous solution of NaOH (2.0 M) until pH 12 and extracted with 
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CH2Cl2 (3 × 100 mL). The combined organic phases were dried (Na2SO4) and 
concentrated under reduced pressure to give a crude product which was purified by 
flash chromatography (petrol–EtOAc 60:20) to give the title compound 53 as a yellow 
oil (1.5 g, 45%). RF: 0.6 (20:80, petrol–EtOAc; νmax/cm
-1
 (film); 3392, 2933, 1602, 
1504, 1317, 1031, 926, 751; δH (500 MHz; CDCl3) 7.17 (2H, dd, J 8.5 and 7.3, phenyl 
2- and 6-H), 6.74 (1H, dd, J 7.3 and 0.9, phenyl 4-H), 6.67 (2H, dd, J 8.5 and 0.9, 
phenyl 3- and 5-H), 5.81 (1H, ddd, J 17.3, 10.4 and 5.4, 4-H), 5.32 (1H, d, J 17.3, 3-
HA), 5.25 (1H, d, J 10.4, 3-HB), 4.04 (1H, app. q, J 6.0, 2-H), 3.95 (1H, br. s, NH), 3.8 
(1H, dt, J 6.9, 5.5, 1-HA), 3.67-3.61 (1H, m, 1-HB), 1.80-1.77 (1H, m, OH); δC (125 
MHz; CDCl3) 147.3 (phenyl C-1), 136.3 (C-3), 129.2 (phenyl C-2 and C-6), 118.1 
(phenyl C-4), 117.4 (C-4), 113.9 (phenyl C-3 and C-5), 64.9 (C-1), 57.6 (C-2); m/z (ES) 
146.1 (100%, fragment [C10H11NH]
+
); HRMS Found: 164.1082 (C10H13NO requires 
M+H 164.107). 
 
3-Ethyl-1-(1-hydroxybut-3-en-2-yl)-1-phenylurea 54
2 
 
Ethylisocyanate (1.0 mL, 12.8 mmol) was added at 0 °C to a solution allyl amine 
53 (1.0 g, 6.4 mmol) in  CH2Cl2 (27 mL) and the resulting mixture was stirred at 0 °C 
for 2 hours, then allowed to warm to r.t. and stirred overnight. Another equivalent of the 
ethylisocyanate was added to the reaction and the resulting mixture was stirred at r.t. for 
2 days. The solvent was removed under reduced pressure to give a crude product which 
was purified by flash chromatography (petrol–EtOAc 60:40) to give the title compound 
54 as a yellow oil (1.2 g, 80%). RF: 0.4 (50:50, petrol-EtOAc); νmax/cm
-1
 (film) 3440, 
3368, 2972, 2932, 1643, 1595, 1515, 1282, 1065, 711; δH (500 MHz; CDCl3) 7.45-7.43 
(2H, m,  phenyl 2- and 6-H), 7.40-7.36 (1H, m, phenyl 4-H), 7.26-7.23 (2H, m, phenyl 
3- and 5-H), 5.75 (1H, ddd, J 17.4, 10.4 and 7.4, 3-H), 5.20 (1H, dt, J 17.4 and 1.3, 4-
HA), 5.19-5.18 (1H, m, 4-HB), 4.83 (1H, ddd, J 8.5, 7.4 and 4.1, 2-H), 4.07 (1H, br. s, 
NH), 3.84 (1H, ddd, J 11.5, 4.1 and 3.9, 1-HA), 3.74-3.67 (1H, m, 1-HB), 3.57 (1H, dd, J 
8.8 and 3.3, OH), 3.19 (2H, dq, J 7.2 and 5.6, ethyl 1-H2), 1.01 (3H, t, J 7.2, ethyl 2-H3); 
δC (125 MHz; CDCl3) 158.4 (CO), 139.8 (phenyl C-1), 134.2 (C-3), 130.1 (phenyl C-2 
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and C-6), 129.9 (phenyl C-3 and C-5), 128.4 (phenyl C-4), 118.2 (C-4), 64.8 (C-1), 62.8 
(C-2), 35.6 (ethyl C-1), 15.4 (ethyl C-2); m/z (ES) 257.0 (100%, [M+Na]
+
); HRMS 
Found: 257.1268 (C13H18N2O requires M+Na 257.1260).  
 
tert-Butyl 2-(3-ethyl-1-phenylureido)but-3-enyl(2-nitrophenylsulfonyl)carbamate 
55
147
 
 
tert-Butyl 2-nitrophenylsulfonylcarbamate (0.31 g, 1.0 mmol) was added to a 
solution of the phenyl urea 54 (0.20 g, 0.85 mmol) in THF (8.5 mL) at 0 °C, followed 
by triphenylphosphine (0.33 g, 1.3 mmol) and by a dropwise addition of diethyl 
azodicarboxylate (0.2 mL, 1.27 mmol). The resulting mixture was stirred at 0 °C for 3 h 
then allowed to warm to r.t. and stirred overnight. The reaction mixture was diluted with 
EtOAc (40 mL), washed with an aqueous solution of HCl (1.0 M) (2 × 15 mL), with a 
saturated aqueous solution of NaHCO3 (2 × 15 mL) and brine (2 × 15 mL). The 
combined organic phases were dried (Na2SO4) and concentrated under reduced pressure 
to give a crude product which was purified by flash chromatography (CH2Cl2–MeOH 
98.5:1.5) to give the title compound 55 as a pale yellow oil (0.2 g, 53%). RF: 0.55 (98:2, 
CH2Cl2 –MeOH); νmax/cm
-1
 (film) 3508, 3004, 2145, 1704, 1660, 1422, 1367, 1230, 
1093, 904; δH (500 MHz; CDCl3) 8.34-8.31 (1H, m, Ns 3-H), 7.74-7.71 (3H, m, Ns 4-, 
5- and 6-H), 7.45-7.40 (2H, m, phenyl 2- and 6-H), 7.36-7.34 (1H, m, phenyl 4-H), 
7.33-7.31 (2H, m, phenyl 3- and 4-H), 5.99 (1H, ddd, J 17.1, 10.1 and 9.0, 3-H), 5.28 
(1H, ddd, J 17.1, 1.4 and 0.9, 4-HA), 5.22 (1H, dd, J 10.1 and 1.6, 4-HB), 4.88 (1H, app. 
m, 2-H), 4.33 (1H, dd, J 14.6 and 7.1, 1-HA), 4.06 (1H, dd, J 14.6 and 7.4, 1-HB), 4.02 
(1H, t, J 5.2, NH), 3.25-3.16 (2H, app. m, ethyl 1-H2), 1.37 (9H, s, 
t
Bu), 1.01 (3H, t, J 
7.2, ethyl 2-H3); δC (125 MHz; CDCl3) 156.7 (CO urea), 150.4 (COO
t
Bu), 140.9 (Ns C-
2), 140.1 (phenyl C-1), 134.8 (C-3), 133.9 (Ns C-3), 133.8 (Ns C-4 or C-5 or C-6), 
133.2 (Ns C-1), 131.7 (Ns C-4 or C-5 or C-6), 130.1 (phenyl C-2 and C-6), 129.9 
(phenyl C-3 and C-5), 128.1 (phenyl C-4), 124.3 (Ns C-4 or C-5 or C-6), 119.4 (C-4), 
85 (C (
t
Bu)), 61.9 (C-2), 50.2 (C-1), 35.4 (ethyl C-1), 27.8 (
t
Bu), 15.4 (ethyl C-2); m/z 
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(ES) 541.14 (100% [M+Na]
+
); HRMS Found: 541.1739 (C24H30N4O7S requires M+Na 
541.1727).  
 
3-Ethyl-1-[1-(methoxymethoxy)but-3-en-2-yl]-1-phenylurea 56
148
 
 
N,N-Diisopropylethylamine (0.11 mL, 0.66 mmol) was added dropwise to a 
solution of the phenyl urea 54 (0.07 g, 0.33 mmol) in CH2Cl2 (2 mL) at 0 °C, followed 
by portionwise addition of chloromethyl ethyl (50 μL, 0.66 mmol). The resulting 
mixture was stirred at 0 °C for 1.5 h, then allowed to warm to r.t. and stirred overnight. 
The reaction mixture was quenched with brine (2.0 mL) and extracted with CH2Cl2 (2 × 
3.0 mL), the combined organic phases were dried (Na2SO4) and concentrated under 
reduced pressure to give a crude product which was purified by flash chromatography 
(petrol–EtOAc 50:50) to give the title compound 56 as a pale yellow oil (40  mg, 41%). 
RF: 0.5 (30:70, petrol–EtOAc); νmax/cm
-1
 (film) 3400, 2987, 2212, 1654, 1648, 1508, 
1279, 1039, 919, 712; δH (500 MHz; CDCl3) 7.42 (2H, app. t, J 7.4, phenyl 2- and 6-H), 
7.36 (1H, app. t, J 7.4, phenyl 4-H), 7.25 (2H, d, J 7.2, phenyl 3- and 5-H), 5.79 (1H, 
ddd, J 17.6, 10.5 and 7.3, 3-H), 5.26-5.16 (3H, m, 4-HA, 4-HB, 2-H), 4.67 (1H, d, J 6.6, 
OCHAHBO), 4.59 (1H, d, J 6.6, OCHAHBO), 3.96 (1H, br. s, NH), 3.62 (1H, dd, J 10.3 
and 6.2, 1-HA), 3.58 (1H, dd, J 10.3 and 9.1, 1-HB), 3.35 (3H, s, OCH3), 3.17 (2H, dq, J 
14.5 and 7.0, ethyl 1-H2), 0.99 (3H, t, J 7.2, ethyl 2-H3); δC (125 MHz; CDCl3) 157.0 
(CO), 144.9 (phenyl C-1), 135.3 (C-3), 130.8 (phenyl C-2 and C-6), 129.7 (phenyl C-3 
and C-5), 128.3 (phenyl C-4), 117.9 (C-4), 96.4 (OCHAHBO), 67.5 (C-1), 57.9 (OCH3), 
53.6 (C-2), 41.8 (ethyl C-1), 18.66 (ethyl C-2); m/z (ES) 301.1 (100%, [M+Na]
+
); 
HRMS Found: 301.1532 (C15H22N2O3 requires M+Na 301.1523). 
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1-(1′-Azidobut-3′-en-2′-yl)-3-ethyl-1-phenylurea 57149 
 
Diphenyl phosphoryl azide (0.7 mL, 3.2 mmol) was added to a solution of the 
phenyl urea 54 (0.25 g, 1.0 mmol) in toluene (27 mL) followed by DBU 0.5 mL, 3.2 
mmol) and the resulting mixture was stirred at 90 °C  for 3 days. The solvent was 
removed under reduced pressure to give a crude material which was partitioned in 
EtOAc (8.0 mL) and an aqueous solution of HCl (1.0 M, 8.0 mL).  The phases were 
separated and the aqueous phase was extracted with EtOAc (3 x 15 mL), the combined 
organic phases were washed with water (2 x 15 mL), with a saturated aqueous solution 
of NaHCO3 (2 x 15 mL) and brine (15 mL), dried (MgSO4) and concentrated under 
reduced pressure. The crude product was purified by flash chromatography (petrol–
EtOAc 60:40) to give the title compound 57 as an orange oil (0.17 g, 63%). RF: 0.6 
(40:60, petrol–EtOAc); νmax/cm
-1
 (film) 3368, 2946, 2931, 2878, 1659, 1508, 1494, 
1273, 923, 713; δH (500 MHz; CDCl3) 7.46-7.42 (2H, m, phenyl 2- and 6-H), 7.40-7.36 
(1H, m, phenyl 4-H), 7.26-7.23 (2H, m, phenyl 3- and 5-H), 5.88 (1H, ddd, J 17.4, 10.4 
and 7.6, 3-H), 5.23 (1H, app. dt , J 17.4 and 1.1, 4-HA), 5.20 (1H, app. dt , J 10.4, and 
1.1, 4-HB), 4.91-4.86 (1H, app. m, 2-H), 4.01 (1H, br. s, NH), 3.65 (1H, dd, J 12.4 and 
8.8, 1-HA), 3.4 (1H, dd, J 12.4 and 6.0, 1-HB), 3.19 (2H, qdd, J 7.2, 5.6 and 1.7, ethyl 1-
H2), 1.01 (3H, t, J 7.2, ethyl 2-H3); δC (125 MHz; CDCl3) 156.7 (CO), 139.5 (phenyl  C-
1), 134.9 (C-3), 130.3 (phenyl C-2 and C-6), 130.0 (phenyl C-3 and C-5), 128.4 (phenyl 
C-4), 118.6 (C-4), 59.8 (C-2), 52.6 (C-1), 35.5 (ethyl C-1), 15.5 (ethyl C-2); m/z (ES) 
282.1 (100%, [M+Na]
+
); HRMS Found: 282.1320 (C13H17N5O requires M+Na 
282.1325).  
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1-Allyl-3-ethyl-1-phenylurea 42
100
 
 
The title compound 42 was prepared according to the general method of Wolfe et 
al.,
100
 described in general procedure B, from the N-allyl-aniline (2.0 g, 15.0 mmol) 
and ethylisocyanate (6.0 mL, 75.0 mmol) in CH2Cl2, stirring for 1 day. The crude 
product was purified by flash chromatography (petrol–EtOAc 75:25) to give a yellow 
oil (2.7 g, 88%). RF: 0.2 (66:33, petrol–EtOAc);  νmax/cm
-1
 (film) 3445, 3356, 2972, 
2873, 1650, 1496, 1271, 1227, 921, 750; δH (500 MHz; CDCl3) 7.43-7.38 (2H, m, 
phenyl 2- and 6-H), 7.31-7.28 (1H, m, phenyl 4-H), 7.24 -7.21 (2H, m, phenyl 3- and 5-
H), 5.90 (1H, ddt, J 17.7, 9.7 and 6.1, allyl 2-H), 5.08 (1H, app. dt, J 17.7 and 1.4 allyl 
3-HA), 5.06 (1H, app. dt, J 9.7 and 1.4 allyl 3-HB), 4.28 (2H, dt, J 6.1 and 1.4, allyl 1-
H2), 4.26 (1H, br. s, NH), 3.21 (2H, dq, J 7.2 and 5.6, ethyl 1-H2), 1.03 (3H, t, J 7.2, 
ethyl 2-H3); δC (125 MHz; CDCl3) 156.7 (CO), 141.9 (phenyl C-1), 134.7 (allyl C-2), 
129.8 (phenyl C-2 and C-6), 128.4 (phenyl C-3 and C-5), 127.4 (phenyl C-4), 116.7 
(allyl C-3), 52.1 (allyl C-1), 35.5 (ethyl C-1), 15.4 (ethyl C-2); m/z (ES) 227.2 (100%, 
[M+Na]
+
); HRMS Found: 227.1152 (C12H16N2O, requires M+Na 227.1155). 
Characterisation data were consistent with those reported in literature.
100
 
 
3-Ethyl-4-(naphthalen-2-ylmethyl)-1-phenylimidazolidin-2-one 43
100
 
 
The title compound 43 was prepared according to the general method of Wolfe et 
al.,
100
 described in general procedure C, from the allyl urea 42 (0.27 g, 1.35 mmol) 
and 2-bromonaphthalenyl (0.56 g, 2.7 mmol) stirring for 2 days. The crude product was 
purified by flash chromatography (petrol–EtOAc 80:20 → 70:30) to give a pale yellow 
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amorphous solid (0.21 g, 48%). RF: 0.5 (60:30, petrol–EtOAc); νmax/cm
-1
 (film) 3380, 
2955, 2926, 2854, 1702, 1597, 1261, 1124, 942, 762, 694; δH (500 MHz; CDCl3) 7.81-
7.77 (3H, m, naphthalenyl 7-, 6- and 4-H), 7.63 (1H, s, naphthalenyl 1-H), 7.48-7.43 
(4H, m, naphthalenyl 3- and 5-H, phenyl 2- and 6-H), 7.30 (1H, d, J 8.3, naphthalenyl 
8-H), 7.26-7.21 (2H, m, phenyl 3- and 5-H), 6.95 (1H, t, J 7.3, phenyl 4-H), 4.08-4.02 
(1H, m, 4-H), 3.68 (1H, dq, J 14.7 and 7.4, ethyl 1-HA), 3.62 (1H, app. t, J 8.9, 5-HA), 
3.46 (1H, dd, J 9.1 and 6.0, 5-HB), 3.35 (1H, dd, J 13.5 and 4.2, 4-CHAHB), 3.21 (1H, 
dq, J 14.0 and 7.0, ethyl 1-HB), 2.76 (1H, dd, J 13.4 and 9.8, 4-CHAHB), 1.27-1.22 (3H, 
app. m, ethyl 2-H3); δC (125 MHz; CDCl3) 157.5 (CO), 140.7 (phenyl C-1), 134.1 
(naphthalenyl C-4a), 133.7 (naphthalenyl C-2), 132.3 (naphthalenyl C-8a), 128.9 
(phenyl C-2 and C-6), 128.8 (naphthalenyl C-6- or C-7), 127.9 (naphthalenyl C-1), 
127.8 (naphthalenyl C-6 or C-7), 127.6 (naphthalenyl C-4), 127.2 (naphthalenyl C-8), 
126.5 (naphthalenyl C-3), 126 (naphthalenyl C-5), 122.3 (phenyl C-4), 117.4 (phenyl C-
3 and C-5), 53 (C-4), 48 (C-5), 39.5 (4-CH2), 36.5 (ethyl C-1), 13.2 (ethyl C-2); m/z 
(ES) 683.4 (100%, [M2+Na]
+
). Characterisation data were consistent with those 
reported in literature.
100
 
 
(4S*, 5S*)-1-Ethyl-5-methyl-4-((naphthalen-2-ylamino)methyl)-3-phenyl 
imidazolin-2-one 58
100
 
 
The title compound 58 was prepared according to general procedure C
100
 from the 
allyl urea 45 (0.18 g, 0.53 mmol) and 2-bromonaphthalenyl (0.16 g, 0.80 mmol) stirring 
for 2 days in the presence of NaO
t
Bu (0.13 g, 1.3 mmol). The crude product was 
purified by flash chromatography (petrol–EtOAc 80:20 → 70:30) to give a yellow oil 
(2.0 mg, 4%). RF: 0.25 (60:30, petrol–EtOAc); νmax/cm
-1
 (film); 3838, 3753, 2956, 2912, 
2852, 1687, 1578, 1219, 1034, 939, 799; δH (500 MHz; CDCl3) 7.66 (1H, dd, J 8.1 and 
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0.6, naphthalenyl 5-H), 7.62 (1H, d, J 8.8, naphthalenyl 4-H), 7.57 (1H, dd, J 8.3 and 
0.6, naphthalenyl 8-H), 7.50-7.48 (2H, dd, J 8.7 and 1.1, phenyl 2- and 6-H), 7.39-7.34 
(3H, m, phenyl 3- and 5-H, naphthalenyl 7-H), 7.21 (1H, ddd, J 8.1, 6.8 and 1.2, 
naphthalenyl 6-H), 7.12 (1H, app. t, J 7.4, phenyl 4-H), 6.81 (1H, dd, J 8.7 and 2.4, 
naphthalenyl 3-H), 6.77 (1H, app. br. s, naphthalenyl 1-H), 4.04 (1H, td, J 5.2 and 3.4, 
4-H), 3.77-3.72 (1H, m, 5-H), 3.58 (1H, dq, J 14.3 and 7.3, ethyl 1-HAHB), 3.47 (1H, dd, 
J 13.2 and 5.1, 4-CHAHB), 3.43 (1H, dd, J 13.1 and 3.4, 4-CHAHB), 3.16 (1H, dq, J 14.2 
and 7.2, ethyl 1-HAHB), 1.35 (3H, d, J 6.2, methyl), 1.17 (3H, t, J 7.2, ethyl 2-H3), NH 
not observed; δC (125 MHz; CDCl3) 157.8 (CO), 139.1 (phenyl C-1), 138.9 
(naphthalenyl C-8a), 130.2 (naphthalene C-4), 129.4 (naphthalenyl C-2), 129.3 (phenyl 
C-2 and C-6), 127.9 (naphthalenyl C-4a), 127.8 (naphthalenyl C-5), 126.7 (naphthalenyl 
C-7), 126.1 (naphthalenyl C-8), 124.5 (phenyl C-4), 122.6 (naphthalenyl C-6), 121.9 
(phenyl C-3 and C-5), 118.2 (naphthalenyl C-3), 105.3 (naphthalenyl C-1), 60.9 (C-4), 
51.8 (C-5), 44.2 (4-CH2), 36.2 (ethyl C-1), 19.5 (Me), 13.4 (ethyl C-2); m/z (ES) 360.1 
(100%, [M+H]
+
); HRMS Found: 382.1909 (C23H25N3O, requires M+Na 382.1890). 
 
(E)-N-(2-(3-ethyl-1-phenylureido)-4-(naphthalen-2-yl)but-3-enyl)-2-
nitrobenzenesulfonamide 59
100 
 
The title compound 59 was obtained from the allyl urea 55 (0.1 g, 0.19 mmol) and 
2-bromonaphthalenyl (90 mg, 0.38 mmol) following general procedure C
100
 and 
stirring for 2 days. The crude product was purified by flash chromatography (98.5:1.5 
CH2Cl2–MeOH) followed by mass directed chromatography to give a yellow oil (13.6 
mg, 13%). RF: 0.25 (60:30, petrol–EtOAc); νmax/cm
-1
 (film); 3063, 2930, 1649, 1541, 
1513, 1362, 1276, 970, 731; δH (500 MHz; CDCl3) 8.30 (1H, dd J 7.7 and 1.5, Ns 3-H), 
7.80 (1H, dd, J 7.8 and 1.5, Ns 5-H), 7.76 (1H, d, J 8.4, naphthalenyl 5-H or 8-H), 7.73 
(1H, d, J 8.5, naphthalenyl 3-H or 4-H), 7.69 (1H, td, J 7.7 and 1.3, Ns 4-H), 7.64 (1H, 
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td, J 7.7 and 1.3, Ns 6-H), 7.60 (1H, s, naphthalenyl 1-H), 7.48-7.40 (7H, m, 5 x phenyl 
CH, naphthalenyl 5-H or 8-H and 3-H or 4-H), 7.24 (2H, dd, J 8.0, 1.2, naphthalenyl 6- 
and 7-H), 6.59 (1H, d, J 15.9, 4-H), 6.16 (1H, dd, J 15.9 and 8.6, 3-H), 6.15 (1H, t, J 
5.5, NHNs), 5.01 (1H, app.td, J 8.8 and 5.5, 2-H), 4.06 (1H, app t, J 5.6, NHEt), 3.66 
(1H, ddd, J 12.5, 9.0 and 5.6, 1-HA), 3.41 (1H, dt, J 12.5 and 5.5, 1-HB), 3.25-3.16 (2H, 
m, ethyl 1-H2), 1.01 (3H, t, J 7.2, ethyl 2-H3); δC (125 MHz; CDCl3) 157.7 (CO), 148.2, 
139.5 (Ar C), 134.3 (4-C), 134.1, 133.8, 133.6 (Ar C), 133.5 (Ar CH), 133.3 (Ar C), 
132.8 (Ar CH), 131.0 (Ns C-3), 130.4 (phenyl C-2 and C-6), 130.3 (phenyl C-3- and C-
5), 128.8, 128.4 128.2, 127.8 (Ar CH), 126.9 (naphthalene C-1), 126.5, 126.3 (Ar CH), 
125.8 (C-3), 125.5 (Ns C-5), 123.6 (Ar CH), 59.5 (C-2), 46.3 (C-1), 35.7 (ethyl C-1), 
15.5 (ethyl C-2); m/z (ES) 522.1 (100%, fragment [MNO2+Na]
+
;
 
 HRMS Found: 
545.1864 (C29H28N4O5S, requires M+H 545.1853). 
 
(4R*, 5S*)-1-Ethyl-4-((methoxymethoxy)methyl)-5-(naphthalen-2-ylmethyl)-3-
phenylimidazolidin-2-one 60
100 
 
The title compound 60 was prepared from the allyl urea (55 mg, 0.2 mmol) 56 and 
2-bromonaphthalenyl (91 mg, 2.2 mmol) according to general procedure C,
100
 stirring 
for 3 days. The crude product was purified by flash chromatography (petrol–EtOAc 
80:20 → 70:30) to give a yellow oil (33 mg, 35%). RF: 0.25 (50:50, petrol–EtOAc); 
νmax/cm
-1
 (film); 3057, 2928, 2825, 1703, 1598, 1425, 1261, 1044, 918, 751; δH (500 
MHz; CDCl3) 7.82-7.79 (3H, m, naphthalenyl 7-, 6- and 4-H), 7.69 (1H, s, naphthalenyl 
1-H), 7.51-7.44 (2H, m, naphthalenyl 3- or 5-H and 8-H), 7.39 (2H, d, J 8.5 phenyl 2- 
and 6-H), 7.35 (1H, d, J 7.5, naphthalenyl 3- or 5-H), 7.24 (2H, d, J 8.5 phenyl 3- and 5-
H), 7.00 (1H, app. t, J 7.4, phenyl 4-H), 4.37 (1H, d, J 6.5, OCHAHBO), 4.35 (1H, d, J 
6.5, OCHAHBO), 4.08 (1H, dt, J 6.3 and 3.1, 4-H), 4.03 (1H, ddd, J 8.3, 4.8 and 3.0, 5-
H), 3.75 (1H, dq, J 14.0 and 7.5, ethyl 1-HAHB), 3.46 (1H, dd, J 10.4 and 6.3, 4-
CHAHB), 3.28-3.26 (2H, m, 4-CHAHB and 5-CHAHB), 3.12 (3H, s, OCH3), 3.13-3.09 
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(1H, m, ethyl 1-HAHB), 2.92 (1H, dd, J 13.7 and 8.3, 5-CHAHB), 1.22 (3H, t, J 7.2, ethyl 
2-H3); δC (125 MHz; CDCl3) 156.6 (CO), 139 (phenyl C-1), 134 (naphthalenyl C-4a), 
133.5 (naphthalenyl C-2), 132.3 (naphthalenyl C-8a), 128.8 (phenyl C-2 and C-6), 
128.4 (naphthalenyl C-7- or C-6- or C-4), 128.0 (naphthalenyl C-1), 127.7 
(naphthalenyl C-7- or C-6- or C-4), 127.5 (naphthalenyl C-7- or C-6- or C-4), 127.3 
(naphthalenyl C-3 or C-5), 126.3 (naphthalenyl C-3 or C-5), 125.7 (naphthalenyl C-8), 
123.1 (phenyl C-4), 120 (phenyl C-2 and C-6), 96.4 (OCHAHBO), 66.1 (4-CH2), 57.9 
(C-4), 55.8 (C-5), 55.2 (OCH3), 39.2 (5-CH2), 36.3 (ethyl C-1), 13.1 (ethyl C-2); m/z 
(ES) 427.1 (100%, [M+Na]
+
); HRMS Found: 427.2000 (C25H28N2O3 requires M+Na 
427.1992). 
 
 (4S*, 5S*)-4-(Azidomethyl)-1-ethyl-5-(naphthalen-2-ylmethyl)-3-phenyl 
imidazolidin-2-one 61
100
 
 
The title compound 61 was prepared from the allyl urea 57 (70 mg, 0.27 mmol) and 
2-bromonaphthalenyl (0.17 g, 0.80 mmol) according to general procedure C,
100
 
stirring for 3 days. The crude product was purified by flash chromatography (petrol–
EtOAc 80:20 → 70:30) to give a yellow oil (6 mg, 5%). RF: 0.6 (50:50, petrol–EtOAc); 
νmax/cm
-1
 (film); 2925, 2105, 1704, 1501, 1423, 1260, 800, 752; δH (500 MHz; CDCl3) 
7.85-7.81 (3H, m, naphthalenyl 7-, 6- and 4-H), 7.69 (1H, s, naphthalenyl 1-H), 7.52-
7.46 (2H, m, naphthalenyl 3- and 8-H), 7.36-7.33 (3H, m, phenyl 2- and 6-H, 
naphthalenyl 5-H), 7.30-7.28 (2H, m, phenyl 3- and 5-H), 7.05 (1H, tt, J 7.5 and 1.0, 
phenyl 4-H), 4.08 (1H, app. dt, J 5.7 and 3.0, 5-H), 3.96 (1H, ddd, J 8.3, 4.2 and 3.0, 4-
H), 3.78 (1H, dq, J 14.6 and 7.2, ethyl 1-HA), 3.37-3.32 (2H, m, 4-CHAHB and 5-
CHAHB), 3.18 (1H, dq, J 14.0 and 7.0, ethyl 1-HB), 2.89-2.82 (2H, m, 4-CHAHB and 5-
CHAHB), 1.27 (3H, t, J 7.2, ethyl 2-H3); δC (125 MHz; CDCl3) 159.4 (CO), 138.1 
(phenyl C-1), 133.6 (naphthalenyl C-4a), 133.4 (naphthalenyl C-2), 132.5 (naphthalenyl 
C-8a), 129.1 (phenyl C-2 and C-6), 128.8 (naphthalenyl C-7 or C-6 or C-4), 128.1 
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(naphthalenyl C-1), 127.8 (naphthalenyl C-7 or C-6 or C-4), 127.6 (naphthalenyl C-7 or 
C-6 or C-4), 127.1 (naphthalenyl C-5), 126.5 (naphthalenyl C-3), 125.9 (naphthalenyl 
C-8), 123.9 (phenyl C-4), 120.7 (phenyl C-3 and C-5), 57.6 (C-5), 55.9 (C-4), 51.1 (5-
CH2), 39.2 (4-CH2), 36.4 (ethyl C-1), 13.1 (ethyl C-2); m/z (ES) 408.1 (100%, 
[M+Na]
+
); HRMS Found: 408.1799 (C23H23N5O requires M+Na 408.1795). 
 
N-Benzylprop-2-en-1-amine70
150
 
 
The title compound 70 was prepared accordint to the method of Mukherjee et al.
150
 
Benzylbromide (2.1 mL, 17.7 mmol) was added via syringe pump over 1 h to a 
suspension of K2CO3 (2.9 g, 21.0 mmol) in allyl amine (10.5 mL, 140.1 mmol) and the 
resulting mixture was stirred at r.t. for 2 days. The reaction mixture was filtered through 
Celite
®
 eluting with CH2Cl2; the filtrate was concentrated under reduce pressure and the 
crude product was purified by flash chromatography (petrol–EtOAc 50:50) to give a 
yellow oil (1.20 g, 47%). RF: 0.5 (10:90, petrol-EtOAc); νmax/cm
-1
 (film) 3311, 3027, 
2813, 1948, 1810, 1643, 1455, 1106, 918, 736; δH (500 MHz; CDCl3); 7.34-7.27 (4H, 
m, phenyl 2-, 6-, 3- and 5-H), 7.23 (1H, dd, J 8.7 and 1.4, phenyl 4-H), 5.87 (1H, ddt, J 
17.1, 10.3 and 6.0, 2-H), 5.13 (1H, dd, J 17.1 and 1.4, 3-HA), 5.04 (1H, dd, J 10.3 and 
1.4, 3-HB), 3.79 (1H, s, benzyl CH2), 3.28 (2H, dt, J 6.0 and 1.4, 1-H2), 1.39 (1H, br. s, 
NH); m/z (ES) 148.2 (100%, [M+H]
+
). Spectra corresponds to the one reported in the 
literature.
150
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1-Allyl-1-benzyl-3-phenylurea 71
100,151
 
 
The title compound 71 was prepared according to general procedure B
100
 from 
phenylisocyanate (1.4 mL, 12.4 mmol) and the amine 70 (1.21 g, 8.2 mmol) in CH2Cl2 
stirring for 2 days. The crude product was purified by flash chromatography (petrol–
EtOAc 70:30) to give a yellow oil (2.1 g, 95%). RF: 0.7 (50:50 petrol–EtOAc); νmax/cm
-1
 
(film) 3031, 2984, 2922, 2278, 1645, 1441, 1231, 928, 754, 696; δH (500 MHz; CDCl3) 
δ 7.41-7.25 (m, 9H, Ar), 7.03 (1H, t, J 7.1, Ar), 6.45 (s, 1H, NH), 5.89 (1H, ddd, J 15.8, 
11.9 and 5.4, allyl 2-H), 5.37-5.31 (2H, m, allyl 3-HA and 3-HB), 4.62 (2H, s, benzyl 
CH2), 3.98 (2H, d, J 5.4 Hz, allyl 1-H); δC (125 MHz; CDCl3) 157.8 (CO), 139.0, 137.6 
(Ar C-1 and C-1′), 133.9 (C-2), 128.9, 128.8, 127.7, 127.5, 123.0, 119.7 (Ar CH), 117.5 
(C-3), 50.7 (benzyl CH2), 50.1 (C-1); m/z (ES) 267.1 (100%, [M+H]
+
); HRMS Found: 
267.1485 (C17H18N2O requires M+H 267.1470). Characterisation data consistent with 
those reported in literature.
151 
 
1-Benzyl-4-(iodomethyl)-3-phenylimidazolidin-2-one 73
124
 
 
Triethylamine (0.25 mL, 2.2 mmol) was added slowly to a solution of the benzyl 
allyl urea 71 (0.30 g, 1.1 mmol) in CH2Cl2 (5 mL) followed by trimethyl- 
silyltrifluoromethansulfonate (0.40 mL, 2.0 mmol). The resulting mixture was stirred 
for 1 h at r.t. and concentrated under reduced pressure. The crude material was 
dissolved in THF (7.0 mL) and I2 (0.57 g, 2.0 mmol) was added. The resulting mixture 
was stirred at r.t. overnight, then it was poured into an aqueous solution of Na2S2O3 
(20%, w/v, 40 mL) and extracted with EtOAc (3.0 × 20 mL). The combined organic 
phases were dried (MgSO4) and concentrated under reduced pressure to give a crude 
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product which was purified by flash chromatography (petrol–EtOAc 60:40) to give the 
title compound 73 as a pale yellow oil (0.24 g, 53%). RF: 0.7 (60:40, petrol–EtOAc); 
νmax/cm
-1
 (film) 2923, 2098, 1698, 1655, 1500, 1441, 1260, 1138, 1028, 755, 696, 525; 
δH (500 MHz; CDCl3) 7.46 (2H, dd, J 8.1 and 1.1, Ar CH), 7.39-7.30 (7H, m, Ar CH), 
7.14 (1H, dd, J 7.3 and 1.2, Ar CH), 4.56 (1H, d, J 14.9, benzyl CHAHB), 4.41 (1H, d, J 
14.9, benzyl CHAHB), 4.35 (1H, app tdd, J 8.9, 4.7 and 2.5, 4-H), 3.54 (1H, app. t, J 9.2, 
5-HA), 3.33 (1H, dd, J 10.3 and 2.5, 4-CHAHB), 3.16 (1H, dd, J 9.3 and 4.7, 5-HB), 3.15 
(1H, dd, J 10.3 and 8.8, 4-CHAHB); δC (125 MHz; CDCl3) 157.4 (CO), 137.8, 136.5 (Ar 
C-1 and C-1′), 129.2, 128.7, 128.3 (Ar CH), 127.7, 124.3 (Ar C-4 and C-4′), 121.4 (Ar 
CH), 54.12 (C-4), 48.1 (C-5), 47.9 (benzyl CH2), 8.0 (4-CH2); m/z (ES) 393.2 (100%, 
[M+H]
+
); HRMS Found: 393.0456 (C17H17N2OI requires M+H 393.0458). 
 
4-(Azidomethyl)-1-benzyl-3-phenylimidazolidin-2-one 74
137, 151
 
 
Sodium azide (0.05 g, 0.8 mmol) was added portionwise at 0 °C to a solution of the 
the imidazolidinone 73 (0.10 g, 0.25 mmol) in DMF (2.5 mL) and the resulting mixture 
was stirred at r.t overnight. EtOAc (5.0 mL) was added to the reaction mixture, the 
resulting mixture was washed with water (2 × 5.0 mL) and brine (2 × 50 mL). The 
combined organic phases were dried (MgSO4) and concentrated under reduced pressure 
to give the title compound 74 as a white amorphous solid which was used without 
further purification (3 mg, 37%). RF: 0.7 (40:60, petrol–EtOAc); νmax/cm
-1
 (film) 2250, 
2106, 1651, 1441, 1357, 1259, 1087, 907, 713, 695; δH (500 MHz; CDCl3) 7.47 (2H, 
dd, J 8.7 and 1.1, Ar CH), 7.40-7.34 (7H, m, Ar CH), 7.31 (1H, dd, J 7.5 and 2.3, Ar 
CH), 4.51 (1H, dd, J 15.0, benzyl CHAHB), 4.46 (1H, dd, J 15.0, benzyl CHAHB), 4.38 
(1H, dddd, J 9.3, 6.4, 4.6 and 3.1, 4-H), 3.49 (1H, dd, J 6.4 and 1.2, 4-CHAHB), 3.48 
(1H, app. t, J 9.2, 5-HA), 3.38 (1H, dd, J 12.7 and 3.1, 4-CHAHB), 3.24 (1H, dd, J 9.2 
and 4.6, 5-HB); δC (125 MHz; CDCl3) 157.5 (CO), 137.9, 136.6 (Ar C-1 and C-1′), 
129.2, 128.7, 128.2 (Ar CH), 127.7, 124.3 (Ar C-4 and C-4′), 121.2 (Ar CH), 52.4 (4-
CH2), 51.4 (C-4), 48.0 (benzyl CH2), 45.0 (C-5); m/z (ES) 308.2 (100%, [M+H]
+
).; 
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HRMS Found: 330.1325 (C17H17N5O requires M+H 330.35). Characterisation data were 
consistent with those reported in literature.
151 
 
4-(Aminomethyl)-1-benzyl-3-phenylimidazolidin-2-one 75
138
 
 
Triphenylphospine (19 mg, 58 μmol) was added to a solution of the imidazolinone 
74 (15 mg, 48 μmol) in THF-H2O (550 μL of THF, 50 μl of H2O) and the resulting 
mixture was stirred at 45 °C overnight. The solvent was removed to give a crude 
product which was purified by flash chromatography (petrol–EtOAc 50:50, then 
CH2Cl2–EtOH–NH4OH 84.7:13.6:1.7) to give the title imidazolidinone 75 as a pale 
yellow oil (11 mg, 81%). RF: 0.7 (70:30, CH2Cl2–MeOH); νmax/cm-1 (film) 3384, 
2920, 1697, 1598, 1500, 1439, 1261, 956, 756; δH (500 MHz; CDCl3) 7.5 (2H, dd, J 8.7 
and 1.0, Ar CH), 7.36-7.28 (7H, m, Ar CH), 7.1 (1H, tt, J 7.8 and 1.0, Ar CH), 4.53 
(1H, d, J 14.9, benzyl CHAHB), 4.42 (1H, d, J 14.9, benzyl CHAHB), 4.31-4.27 (1H, m, 
4-H), 3.47 (1H, app. t, J 9.0, 5-HA), 3.27 (1H, dd, J 9.0 and 5.1, 5-HB), 2.93 (1H, dd, J 
13.4 and 6.3, 4-CHAHB), 2.83 (1H, app. d, J 13.4, 4-CHAHB), 1.61 (2H, br. s, NH2); δC 
(125 MHz; CDCl3) 158.1 (CO), 138.6, 136.8 (Ar C-1 and C-1′), 129.0, 128.7, 128.3 (Ar 
CH), 127.6, 123.9 (Ar C-4 and C-4′), 121.1 (Ar CH), 54.7 (C-4), 48.4 (benzyl CH2), 
44.9 (C-5), 42.4 (4-CH2); m/z (ES) 282.2 (100%, [M+H]
+
); HRMS Found: 282.1603 
(C17H19N3O requires M+H 282.1601). 
 
N-(Diphenylmethylene)prop-2-en-1-amine 78
126
 
 
The title compound 78 was prepared according to the general method of Blacker et 
al.
126
 Allyl amine (4.0 g, 77.0 mmol) was added to a solution of benzophenone (8.6 g, 
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47.0 mmol) in toluene (45 mL) at r.t., followed by titanium isopropoxide (9.4 mL, 32.0 
mmol) and the resulting mixture was stirred at 80 °C overnight. After cooling down at 
r.t., water (2.0 mL) and toluene (35 mL) were added and the reaction mixture was 
stirred for 2 h at r.t., filtered through Celite
®
, washed with toluene (2 × 20 mL). The 
organic phases were concentrated under reduced pressure to give the title compound 78 
as a yellow oil that was used withour further purification (10.4 g, 98%). RF: 0.8 (20:80, 
petrol–EtOAc); νmax/cm
-1
 (film) 3059, 3024, 2912, 1957, 1661, 1622, 1491, 1446, 1314, 
1287, 1179, 1074, 918, 780; δH (500 MHz; CDCl3) 7.64 (2H, dd, J 8.4 and 1.3, Ar CH), 
7.48-7.36 (4H, m, Ar CH), 7.32-7.31 (2H, m, Ar CH), 7.18 (2H, dd , J 7.7 and 1.6, Ar 
CH), 6.06 (2H, ddt, J 17.2, 10.5 and 5.4, 2-H), 5.18 (1H, dq, J 17.2 and 1.8, 3-HA), 5.11 
(1H, dq, J 10.5 and 1.8, 3-HB), 4.04 (2H, dt, J 5.4 and 1.8, 1-H2); δC (75 MHz; CDCl3) 
168.8 (N=CPh2), 139.8, 136.7 (Ar C), 136.6 (Ar CH), 130.0 (C-2), 129, 128.5, 128.3, 
128.1, 127.7 (Ar CH), 115.1 (C-3), 56.4 (C-1); HRMS Found: 222.1281 (C16H15N 
requires M+H 222.1107). Characterisation data were consistent with those reported in 
literature.
126
 
 
1-phenylbut-3-en-2-amine 76
126
 
 
The title compound 78 was prepared according to the general method of Blacker et 
al.
126
 The amine 76 (4.0 g, 18.1 mmol) and benzylchloride (2.1 mL, 18.1 mmol) were 
mixed in the presence of n-butyl lithium (11.3 mL, 18.1 mmol) according to general 
procedure D. The crude product was purified by flash chromatography (petrol–EtOAc 
80:20 → 70:30) to give a yellow oil (0.85 g, 50%). RF: 0.15 (99.5:0.5, CH2Cl2–MeOH); 
νmax/cm
-1
 (film) 3910, 3758, 2107, 1644, 1495, 1454, 1371, 1260, 1078, 994, 746; δH 
(500 MHz; CDCl3) 7.3 (2H, t, J 7.3, Ar), 7.26-7.19 (3H, m, Ar), 5.89 (1H, ddd, J 17.0, 
10.3, 6.4, 3-H), 5.14 (1H, d, J 17.0, 4-HA), 5.04 (1H, d, J 10.3, 4-HB), 3.6 (1H, ddd, J 
8.3, 6.4 and 5.4, 2-H), 2.83 (1H, dd, J 13.3 and 5.4, 1-HA), 2.62 (1H, dd, J 13.3 and 8.3, 
1-HB), 1.47 (2H, br. s., NH2); δC (75 MHz; CDCl3) 142.4 (phenyl C-1), 138.8 (phenyl 
C-4), 129.4 (phenyl C-2 and C-6 or C-3 and C-5), 128.4 (phenyl C-2 and C-6 or C-3 
and C-5), 126.3 (C-4), 113.6 (C-3), 55.5 (C-2), 44.4 (C-1); HRMS Found: 148.1147 
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(C10H13N, M+H requires 148.1121). Characterisation data were consistent with those 
reported in literature.
126
 
 
1-(3,5-dimethylisoxazol-4-yl)but-3-en-2-amine 77
126
 
 
The title compound 77 was prepared from the amine 78 (6.4 g, 29.0 mmol) and 4-
chloromethyl-3,5-dimethylisoxazolyl (3.6 mL, 29.0 mmol) in the presence of n-Butyl 
lithium (11.6 mL, 29.0 mmol) according to general procedure D.
126
 A yellow oil (2.4 
g, 49%) was obtained and used without further purification. RF: 0.1 (99.5:0.5, CH2Cl2–
MeOH); νmax/cm
-1
 (film) 3698, 2962, 1956, 1637, 1577, 1492, 1450, 1260, 1195, 1015, 
923, 745; δH (500 MHz; CDCl3) 5.80 (1H, ddd, J 17.2, 10.3 and 6.6, 3-H), 5.11 (1H, dt, 
J 17.2 and 1.2, 4-HA), 5.05 (1H, dt, J 10.3 and 1.2, 4-HB), 3.45 (1H, app. q, J 6.6, 2-H), 
2.43 (1H, app. d, J 6.6, 1-HA), 2.42 (1H, app. d, J 7.2, 1-HB), 2.33 (3H, s, isoxazolyl 5-
CH3), 2.23 (3H, s, isoxazolyl 3-CH3), 1.49 (2H, br. s., NH2); δC (75 MHz; CDCl3) 166.0 
(isoxazolyl C-5), 159.9 (isoxazolyl C-3), 141.8 (C-3), 114.5 (C-4), 110.5 (isoxazolyl C-
4), 54.5 (C-2), 30.8 (C-1), 11.3 (isoxazolyl 5-CH3), 10.5 (isoxazolyl 3-CH3); HRMS 
Found 167.1190 (C9H14N2O requires M+H 167.1179). 
 
1-(3,5-Dimethylisoxazol-4-yl)-N-(furanyl-2-ylmethyl)but-3-en-2-amine 80
136 
 
The title compound 80 was prepared from the amine 77 (1.3 g, 7.9 mmol) and 
furanylaldehyde  (0.8 mL, 9.5 mmol) according to general procedure E,
136
 stirring for 
4 h at r.t., before adding NaBH4 (2.0 eq.). A yellow oil (1.9 g, 98%) was obtained and 
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used without further purification. RF: 0.2 (99:1, CH2Cl2–MeOH); νmax/cm
-1
 (film) 3307, 
2978, 2931, 1651, 1636, 1455, 1424, 1195, 1148, 1011, 922, 742; δH (500 MHz; CDCl3)  
7.33 (1H, dd, J 1.8 and 0.8, furanyl 5-H), 6.29 (1H, dd, J 3.1 and 1.8, furanyl 4-H), 6.10 
(1H, dd, J 3.1 and 0.8, furanyl 3-H), 5.60 (1H, ddd, J 17.1, 10.2 and 8.2, 3-H), 5.14 (1H, 
ddd, J 10.2, 1.5 and 0.5, 4-HA), 5.08 (1H, ddd, J 17.1, 1.5 and 0.8, 4-HB), 3.80 (1H, d, J 
14.6, CHAHBN), 3.64 (1H, d, J 14.6, CHAHBN), 3.12 (1H, app. dq, J 7.1 and 0.5, 2-H), 
2.48 (1H, d, J 14.4 and 7.0, 1-HA), 2.71 (1H, d, J 14.4 and 7.1, 1-HB), 2.27 (3H, s, 
isoxazolyl 5-CH3), 2.15 (3H, s, isoxazolyl 3-CH3), 1.56 (1H, br. s, NH); δC (75 MHz; 
CDCl3) 166.2 (isoxazolyl C-5), 159.9 (isoxazolyl C-3), 153.6 (furanyl C-2), 141.8 
(furanyl C-5), 139.6 (C-3), 117.5 (C-4), 110.2 (isoxazolyl C-4), 110.1 (furanyl C-4), 
106.9 (furanyl C-3), 60.3 (C-2), 43.6 (CH2NH), 29.0 (C-1), 11.2 (isoxazolyl 5-CH3), 
10.3 (isoxazolyl 3-CH3); m/z  (ES) 247.1 (100%, [M+H]
+
); HRMS Found: 247.1439 
(C14H18N2O2, M+H requires 247.1441). 
 
N-(4-Chlorobenzyl)-1-(3,5-dimethylisoxazol-4-yl)but-3-en-2-amine 81
136 
 
The title compound 81 was prepared from the amine 77 (1.3 g, 7.6 mmol) and p-
chlorobenzaldehyde (2.6 mL, 18.2 mmol) according to general procedure E,
136
 stirring 
at reflux overnight, before adding NaBH4 (6.0 eq.). The crude product was dissolved in 
EtOAc (15 mL), extracted with a aqueous solution of HCl (2.0 M) (3.0 x 10 mL), then 
the combined water phases were basified with an aqueous solution of NaOH (50% w/v) 
until pH 10-11, and  extracted with EtOAc (3.0 x 20 mL). The organic phases were 
dried (MgSO4) and concentrated under reduced pressure to give a yellow oil (0.99 g, 
45%). RF: 0.6 (95:5, CH2Cl2–MeOH); νmax/cm
-1
 (film) 3354, 2926, 1637, 1491, 1449, 
1196, 1089, 1014, 924, 800; δH (500 MHz; CDCl3) 7.27 (2H, d, J 8.3, phenyl 3- and 5-
H), 7.17 (2H, d, J 8.3, phenyl 2- and 6-H), 5.61 (1H, ddd, J 17.1, 10.1 and 8.2, 3-H), 
5.15 (1H, d, J 10.1, 4-HA), 5.06 (1H, d, J 17.1, 4-HB), 3.79 (1H, d, J 13.6, benzyl 
CHAHB), 3.59 (1H, d, J 13.6, benzyl CHAHB), 3.09 (1H, app. q, J 7.2, 2-H), 2.48 (1H, 
dd, J 14.4 and 6.9, 1-HA), 2.43 (1H, dd, J 14.4 and 6.9, 1-HB), 2.27 (3H, s, isoxazolyl 5-
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CH3), 2.15 (3H, s, isoxazolyl 3-CH3); δC (75 MHz; CDCl3) 166.0 (isoxazolyl C-5), 
159.9 (isoxazolyl C-3), 139.7 (phenyl C-1), 132.7 (C-3), 129.3 (phenyl C-2- and C-6), 
128.5 (phenyl C-3- and C-5), 128.3 (phenyl C-4), 117.2 (C-4), 110.3 (isoxazolyl C-4), 
60.8 (C-2), 50.4 (benzyl CH2), 29.1 (C-1), 11.3 (isoxazolyl 5-CH3), 10.4 (isoxazolyl 3-
CH3); m/z (ES) 291.3 (100%, [M+H]
+
).; HRMS Found 291.1259 (C16H19ClN2O, M+H 
requires 291.1272). 
 
N-(4-Chlorobenzyl)-1-phenylbut-3-en-2-amine 82
152 
 
p-Chlorobenzaldehyde (0.7 g, 5.0 mmol) was added to a solution of the amine 76 (0.49 
g, 3.3 mmol) in MeOH (0.25 M), followed by molecular sieves (4 Å) and the mixture 
was stirred at reflux overnight. The reaction was filtered through Celite
®
, concentrated 
under reduced pressure and resuspended in dry MeOH. NaBH4 (2.0 eq.) was then added 
at 0 
o
C and the mixture was left stirring at r.t. overnight. The reaction mixture was 
quenched with water (5.0 mL), diluted with CH2Cl2 (20 mL) and the phases were 
separated. The aqueous phase was extracted with CH2Cl2 (3 x 10 mL) and the combined 
organic phases were dried (MgSO4) and concentrated under reduced pressure to give a 
crude product, which was purified by flash chromatography (80:20 hexane–EtOAc) to 
give the title amine 82 as a colourless oil (0.6 g, 65%). RF: 0.4 (50:50, petrol–EtOAc); 
νmax/cm
-1
 (film) 3346, 2922, 2849, 1491, 1455, 1090, 1014, 700; δH (500 MHz; CDCl3) 
7.34-7.26 (4H, m, Ar CH), 7.22 (2H, dd, J 8.0 and 2.0 Ar CH), 7.16 (2H, d, J 6.8, Ar 
CH), 7.08 (1H, d, J 8.2 Ar CH), 5.70 (1H, ddd, J 17.1, 10.3, 8.0, 3-H), 5.13 (1H, ddd, J 
10.3, 1.6 and 0.6, 4-HA), 5.09 (1H, ddd, J 17.1, 1.6 and 0.8, 4-HB), 4.68 (1H, br. s., NH), 
3.78 (1H, d, J 13.8 benzyl CHAHB), 3.57 (1H, d, J 13.8 benzyl CHAHB), 3.27 (1H, app. 
td, J 8.0 and 5.7, 2-H), 2.81 (1H, dd, J 13.5 and 5.7, 1-HA), 2.75 (1H, dd, J 13.5 and 8.0, 
1-HB); δC (75 MHz; CDCl3) 140.5 (Ar C), 138.4 (C-3), 132.5 (Ar C), 129.4, 129.3 (Ar 
CH), 128.7 (Ar C), 128.3, 126.5, 126.5 (Ar CH), 116.5 (C-4), 61.8 (C-2), 50.3 (benzyl 
CH2), 42.5 (C-1); m/z (ES) 271.4 (100%, [M+H]
+
); HRMS Found 272.1194 
(C17H18ClN, M+H requires 272.1200).  
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N-(4-Chlorobenzyl)prop-2-en-1-amine 83
136, 153
 
 
The title compound 83 was prepared from allylamine (0.4 mL, 5.2 mmol) and p-
chlorobenzaldehyde (0.6 mL, 4.3 mmol) according to general procedure E,
136
 stirring 
at reflux for 4 h, before adding NaBH4 (4 eq.). A yellow oil (0.33 g, 43%) was obtained 
and used without further purification. RF: 0.4 (95:5, CH2Cl2–MeOH); νmax/cm
-1
 (film) 
3368, 2927, 1643, 1491, 1462, 1407, 1090, 10115, 819; δH (500 MHz; CDCl3) 7.28 
(2H, d, J 8.4, phenyl 3- and 5-H),  7.25 (2H, d, J 8.4, phenyl 2- and 6-H),  5.91 (1H, 
ddd, J 17.1, 10.2 and 6.0, 2-H), 5.22 (1H, dd, J 17.1 and 1.5, 3-HA), 5.18 (1H, dt, J 10.2 
and 1.1, 3-HB), 3.79 (2H, s, benzyl CH2), 3.25 (2H, dd, J 6.0 and 1.1, 1-H2), 1.55 (2H, 
br. s., NH2); δC (75 MHz; CDCl3) 138.9 (C-3), 136.7 (phenyl C-1), 132.8 (phenyl C-4), 
129.6 (phenyl C-3 and C-5), 128.6 (phenyl C-2 and C-6), 116.3 (C-4), 52.6 (benzyl 
CH2), 51.8 (C-2); m/z (ES) 181.9 (100%, [M+H]
+
).; HRMS Found 182.0730 
(C9H14N2O requires M+H 182.0731). Characterisation data were consistent with those 
reported in literature.
153
 
 
1-(3,5-Dimethylisoxazol-4-yl)-N-isopropylbut-3-en-2-amine 84
154
 
 
Acetone (0.17 mL, 2.4 mmol) was added to a solution of the amine 77 (0.2 g, 1.2 
mmol) in EtOH (0.8 M, 1.5 mL), followed by MgSO4 (15 mg) and the mixture was 
stirred at r.t. for 8 h; then NaBH4 (0.1 g, 7.2 mmol) was added and the mixture was left 
stirring at r.t overnight. The reaction mixture was quenched with an aqueous solution of 
NaOH (1.0 M, 2.0 mL), EtOH was removed under reduced pressure and the remaining 
solution was extracted with EtOAc (3 x 10 mL). The combined organic phases were 
washed with brine (2 x 5.0 mL), dried (Na2SO4) and concentrated under reduced 
pressure to give the title amine 84 as a pale yellow oil (0.15 g, 61%). RF: 0.2 (99.5:0.5, 
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CH2Cl2–MeOH); νmax/cm
-1
 (film) 3365, 2962, 1660, 1638, 1454, 1426, 1195, 996, 921, 
744; δH (500 MHz; CDCl3) 5.56 (1H, ddd, J 17.1, 10.1 and 8.4, 3-H), 5.06 (1H, dd, J 
10.1 and 1.1, 4-HA), 4.99 (1H, dd, J 17.1 and 1.1, 4-HB), 3.22 (1H, app. td, J 8.1, and 
6.1, 2-H), 2.84 (1H, m, isopropyl CH), 2.50 (1H, dd, J 13.7 and 6.1, 1-HA), 2.38 (1H, 
dd, J 13.7 and 7.8, 1-HB), 2.33 (3H, s, isoxazolyl 5-CH3), 2.22 (3H, s, isoxazolyl 3-
CH3), 1.06 (3H, d, J 6.1, isopropyl CH3), 0.97 (3H, d, J 6.2, isopropyl CH3); δC (75 
MHz; CDCl3) 165.9 (isoxazolyl C-5), 159.9 (isoxazolyl C-3), 140.3 (C-3), 120.9 (C-4), 
110.6 (isoxazolyl C-4), 59.1 (C-2), 45.7 (isopropyl C-1), 29.4 (C-1), 24.0 (isopropyl 
CH3A), 22.0 (isopropyl CH3B), 11.3 (isoxazolyl 5-CH3), 10.5 (isoxazolyl 3-CH3); m/z 
(ES) 209.1 (100%, [M+H]
+
); HRMS Found: 209.1648 (C12H20N2O, M+H requires 
209.1651). 
 
3-(3,5-Dimethylisoxazol-4-yl)-1-(1-(3,5-dimethylisoxazol-4-yl)but-3-en-2-yl)-1- 
(furanyl-2-ylmethyl)urea 85
100
 
 
The title compound 85 was prepared from the amine 80 (0.5 g, 2.1 mmol) and 4-
isocyanato-3,5-dimethylisoxazolyl (0.7 mL, 6.45 mmol) in CH2Cl2 stirring at 35 °C for 
1 day, according to general procedure B.
100
 The crude product was purified by flash 
chromatography (50:50, petrol–EtOAc) to give a yellow oil (0.60 g, 77%). RF: 0.3 
(60:40, petrol–EtOAc); νmax/cm
-1 
(film) 3320, 2928, 1722, 1660, 1651, 1645, 1515, 
1456, 1427, 1241, 1012, 917, 734 ; δH (500 MHz; CDCl3) 7.41 (1H, dd, J 1.9 and 0.8, 
furanyl 5-H), 6.40 (1H, dd, J 3.2 and 1.9, furanyl 4-H), 6.27 (1H, dd, J 3.2 and 0.8, 
furanyl 3-H), 5.60 (1H, ddd, J 17.3, 10.5 and 6.1, 3-H), 5.92 (1H, br. s., NH), 5.26 (1H, 
ddd, J 10.5, 1.5 and 1.1, 4-HA), 5.21 (1H, ddd, J 17.3, 1.5 and 1.1, 4-HB), 4.73 (1H, app. 
td, J 7.7 and 6.1, 2-H), 4.37 (1H, d, J 17.0, CHAHBN), 4.33 (1H, d, J 17.0, CHAHBN), 
2.78 (1H, d, J 14.6 and 7.8, 1-HA), 2.70 (1H, d, J 14.6 and 7.5, 1-HB), 2.30 (3H, s, 
isoxazolyl 5-CH3), 2.23 (3H, s, isoxazolyl 5′-CH3),  2.22 (3H, s, isoxazolyl 3-CH3), 2.08 
(3H, s, isoxazolyl 3′-CH3); δC (75 MHz; CDCl3) 166.3 (isoxazolyl C-5), 163.5 
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(isoxazolyl C-3), 160.1 (isoxazolyl C-5′), 158.26 (isoxazolyl C-3′), 156.0 (CO), 151.2 
(furanyl C-2), 143.2 (furanyl C-5), 136.8 (C-3), 118.5 (C-4), 114.8 (isoxazolyl C-4′),  
111.3 (furanyl C-4), 110.3 (isoxazolyl C-4), 108.9 (furanyl C-3), 59.1 (C-2), 42.8 
(CH2N), 25.7 (C-1), 11.6 (isoxazolyl 5-CH3), 11.3 (isoxazolyl 5′-CH3), 10.7 (isoxazolyl 
3-CH3), 9.8 (isoxazolyl 3′-CH3); m/z (ES) 385.1 (100%, [M+H]
+
); HRMS Found: 
407.1702 (C20H24N4O4, M+Na requires 407.1690). 
 
Ethyl 2-(3-(1-(3,5-dimethylisoxazol-4-yl)but-3-en-2-yl)-3-(furanyl-2-ylmethyl) 
ureido)acetate 86
100
 
 
The title compound 86 was prepared from the amine 80 (0.5 g, 2.0 mmol) and ethyl 
2-isocyanatoacetate (0.7 mL, 6.1 mmol) in CH2Cl2 stirring at 35 °C for 3 days, 
according to general procedure B.
100
 The crude product was purified by flash 
chromatography (99.5:0.5, CH2Cl2–MeOH) to give a yellow oil (0.52 g, 70%). RF: 0.45 
(95:5, CH2Cl2–MeOH); νmax/cm
-1 
(film) 3383, 2982, 1748, 1644, 1526, 149, 1377, 1195, 
1023, 933, 746; δH (500 MHz; CDCl3) 7.37 (1H, d, J 1.8, furanyl 5-H), 6.33 (1H, dd, J 
3.2 and 1.8, furanyl 4-H), 6.25 (1H, dd, J 3.2, furanyl 3-H), 5.92 (1H, ddd, J 17.3, 10.5 
and 6.3, 3-H), 5.26 (1H, t, J 4.9 NH), 5.19 (1H, d, J 10.5, 4-HA), 5.13 (1H, d, J 17.3, 4-
HB), 4.43 (1H, app. q, J 7.1, 2-H), 4.37 (1H, d, J 17.0, CHAHBN), 4.25 (1H, d, J 17.0, 
CHAHBN), 4.20 (2H, q, J 7.2, ethyl 1-H2), 3.99 (2H, d, J 4.9, CH2CO), 2.81 (1H, d, J 
14.5 and 7.1, 1-HA), 2.70 (1H, d, J 14.5 and 8.1, 1-HB), 2.27 (3H, s, isoxazolyl 5-CH3), 
2.20 (3H, s, isoxazolyl 3-CH3), 1.27 (3H, t, J 7.2 ethyl 2-H3); δC (75 MHz; CDCl3) 
170.9 (CO2Et), 166.0 (NCON), 159.7 (isoxazolyl C-5), 157.5 (isoxazolyl C-3), 151.0 
(furanyl C-2), 142.6 (furanyl C-5), 136.0 (C-3), 117.9 (C-4), 110.7 (furanyl C-4), 110.4 
(isoxazolyl C-4), 108.4 (furanyl C-3), 61.5 (ethyl C-1), 59.7 (C-2), 43.2 (CH2NCONH), 
43.0 (CH2CO2Et), 25.6 (C-1), 14.3 (ethyl C-2), 11.0 (isoxazolyl 5-CH3), 10.4 
(isoxazolyl 3-CH3); m/z (ES) 398.1 (100%, [M+Na]
+
); HRMS Found: 376.1882 
(C19H25N3O5, M+H requires 379.1867).  
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1-(4-Chlorobenzyl)-3-(3,5-dimethylisoxazol-4-yl)-1-(1-(3,5-dimethylisoxazol-4-yl) 
but-3-en-2-yl)urea 87
100
 
 
The title compound 87 was prepared from the amine 81 (0.3 g, 1.2 mmol) and 4-
isocyanato-3,5-dimethylisoxazolyl (0.4 mL, 3.6 mmol) in CH2Cl2 stirring at 35 °C for 1 
day, according to general procedure B.
100
 The crude product was dissolved in EtOAc 
(~10 mL), petrol was added until the precipitation was completed and the precipitate 
was removed by filtration. The filtrate was concentrated under reduced pressure to give 
a yellow oil (0.3 g, 58%). RF: 0.4 (95:5, CH2Cl2–MeOH); νmax/cm
-1
 (film) 3286, 2925, 
1663, 1643, 1492, 1463, 1242, 1091, 932, 751; δH (500 MHz; CDCl3) 7.35 (2H, d, J 8.4, 
phenyl 3- and 5- H), 7.20 (2H, d, J 8.4, phenyl 2- and 6-H), 5.93 (1H, ddd, J 17.1, 10.7 
and 6.6, 3-H), 5.44 (1H, br. s., NH), 5.25-5.18 (2H, m, 4-HA and 4-HB), 4.85 (1H, dt, J 
8.0 and 6.8, 2-H), 4.51 (1H, d, J 13.6, benzyl CHAHB), 4.30 (1H, d, J 13.6, benzyl 
CHAHB), 2.75 (1H, dd, J 14.5 and 8.0, 1-HA), 2.67 (1H, dd, J 14.5 and 7.3, 1-HB), 2.27 
(3H, s, isoxazolyl 5-CH3), 2.21 (3H, s, isoxazolyl 5′-CH3), 2.06 (3H, s, isoxazolyl 3-
CH3), 1.90 (3H, s, isoxazolyl 3′-CH3); δC (75 MHz; CDCl3) 165.9 (isoxazolyl C-5), 
163.4 (isoxazolyl C-5′), 159.7 (isoxazolyl C-3), 157.9 (isoxazolyl C-3′), 155.7 (CO), 
135.8 (C-3), 135.3 (phenyl C-1), 134.0 (phenyl C-4), 129.3 (phenyl C-3 and C-6),  
127.8 (phenyl C-2 and C-6), 119.0 (C-4), 114.1 (isoxazolyl C-4′), 110.3 (isoxazolyl C-
4), 58.5 (C-2), 47.9 (benzyl CH2), 25.6 (C-1), 11.2 (isoxazolyl 5-CH3), 10.7 (isoxazolyl 
3-CH3), 10.3 (isoxazolyl 5′-CH3), 9.4 (isoxazolyl 3′-CH3); m/z  (ES) 451.4 (100%, 
[M+Na]+); HRMS Found 451.1523 (C22H25ClN4O3, M+Na requires 451.1507).  
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1-Allyl-1-(4-chlorobenzyl)-3-(3,5-dimethylisoxazol-4-yl)urea 88
100
 
 
The title compound 88 was prepared from the amine 83 (0.3 g, 1.8 mmol) and 4-
isocyanato-3,5-dimethylisoxazolyl (0.6 mL, 5.3 mmol) in CH2Cl2 stirring at 35 °C for 2 
days, according to general procedure B.
100
 The crude product was dissolved in EtOAc 
(~10 mL), petrol was added until the precipitation was completed and the precipitate 
was removed by filtration. The filtrate was concentrated under reduced pressure to give 
a yellow oil (0.47 g, 82%). RF: 0.7 (80:20, petrol–EtOAc); νmax/cm
-1
 (film) 3295, 2926, 
1723, 158, 1635, 1515, 1492, 1248, 1092, 1014, 795; δH (500 MHz; MeOD-d4) 7.38 
(2H, d, J 8.6, phenyl 3- and 5-H), 7.31 (2H, d, J 8.6, phenyl 2- and 6-H),  5.88 (1H, ddd, 
J 17.1, 10.3 and 5.1, 2-H), 5.25 (1H, d, J 10.3 and 1.4, 3-HA), 5.23 (1H, dd, J 17.1, 3-
HB), 4.89 (2H, s, benzyl CH2), 4.00 (1H, d, J 5.1, 1-H2), 2.28 (3H, s, isoxazolyl 5-CH3), 
2.15 (3H, s, isoxazolyl 3-CH3); δC (75 MHz; MeOD-d4) 165.8 (isoxazolyl C-5), 160.4 
(isoxazolyl C-3), 158.8 (CO), 138.1 (phenyl C-1) 134.3 (C-2), 134.2 (phenyl C-4), 
134.2 (phenyl C-2 and C-6), 130.1 (phenyl C-3 and C-5), 117.1 (C-3), 116.4 (isoxazolyl 
C-4), 50.4 (benzyl CH2), 10.6 (isoxazolyl 5-CH3), 9.3 (isoxazolyl 3-CH3); m/z (ES) 
342.7 (100%, [M+Na]
+
) HRMS Found 320.1168 (C16H19ClN3O2 requires MH
+
 
320.1160). 
 
1-(4-Chlorobenzyl)-1-(1-(3,5-dimethylisoxazol-4-yl)but-3-en-2-yl)-3-ethylurea 89
100
 
 
The title compound 89 was prepared from the amine 81 (0.28 g, 1.0 mmol) and 
ethylisocyanate (0.23 mL, 3.0 mmol) in CH2Cl2 stirring at 35 °C for 1 day, according to 
general procedure B.
100
 The crude product was dissolved in EtOAc (~15 mL), washed 
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with an aqueous saturated solution of NaHCO3 (2 x 7.0 mL) and brine (2 x 7.0 ml). The 
organic phase was dried (MgSO4) and concentrated under reduced pressure to give a 
yellow oil (0.3 g, 87%). RF: 0.3 (94:6, CH2Cl2–MeOH); νmax/cm
-1
 (film) 3357, 2972, 
2930, 1633, 1530, 1450, 1293, 114, 929, 746; δH (500 MHz; CDCl3) 7.30 (2H, d, J 8.3, 
phenyl 3- and 5- H), 7.12 (2H, d, J 8.3, phenyl 2- and 6-H), 5.88 (1H, ddd, J 17.2, 10.4 
and 6.7, 3-H), 5.16 (1H, dd, J 17.2 and 1.0 4-HA), 5.12 (1H, dd, J 10.4 and 1.0 4-HB), 
4.55 (1H, app. q, J 7.0, 2-H), 4.38 (1H, d, J 17.4, benzyl CHAHB), 4.19 (1H, br. s., NH), 
4.15 (1H, d, J 17.4, benzyl CHAHB), 3.18 (2H, m, ethyl 1-H2), 2.79 (1H, dd, J 14.3 and 
7.1, 1-HA), 2.60 (1H, dd, J 14.3 and 8.1, 1-HB), 2.26 (3H, s, isoxazolyl 5-CH3), 2.19 
(3H, s, isoxazolyl 3-CH3), 1.00 (3H, t, J 7.2, ethyl 2-H3); δC (75 MHz; CDCl3) 165.9 
(isoxazolyl C-5), 159.7 (isoxazolyl C-3), 157.9 (CO), 136.2 (phenyl C-1), 136.1 (C-3), 
133.4 (phenyl C-4), 129.1 (phenyl C-3 and C-5), 127.9 (phenyl C-2 and C-6), 118.2 (C-
4), 110.2 (isoxazolyl C-4), 59.2 (C-2), 48.5 (benzyl CH2), 35.6 (ethyl C-1), 25.7 (C-1), 
15.4 (ethyl C-2), 11.1 (isoxazolyl 5-CH3), 10.3 (isoxazolyl 3-CH3); m/z (ES) 384.5 
(100%, [M+Na]
+
); HRMS Found 362.1634 (C19H24ClN3O2, M+H requires 362.1629).  
 
1-(4-Chlorobenzyl)-1-(1-(3,5-dimethylisoxazol-4-yl)but-3-en-2-yl)-3-(pyridin-3-
yl)urea 90
100
 
NN
H
O
O N
Cl
N
 
The title compound 90 was prepared from the amine 81 (0.4 g, 1.4 mmol) and 3-
isocyanatopyridine (0.5 g, 4.5 mmol) in CH2Cl2 stirring at 35 °C for 1 day, according to 
general procedure B.
100
 The crude product was purified by flash chromatography 
(99:1, CH2Cl2–MeOH) to give a yellow oil (0.5 g, 80%). RF: 0.6 (95:5, CH2Cl2–
MeOH); νmax/cm
-1
 (film) 3588, 2923, 1731, 1655, 1533, 1483, 1421, 1227, 1089, 931, 
801; δH (500 MHz; CDCl3) 8.26 (1H, d, J 3.9, py 4-H), 8.16 (1H, s, py 2-H), 7.86-7.84 
(1H, m, py 6-H), 7.30 (2H, d, J 8.3, phenyl 3- and 5- H), 7.29-7.26 (1H, m, py 5-H)
a
, 
                                                 
a 
Signal overlapping with δH 7.3
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7.12 (2H, d, J 8.3, phenyl 2- and 6-H), 5.88 (1H, ddd, J 17.2, 10.4 and 6.7, 3-H), 5.16 
(1H, dd, J 17.2 and 1.0, 4-HA), 5.12 (1H, dd, J 10.4 and 1.0, 4-HB), 4.55 (1H, app. q, J 
7.0, 2-H), 4.38 (1H, d, J 17.4, benzyl CHAHB), 4.19 (1H, br. s., NH), 4.15 (1H, d, J 17.4, 
benzyl CHAHB), 2.79 (1H, dd, J 14.2 and 7.1, 1-HA), 2.60 (1H, dd, J 14.2 and 8.1, 1-
HB), 2.26 (3H, s, isoxazolyl 5-CH3), 2.19 (3H, s, isoxazolyl 3-CH3); δC (75 MHz; 
CDCl3) 166.2 (isoxazolyl C-5), 162.9 (isoxazolyl C-3), 159.6 (CO), 155.14 (py C), 
144.65, 141.65, (py CH), 138.6 (phenyl C-1), 135.9 (C-3), 135.2 (phenyl C-4), 129.5 
(phenyl C-3 and C-5), 128.1 (phenyl C-2 and C-6), 127.3, 123.6 (py CH), 119.1 (C-4), 
109.8 (isoxazolyl C-4), 59.6 (C-2), 49.3 (benzyl CH2), 25.5 (C-1), 11.2 (isoxazolyl 5-
CH3), 10.3 (isoxazolyl 3-CH3); m/z (ES) 411.2 (100%, [M+H]
+
); HRMS Found 
411.1614 (C22H23ClN4O2, M+H requires 411.1631). 
 
1-(4-chlorobenzyl)-3-(3,5-dimethylisoxazol-4-yl)-1-(1-phenylbut-3-en-2-yl)urea 
91
100
 
 
The title compound 91 was prepared from the amine 82 (0.35 g, 1.3 mmol) and 4-
isocyanato-3,5-dimethylisoxazolyl (0.4 mL, 3.9 mmol) in CH2Cl2 stirring at 35 °C for 1 
day, according to general procedure B.
100
 The crude product was purified by flash 
chromatography (70:30, petrol–EtOAc) to give a yellow oil (0.43 g, 81%). RF: 0.4 
(50:50, petrol–EtOAc); νmax/cm
-1
 (film) 3311, 1367, 1494, 1465, 1245, 1089, 929, 748; 
δH (500 MHz; CDCl3) 7.33-7.27 (5H, m, Ar), 7.23 (2H, dd, J 8.0 and 6.7, Ar), 7.13 (2H, 
d, J 8.5, Ar), 6.0 (1H, ddd, J 17.3, 10.5, 5.6, 3-H), 5.31 (1H, ddd, J 17.3 4-HA), 5.25 
(1H, ddd, J 10.5, 4-HB), 5.00 (1H, app. dt, J 7.8, 5.5, 2-H), 4.51 (1H, d, J 17.1 benzyl 
CHAHB), 4.11 (1H, d, J 17.1 benzyl CHAHB), 3.08 (1H, dd, J 12.7 and 7.8, 1-HA), 3.04 
(1H, dd, J 12.7 and 5.5, 1-HB), 2.08 (3H, s, isoxazolyl 5-CH3), 1.93 (3H, s, isoxazolyl 3-
CH3); δC (75 MHz; CDCl3) 163.2 (isoxazolyl 5-C), 157.9 (isoxazolyl C-3), 155.8 (CO), 
137.8 (C Ar), 137.0 (C-3), 136.0, 133.7 (Ar C), 129.2, 129.1, 128.6, 128.5, 126.7 (Ar 
CH), 117.7 (C-4), 114.3 (isoxazolyl C-4), 60.4 (C-2), 48.3 (benzyl CH2), 38.0 (C-1) 
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14.2 (isoxazolyl 5-CH3), 10.8 (isoxazolyl 3-CH3); HRMS Found 410.1637 
(C23H24ClN4O2, M+H requires 410.1629). 
 
1-(1-(3,5-dimethylisoxazol-4-yl)but-3-en-2-yl)-3-ethyl-1-isobutylurea 92
100
 
 
The title compound 92 was prepared in from the amine 84 (80 mg, 0.4 mmol) and 
ethylisocyanate (0.1 mL, 1.2 mmol) in CH2Cl2 stirring at 35 °C for 2 days, according to 
general procedure B.
100
 The crude product was purified by flash chromatography 
(97.5:2.5, CH2Cl2–MeOH) to give a yellow oil (80 mg, 68%). RF: 0.4 (95:5, CH2Cl2–
MeOH); νmax/cm
-1
 (film) 3372, 2963, 1633, 1531, 1455, 1325, 1195, 1000, 919, 744; δH 
(500 MHz; CDCl3) 6.07 (1H, ddd, J 17.4, 10.5 and 5.4, 3-H), 5.14 (1H, dd, J 10.5 and 
1.2, 4-HA), 5.08 (1H, dd, J 17.4, 1.2, 4-HB), 4.32 (1H, t, J 4.7, NH), 4.07-4.01 (1H, m, 
isopropyl CH), 3.71-3.67 (1H, m, 2-H), 3.13 (2H, dd, J 13.7 and 7.0, propyl 1-H2), 2.90 
(1H, dd, J 14.6 and 8.3, 1-HA), 2.76 (1H, dd, J 14.6 and 7.0, 1-HB), 2.23 (3H, s, 
isoxazolyl 5-CH3), 2.16 (3H, s, isoxazolyl 3-CH3), 1.47-1.43 (2H, m, J 6.1, propyl 2-
H2), 1.03 (3H, d, J 6.7, isopropyl CH3A), 0.86 (3H, t, J 7.4, propyl 3-H3), 0.97 (3H, d, J 
6.27, isopropyl CH3B); δC (75 MHz; CDCl3) 166.3 (isoxazolyl C-5), 159.7 (isoxazolyl 
C-3), 157.3 (CO), 138.7 (C-3), 116.5 (C-4), 111.2 (isoxazolyl C-4), 55.9 (C-2), 47.2 
(isopropyl C-1), 42.5 (propyl C-1), 25.3 (C-1), 23.4 (propyl C-2), 21.3 (isopropyl 
CH3A), 21.1 (isopropyl CH3B), 11.5 (isoxazolyl 5-CH3), 11.0 (propyl C-3), 10.3 
(isoxazolyl 3-CH3); m/z (ES) 294.1 (100%, [M+H]
+
).; HRMS Found: 316.1987 
(C16H27N3O2, M+Na requires 316.1995).  
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(4S*, 5S*)-4-(Azidomethyl)-3-(3,5-dimethylisoxazol-4-yl)-5-((3,5-dimethylisoxazol-
4-yl) methyl)-1-(furan-2-ylmethyl)imidazolidin-2-one 93
124,137
 
 
The title compound 93 was prepared from the allyl urea 85 (1.6 mmol) according to 
general procedure F.
124,137
 The crude product was purified by flash chromatography 
(98.5:1.5, CH2Cl2–MeOH) to give a yellow oil (108 mg, 16% over two steps). RF: 0.6 
(94:6, CH2Cl2–MeOH); νmax/cm
-1 
(film) 2932, 2109, 1711, 1441, 1254, 1011, 750; δH 
(500 MHz; CDCl3) 7.43 (1H, dd, J 1.9 and 0.9, furanyl 5-H), 6.39 (1H, dd, J 3.2 and 
1.9, furanyl 4-H), 6.29 (1H, dd, J 3.2 and 0.9, furanyl 3-H), 4.91 (1H, d, J 15.8, 
NCHAHB), 4.05 (1H, d, J 15.8, NCHAHB), 3.55 (1H, ddd, J 7.7, 5.4 and 4.3, 5-H), 3.46 
(1H, ddd, J 5.8, 4.3 and 3.6, 4-H), 3.13 (1H, dd, J 12.5 and 5.8, 4-CHAHB), 3.05 (1H, 
dd, J 12.5 and 3.6, 4-CHAHB), 2.82 (1H, dd, J 14.8 and 5.4, 5-CHAHB), 2.55 (1H, dd, J 
14.8 and 7.7, 5-CHAHB), 2.34 (3H, s, isoxazolyl 5-CH3), 2.31 (3H, s, isoxazolyl 5′-
CH3), 2.21 (3H, s, isoxazolyl 3-CH3), 2.15 (3H, s, isoxazolyl 3′-CH3); δC (75 MHz; 
CDCl3) 166.5 (isoxazolyl C-5), 166.3 (CO), 159.3 (isoxazolyl C-3), 158.1 (furanyl C-2), 
157.0 (isoxazolyl C-5′), 149.7 (isoxazolyl C-3′), 142.8 (furanyl C-5), 113.2 (isoxazolyl 
C-4′), 110.7 (furanyl C-4), 109.2 (furanyl C-3), 108.4 (isoxazolyl C-4), 59.4 (C-5), 55.1 
(C-4), 52.0 (5-CH2), 39.5 (CH2NCO), 26.5 (4-CH2), 11.3 (isoxazolyl 5-CH3), 11.1 
(isoxazolyl 5′-CH3), 10.4 (isoxazolyl 3-CH3), 9.4 (isoxazolyl 3′-CH3); m/z (ES) 448.2 
(100%, [M+Na]
+
); HRMS Found: 448.1720 (C20H23N7O4, M+Na requires 448.1704). 
  159  
   
Ethyl 2-((4S*, 5S*)-5-(azidomethyl)-4-((3,5-dimethylisoxazol-4-yl)methyl)-3-
(furan-2-yl methyl)-2-oxoimidazolidin-1-yl)acetate 95
124,137
 
 
The title compound 95 was prepared from the allyl urea 86 (1.4 mmol) according to 
general procedure F.
124,137
 The crude product was purified by flash chromatography 
(99.5:0.5, CH2Cl2–MeOH) to give a yellow oil (116 mg, 20% over two steps). RF: 0.6 
(94:6, CH2Cl2–MeOH); νmax/cm
-1 
(film) 2934, 2107, 1742, 1704, 1457, 1202, 1015, 754; 
δH (500 MHz; CDCl3, 325 K) 7.37 (1H, dd, J 1.8 and 0.8, furanyl 5-H), 6.34 (1H, dd, J 
3.2 and 1.8, furanyl 4-H), 6.23 (1H, dd, J 3.2 and 0.8, furanyl 3-H), 4.85 (1H, d, J 15.8, 
3-CHAHB), 4.43 (1H, d, J 18.1, CHAHBCO2Et), 4.20 (2H, qd, J 7.1 and 3.3 ethyl 1-H2), 
4.04 (1H, d, J 15.8, 3-CHAHB), 3.69 (1H, d, J 18.1, CHAHBCO2Et), 3.37 (1H, app. td,  J 
5.3 and 4.1, 4-H), 3.29 (1H, ddd, J 9.1, 5.1 and 4.1, 5-H), 3.09 (1H, dd, J 12.6 and 5.2, 
4-CHAHB), 3.04 (1H, dd, J 12.6 and 5.6, 4-CHAHB), 2.81 (1H, dd, J 14.4 and 5.1, 5-
CHAHB), 2.54 (1H, dd, J 14.4 and 9.1, 5-CHAHB), 2.32 (3H, s, isoxazolyl 5-CH3), 2.17 
(3H, s, isoxazolyl 3-CH3), 1.29 (3H, t, J 7.1, ethyl 2-H3); δC (75 MHz; CDCl3) 169.6 
(CO2Et), 166.5 (isoxazolyl C-5), 159.4 (isoxazolyl C-3), 158.5 (NCON), 150.1 (furanyl 
C-2), 142.6 (furanyl C-5), 110.6 (furanyl C-4), 108.8 (furanyl C-3), 108.6 (isoxazolyl 
C-4), 61.4 (ethyl C-1), 57.6 (C-4), 55.5 (C-5), 51.4 (4-CH2), 43.5 (CH2CO2Et), 38.9 (3-
CH2), 26.0 (5-CH2), 14.2 (ethyl C-2), 11.1 (isoxazolyl 5-CH3), 10.3 (isoxazolyl 3-CH3); 
m/z (ES) 439.4 (100%, [M+Na]
+
). HRMS Found: 439.2204 (C19H24N6O5, M+Na 
requires 439.2197).  
  160  
   
(4S*, 5S*)-4-(Azidomethyl)-1-(4-chlorobenzyl)-3-(3,5-dimethylisoxazol-4-yl)-5-
((3,5-dimethyl isoxazol-4-yl)methyl)imidazolidin-2-one 98
124,137
 
 
The title compound 98 was prepared from the allyl urea 87 (0.7 mmol) according to 
general procedure F.
124,137
 The crude product was purified by flash chromatography 
(99.5:0.5, CH2Cl2–MeOH) to give a yellow oil (65 mg, 20% over two steps). RF: 0.3 
(95:5, CH2Cl2–MeOH); νmax/cm
-1 
(film) 2926, 2109, 1688, 1492, 1440, 1424, 1218, 
1200, 1062, 733; δH (500 MHz; CDCl3) 7.37 (2H, d, J 8.3, phenyl 3- and 5-H), 7.26 
(2H, d, J 8.3, phenyl 2- and 6-H), 5.03 (1H, d, J 14.9, benzyl CHAHB), 4.12 (1H, d, J 
14.9, benzyl CHAHB), 4.11 (1H, app. q, J 4.5, 5-H),  3.53 (1H, app. dt, J 8.6 and 5.0, 4-
H), 3.32 (1H, dd, J 13.5 and 4.3, 5-CHAHB), 3.04 (1H, dd, J 13.5 and 4.1, 5-CHAHB), 
2.72 (1H, dd, J 14.8 and 5.2, 4-CHAHB), 2.44 (1H, dd, J 14.8 and 8.6, 4-CHAHB), 2.25 
(3H, s, isoxazolyl 5-CH3), 2.24 (3H, s, isoxazolyl 5′-CH3), 2.15 (3H, s, isoxazolyl 3-
CH3), 2.09 (3H, s, isoxazolyl 3′-CH3); δC (75 MHz; CDCl3) 166.3 (isoxazolyl C-5), 
158.9 (isoxazolyl C-3), 156.6 (isoxazolyl C-5′), 153.1 (CO), 134.3 (phenyl C-4), 134.1 
(phenyl C-1), 129.6 (phenyl C-3 and C-5), 129.1 (phenyl C-2 and C-6), 107.8 
(isoxazolyl C-4), 79.4 (C-5), 56.9 (C-4), 52.5 (5-CH2), 46.8 (benzyl CH2), 25.8 (4-CH2), 
11.2 (isoxazolyl 5-CH3), 11.1 (isoxazolyl 5′-CH3), 10.3 (isoxazolyl 3-CH3), 9.9 
(isoxazolyl 3′-CH3), isoxazolyl C-3′ and isoxazolyl C-4 not observed; m/z (ES) 470.4 
(100%, [M+H]
+
); HRMS Found: 470.1709 (C22H24ClN7O3, M+H requires 470.1702).  
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4-(Azidomethyl)-1-(4-chlorobenzyl)-3-(3,5-dimethylisoxazol-4-yl)imidazolidin-one 
100
124,137
 
 
The title compound 100 was prepared from the allyl urea 88 (1.5 mmol) according 
to general procedure F.
124,137
 The crude product was purified by flash chromatography 
(20:80, hexane–EtOAc) to give a yellow oil (97 mg, 18% over two steps). RF: 0.7 
(96.5:3.5, CH2Cl2–MeOH); νmax/cm
-1 
(film) 3404, 3226, 2107, 1682, 1443, 1254, 1045, 
814; δH (500 MHz; CDCl3) 7.35 (2H, d, J 8.5, phenyl 3- and 5-H), 7.31 (2H, d, J 8.5, 
phenyl 2- and 6-H), 4.65 (1H, app. ddt, J 8.5, 6.3 and 4.4, 4-H), 4.54 (2H, s, benzyl 
CH2), 3.58 (1H, dd, J 13.3 and 4.3, 4-CHAHB), 3.50 (1H, app. t, J 8.5, 5-HA), 3.42 (1H, 
dd, J 13.3 and 4.5, 4-CHAHB), 3.27 (1H, dd, J 8.6 and 6.3, 5-HB), 2.26 (3H, s, isoxazolyl 
5-CH3), 2.17 (3H, s, isoxazolyl 3-CH3); δC (75 MHz; CDCl3) 156.8 (isoxazolyl C-5), 
156.4 (isoxazolyl C-3), 153.2 (CO), 134.6 (phenyl C-1), 133.8 (phenyl C-4), 129.5 
(phenyl C-3 and C-5), 129.0 (phenyl C-2 and C-6), 122.9 (isoxazolyl C-4), 74.0 (C-4), 
52.8 (benzyl CH2), 48.4 (C-5), 47.6 (4-CH2), 11.0 (isoxazolyl 3-CH3), 9.9 (isoxazolyl 5-
CH3); m/z (ES) 361.3 (100%, [M+H]
+
); HRMS Found: 361.1180 (C16H17ClN6O2, M+H 
requires 361.1179).  
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(4S*, 5S*)-4-(azidomethyl)-1-(4-chlorobenzyl)-5-((3,5-dimethylisoxazol-4-
yl)methyl)-3-ethyl imidazolidin-2-one 102
124,137
 
 
 The title compound 102 was prepared from the allyl urea 89 (0.9 mmol) according 
to general procedure F.
124,137
 The crude product was purified by flash chromatography 
(99.5:0.5, CH2Cl2–MeOH) to give a yellow oil (25 mg, 7% over two steps). RF: 0.8 
(96:4, CH2Cl2–MeOH); νmax/cm
-1 
(film) 3456, 2930, 2109, 1696, 1495, 1087, 936; δH 
(500 MHz; CDCl3) 7.30 (2H, dd, J 8.2, phenyl 3- and 5-H), 6.92 (2H, d, J 8.2, phenyl 2- 
and 6-H), 4.30 (1H, app. td, J 4.7 and 2.6, 5-H), 4.11 (1H, d, J 14.7, benzyl CHAHB), 
4.04 (1H, d, J 14.7, benzyl CHAHB), 3.64 (1H, dd J 12.7 and 2.6, 5-CHAHB), 3.42 (1H, 
m, 4-H), 3.39 (1H, dd, J 12.7 and 6.1, 5-CHAHB), 3.18-3.12 (3H, m, 4-CHAHB and ethyl 
1-H2), 2.75 (1H, dd, J 14.5 and 4.5, 4-CHAHB), 2.21 (3H, s, isoxazolyl 5-CH3), 2.18 
(3H, s, isoxazolyl 3-CH3) 1.00 (3H, t, J 6.7, ethyl 2-H3); δC (75 MHz; CDCl3) 166.2 
(isoxazolyl C-5), 159.6 (isoxazolyl C-3), 157.7 (CO), 134.7 (phenyl C-4), 134.1 (phenyl 
C-1), 129.4 (phenyl C-3 and C-5), 127.9 (phenyl C-2 and C-6), 110.5 (isoxazolyl C-4), 
64.9 (C-5), 53.0 (C-4), 39.7 (benzyl CH2), 35.6 (5-CH2), 29.7 (ethyl C-1), 22.5 (4-CH2), 
15.3 (ethyl C-3), 10.9 (isoxazolyl 5-CH3), 10.2 (isoxazolyl 3-CH3); m/z (ES) 403.2 
(100%, [M+H]
+
); HRMS Found: 403.1650 (C19H23ClN6O2, M+H requires 403.1649).  
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(4S*, 5S*)-4-(azidomethyl)-1-(4-chlorobenzyl)-5-((3,5-dimethylisoxazol-4-
yl)methyl)-3-(pyridin-3-yl)imidazolidin-2-one 103
124,137
 
 
The title compound 103 was prepared from the allyl urea 90 (1.1 mmol) according 
to general procedure F.
124,137
 The crude product was purified by flash chromatography 
(99.2:0.8, CH2Cl2–MeOH) to give a yellow oil (89 mg, 18% over two steps). RF: 0.2 
(96:4, CH2Cl2–MeOH); νmax/cm
-1 
(film) 2930, 2103, 1698, 1485, 1243, 1150, 1080, 801;  
δH (500 MHz; CDCl3) 8.49 (1H, app. s, py 4-H), 8.41 (1H, s, py 2-H), 8.24 (1H, app. d, 
J 3.9, py 6-H), 7.38 (2H, dd, J 8.4, phenyl 3- and 5-H), 7.36-7.33 (1H, app. m, py 5-H), 
7.28 (2H, d, J 8.4, phenyl 2- and 6-H), 5.11 (1H, d, J 15.3, benzyl CHAHB), 4.19 (1H, 
app. dd, J 5.1 and 4.3, 5-H)
a
, 4.15 (1H, d, J 15.3, benzyl CHAHB), 3.99 (1H, app. dt, J 
9.0 and 5.1, 4-H), 3.35 (1H, dd, J 13.4 and 4.1, 5-CHAHB), 3.01 (1H, dd, J 13.4 and 4.2, 
5-CHAHB), 2.76 (1H, dd, J 14.7 and 5.3, 4-CHAHB), 2.44 (1H, dd, J 14.7 and 9.0, 4-
CHAHB), 2.25 (3H, s, isoxazolyl 5-CH3), 2.07 (3H, s, isoxazolyl 3-CH3); δC (75 MHz; 
CDCl3) 166.3 (isoxazolyl C-5), 160.3 (isoxazolyl C-3), 159.0 (CO), 154.4, 145.7, 143.5 
(py CH), 140.6 (py C-1) 134.2 (phenyl C-4), 130.2 (phenyl C-1), 129.7 (phenyl C-3 and 
C-5), 129.6 (phenyl C-2 and C-6), 107.9 (isoxazolyl C-4), 79.4 (C-5), 56.4 (C-4), 52.6 
(5-CH2), 46.8 (benzyl CH2), 25.9 (4-CH2), 11.2 (isoxazolyl 5-CH3), 10.3 (isoxazolyl 3-
CH3); m/z (ES) 452.2 (100%, [M+H]
+
); HRMS Found: 452.1601 (C22H22ClN7O2, M+H 
requires 452.1596).   
                                                 
a 
Overlapping with signal at δH 4.15 
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 (4S*, 5S*)-4-(azidomethyl)-5-((3,5-dimethylisoxazol-4-yl)methyl)-3-isopropyl-1-
propyl imidazolidin-2-one 107
124,137
 
 
The title compound 107 was prepared from the allyl urea 92 (0.3 mmol) according 
to general procedure F.
124,137
 The crude product was purified by flash chromatography 
(50:50, petrol–EtOAc) to give a yellow oil (13 mg, 13% over two steps). RF: 0.1 (99:1, 
CH2Cl2–MeOH); νmax/cm
-1 
(film) 2962, 2930, 2106, 1699, 1635, 1455, 1198, 1035, 931, 
δH (500 MHz; CDCl3) 4.12 (1H, hept, J 6.9, isopropyl CH), 3.97 (1H, app. td, J 5.2 and 
3.0, 5-H), 3.55 (1H, app. dt J 10.5 and 3.5, 4-H), 3.20-3.16 (2H, m, propyl 1-H2), 3.12-
3.05 (2H, m, 5-CHAHB and 5-CHAHB), 2.77 (1H, dd, J 14.6 and 3.9, 4-CHAHB), 2.43 
(1H, dd, J 14.6 and 10.5, 4-CHAHB), 2.37 (3H, s, isoxazolyl 5-CH3), 2.26 (3H, s, 
isoxazolyl 3-CH3), 1.54-1.47 (2H, m, propyl 2-H2), 1.31 (1H, d, J 6.8, isopropyl CH3A), 
1.26 (1H, d, J 6.9, isopropyl CH3B), 0.9 (3H, t, J 7.4, propyl-3H3); δC (75 MHz; CDCl3) 
170.3 (isoxazolyl C-5), 166.7 (isoxazolyl C-3), 159.2 (CO), 108.9 (isoxazolyl C-4), 77.8 
(C-5), 55.7 (C-4), 53.1 (5-CH2), 48.3 (propyl C-1), 46.0 (isopropyl CH), 28.3 (4-CH2) 
25.3 (propyl C-2), 22.0, 19.3 (isopropyl CH3A and CH3B) 15.6 (propyl C-3), 11.3 
(isoxazolyl 5-CH3), 10.6 (isoxazolyl 3-CH3); m/z (ES) 335.0 (100%, [M+H]
+
); HRMS 
Found: 335.2202 (C16H26N6O2, M+H requires 335.2190).  
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(4S*, 5S*)-4-(Aminomethyl)-3-(3,5-dimethylisoxazol-4-yl)-5-((3,5-dimethylisoxazol-
4-yl) methyl)-1-(furan-2-ylmethyl)imidazolidin-2-one 94
138
 
 
The title compound 94 was prepared from the azide 93 (0.1 mmol) and 
trimethylphospine (solution 1 M in THF, 0.16 mL, 0.16 mmol), according to general 
procedure G.
138
 The crude product was purified by HPLC (5:95, MeCN–H2O in 45 
minutes) to give a yellow oil (8.0 mg, 18%). RF: 0.3 (95:5, CH2Cl2–MeOH)
a
; δH (500 
MHz; CDCl3) 7.43 (1H, d, J 1.9, furanyl 5-H), 6.33 (1H, dd, J 3.1 and 1.9, furanyl 4-H), 
6.27 (1H, d, J 3.1 furanyl 3-H), 4.70 (1H, d, J 15.8, 3-CHAHB), 4.10 (1H, d, J 15.8, 3-
CHAHB), 3.60 (1H, app. td, J 5.6 and 3.8, 5-H), 3.31 (1H, app. dt, J 7.6 and 3.6, 4-H), 
2.73 (1H, app. d, J 5.8, 5-CHAHB), 2.72 (1H, app. d, J 5.4, 5-CHAHB)
b
, 2.49 (1H, dd, J 
13.1 and 3.4, 4-CHAHB), 2.35 (1H, dd, J 13.1 and 7.6, 4-CHAHB), 2.29 (3H, s, 
isoxazolyl 5-CH3), 2.11 (6H, s, isoxazolyl 5′-CH3 and isoxazolyl 3-CH3), 1.97 (3H, s, 
isoxazolyl 3′-CH3), NH2 not observed; δC (75 MHz; CDCl3) 168.6 (isoxazolyl C-5), 
168.2 (isoxazolyl C'-5), 161.5 (CO) 160.1 (isoxazolyl C-3), 159.8 (isoxazolyl C-3′), 
151.5 (furanyl C-2), 144.2 (furanyl C-5), 111.7 (isoxazolyl C-4), 111.6 (furanyl C-4), 
110.7 (isoxazolyl C-4'), 110.2 (furanyl C-3), 63.5 (C-5), 57.3 (C-4), 44.2 (5-CH2), 40.3 
(3-CH2), 26.7 (4-CH2), 11.3 (isoxazolyl 5-CH3), 11.0 (isoxazolyl 5′-CH3), 10.5 
(isoxazolyl 3-CH3), 9.7 (isoxazolyl 3′-CH3); m/z (ES) 400.32 (100%, [M+H]
+
).; HRMS 
Found: 400.1988 (C20H25N5O4 M+H requires 400.1979).  
                                                 
a 
Insufficient quantity to perform the 
 
I.R. analysis  
b
 Signal overlapping with the one at 2.73 
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(1S*, 8aS*)-1-((3,5-Dimethylisoxazol-4-yl)methyl)-2-(furan-2-ylmethyl) 
tetrahydroimidazo[1,5-a]pyrazine-3,6(5H,7H)-dione 97
138
 
 
The title compound 97 was prepared from the azide 95 (0.07 mmol) and 
trimethylphospine (solution 1M in THF, 0.1 mL, 0.1 mmol), according to general 
procedure G.
138
 The crude product was purified by HPLC (5:95, MeCN–H2O in 45 
minutes) to give a yellow oil (2.0 mg, 8%). RF: 0.2 (94:6, CH2Cl2–MeOH)
a
; δH (500 
MHz; CDCl3) 7.39 (1H, dd, J 1.2 and 0.5, furanyl 5-H), 6.36 (1H, dd, J 2.8 and 1.2, 
furanyl 4-H), 6.27 (1H, dd, J 2.8 and 0.5, furanyl 3-H), 4.88 (1H, d, J 15.7, 2-CHAHB), 
4.49 (1H, d, J 18.1, 5-HA), 4.03 (1H, d, J 15.7 2-CHAHB), 3.73 (1H, d, J 18.1, 5-HB), 
3.36 (1H, app. dt J 10.6 and 3.7, 9-H), 3.12 (1H, app. dt, J 9.3, and 3.5, 1-H), 3.07 (1H, 
app. t, J 11.2, 8-HA), 2.90 (1H, dd, J 11.5 and 4.5, 8-HB), 2.85 (1H, dd, J 14.6, 5.3, 1-
CHAHB), 2.45 (1H, dd, J 14.6, 9.3, 1-CHAHB), 2.33 (3H, s, isoxazolyl 5-CH3), 2.17 (3H, 
s, isoxazolyl 3-CH3), NH not observed; δC (75 MHz; MeOD-d4)b 168.9 (CO2NH), 
166.9 (isoxazolyl C-5), 160.1 (isoxazolyl C-3), 159.1 (NCON), 150.9 (furanyl C-2), 
144.3 (furanyl C-5), 111.6 (furanyl C-4), 110.3 (furanyl C-3), 109.0 (isoxazolyl C-4), 
57.6 (ethyl C-1), 54.6 (C-9), 45.2 (1-CH2), 44.8 (C-5), 39.7 (2-CH2), 25.7 (C-8), 17.4 
(isoxazolyl 5-CH3), 16.9 (isoxazolyl 3-CH3); m/z (ES) 367.1 (100%, [M+Na]
+
); HRMS 
Found: 367.1379 (C17H20N4O4, M+Na requires 367.1377).   
                                                 
a 
Quantity was not sufficient to perform the 
 
I.R. analysis  
b 
Quaternary carbons assigned through HMBC experiment 
  167  
   
 (4S*, 5S*)-4-(aminomethyl)-1-(4-chlorobenzyl)-3-(3,5-dimethylisoxazol-4-yl)-5-
((3,5-dimethyl isoxazol-4-yl)methyl)imidazolidin-2-one 99
138
 
 
The title compound 98 was prepared from the azide 99 (0.11 mmol) and 
trimethylphospine (solution 1 M in THF, 0.17 mL, 0.17 mmol), according to general 
procedure G.
138
 The crude product was purified by mass directed chromatography 
(5:95, MeOH–H2O) to give a yellow oil (4.6 mg, 9%). RF: 0.2 (95:5, CH2Cl2–MeOH)
a
; 
δH (500 MHz; MeOD-d4) 7.55-7.46 (4H, m, phenyl 3-, 5-, 2- and 6-H), 5.01 (1H, d, J 
15.5, benzyl CHAHB), 4.61 (app. dt, J 8.8 and 4.3, 5-H), 4.47 (1H, d, J 15.5, benzyl 
CHAHB), 3.79 (1H, app. dt J 6.4 and 4.9, 4-H),  3.02 (1H, dd, J 14.0 and 8.8, 5-CHAHB), 
2.99 (1H, d, J 14.0 and 4.1, 5-CHAHB), 2.95 (1H, dd, J 15.1 and 4.9, 4-CHAHB), 2.50 
(1H, dd, J 15.1 and 6.4, 4-CHAHB), 2.41 (3H, s, isoxazolyl 5-CH3), 2.26 (3H, s, 
isoxazolyl 5′-CH3), 2.23 (3H, s, isoxazolyl 3-CH3), 2.15 (3H, s, isoxazolyl 3′-CH3), NH2 
not observed; δC (75 MHz; MeOD-d4) 168.8 (isoxazolyl C-5), 161.1 (isoxazolyl C-3), 
158.2 (isoxazolyl C-5′), 158.1 (CO), 154.4 (isoxazolyl C-3'), 135.3 (phenyl C-4), 131.0 
(phenyl C-2 and C-6), 130.5 (phenyl C-1), 130.3 (phenyl C-3 and C-5), 114.2 
(isoxazolyl C-4), 109.4 (isoxazolyl C-4'), 79.8 (C-5), 60.3 (C-4), 47.4 (benzyl CH2), 
43.0 (5-CH2), 25.2 (4-CH2); 11.3 (isoxazolyl 5-CH3), 10.9 (isoxazolyl 5′-CH3), 10.4 
(isoxazolyl 3-CH3), 9.9 (isoxazolyl 3′-CH3); m/z (ES) 444.3 (100%, [M+H]
+
); HRMS 
Found: 444.1800 (C22H26ClN5O3, M+H requires 444.1797).  
                                                 
a 
Insufficient quantity to perform the 
 
I.R. analysis  
  168  
   
4-(Aminomethyl)-1-(4-chlorobenzyl)-3-(3,5-dimethylisoxazol-4-yl)imidazolidin-2-
one 101
138
 
 
The title compound 101 was prepared from the azide 100 (0.27 mmol) and 
trimethylphospine (solution 1 M in THF, 0.41 mL, 0.41 mmol), according to general 
procedure G
138
. The crude product was purified by HPLC (5:95, MeCN–H2O in 45 
minutes) to give a yellow oil (2.6 mg, 7%). RF: 0.4 (95:5, CH2Cl2–MeOH)
a
; δH (500 
MHz; DMSO-d6) 7.44 (2H, d, J 8.5, phenyl 3- and 5-H), 7.41 (2H, d, J 8.5, phenyl 2- 
and 6-H), 4.84 (1H, app. ddt, J 8.5, 7.7 and 4.0, 4-H), 4.52 (1H, d, J 15.3, benzyl 
CHAHB), 4.47 (1H, d, J 15.3, benzyl CHAHB), 3.59 (1H, app. t, J 8.5, 4-CHAHB), 3.25 
(1H, app d, J 8.5, 4-CHAHB)
b
, 3.16 (1H, dd, J 13.8 and 4.0, 5-HA), 3.08 (1H, dd, J 13.8 
and 7.7, 5-HB), 2.18 (3H, s, isoxazolyl 5-CH3), 2.03 (3H, s, isoxazolyl 3-CH3), NH2 not 
observed; δC (75 MHz; DMSO-d6) 156.2 (isoxazolyl C-5), 155.4 (isoxazolyl C-3), 
153.0 (CO), 135.6 (phenyl C-4), 132.0 (phenyl C-1), 129.9 (phenyl C-2 and C-6), 128.5 
(phenyl C-3 and C5), 95.9 (isoxazolyl C-4), 73.2 (C-4), 48.0 (4-CH2), 47.4 (benzyl 
CH2), 40.1 (C-5), 10.9 (isoxazolyl 5-CH3), 9.7 (isoxazolyl 3-CH3); m/z (ES) 335.1 
(100%, [M+H]
+
); HRMS Found: 669.2457 (C16H19ClN4O2, M2+H requires 669.2465).  
                                                 
a
 Insufficient quantity to perform the 
 
I.R. analysis  
b 
Signal masked by solvent 
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(4S*, 5S*)-4-(Aminomethyl)-1-(4-chlorobenzyl)-5-((3,5-dimethylisoxazol-4-
yl)methyl)-3-(pyridin-3-yl)imidazolidin-2-one 104
138
 
 
The title compound 104 was prepared from the azide 103 (0.23 mmol) and 
triphenylphospine (90 mg, 0.34 mmol), according to general procedure G.
138
 The 
crude product was purified by flash chromatography (99:1, CH2Cl2–MeOH); to give a 
yellow oil (28 mg, 27%). RF: 0.4 (92:8, CH2Cl2–MeOH); νmax/cm
-1 
(film) 3407, 2922, 
1695, 1488, 1432, 1252, 1086, 739; δH (500 MHz; CDCl3) 8.61 (1H, d, J 2.5 py 2-H), 
8.34 (1H, dd, J 4.5 and 1.1, py 4-H), 8.12 (1H,. ddd, J 8.4, 2.5 and 1.1, py 6-H), 7.34 
(2H, dd, J 8.4, phenyl 3- and 5-H), 7.30 (1H, dd, J 8.4 and 4.5, py 5-H), 7.21 (2H, d, J 
8.4, phenyl 2- and 6-H), 4.96 (1H, d, J 15.3, benzyl CHAHB), 4.02 (1H, d, J 15.3, benzyl 
CHAHB),  3.74 (1H, app. dt J 6.3 and 3.2, 4-H), 3.59 (1H, ddd, J 8.5, 5.6 and 3.2, 5-H), 
2.73 (1H, dd, J 14.7 and 5.6, 5-CHAHB), 2.69 (1H, dd, J 13.5 and 6.3, 4-CHAHB), 2.59 
(1H, dd, J 13.3 and 3.0, 4-CHAHB), 2.44 (1H, dd, J 14.7 and 8.5, 5-CHAHB), 2.27 (3H, s, 
isoxazolyl 5-CH3), 2.11 (3H, s, isoxazolyl 3-CH3), NH2 not observed; δC (75 MHz; 
CDCl3) 166.2 (isoxazolyl C-5), 159.3 (isoxazolyl C-3), 156.6 (phenyl C-1), 144.6 (py 
C-1), 140.5, (py C-5), 135.5 (phenyl C-4), 134.0 (CO), 133.9 (py C-4) 129.6 (phenyl C-
3 and C-5), 129.0 (phenyl C-2 and C-6), 127.5 (py C-2), 123.7 (py C-6), 108.3 
(isoxazolyl C-4), 59.8 (C-4), 54.2 (C-5), 45.5 (benzyl CH2), 41.8 (5-CH2),  26.8 (4-
CH2), 11.2 (isoxazolyl 5-CH3), 10.4 (isoxazolyl 3-CH3); m/z (ES) 426.2 (100%, 
[M+H]
+
); HRMS Found: 426.1704 (C22H22ClN5O2, M+H requires 426.1691).  
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 (4S*, 5S*)-4-(Aminomethyl)-5-benzyl-1-(4-chlorobenzyl)-3-(3,5-dimethylisoxazol-
4-yl) imidazolidin-2-one 106
124,137, 138
 
 
The azide 105 (0.08 mmol) was prepared from the allyl urea 91 (1.0 mmol) 
according to general procedure F.
124,137
 After elution through a silica plug (40:60, 
petrol–EtOAc) and evaporation under reduced pressure, the azide 105 was mixed with 
triphenylphosphine (0.03 g, 0.13 mmol) according to general procedure G
138
 and the 
crude product was purified by flash chromatography (50:50 → 100:0, petrol–EtOAc); to 
give the title imidazolidinone 106, as a yellow oil (11 mg, 2.5% over three steps). RF: 
0.1 (10:90, petrol–EtOAc); νmax/cm
-1 
(film) 2922, 1717, 1678, 1446, 1408, 1247, 1091, 
1064, 725; δH (500 MHz; CDCl3) 7.44 (3H, app. s, Ar CH), 7.39-7.36 (3H, m, Ar CH), 
7.32-7.29 (1H, m, Ar CH), 7.28 (2H, dd, J 6.8 and 1.3, Ar CH), 4.95 (1H, d, J 15.7, 
benzyl CHAHB), 4.45 (1H, d, J 15.7, benzyl CHAHB), 4.41 (1H, app. dt J 6.9 and 4.7, 4-
H), 3.99 (1H, app. dt, J 6.7 and 4.7, 5-H), 3.07 (1H, dd, J 13.8 and 4.5, 5-CHAHB), 2.99 
(1H, dd, J 13.8 and 6.7, 5-CHAHB), 2.54 (1H, dd, J 13.7 and 6.9, 4-CHAHB), 2.47 (1H, 
dd, J 13.7 and 4.6, 4-CHAHB), 2.15 (3H, s, isoxazolyl 5-CH3), 2.04 (3H, s, isoxazolyl 3-
CH3), NH2 not observed; δC (75 MHz; CDCl3) 158.5 (isoxazolyl C-5), 158.3 (isoxazolyl 
C-3), 156.8 (CO), 137.2 (phenyl C-1), 137.0 (phenyl C-1'), 134.7 (phenyl C-4), 130.9, 
130.8, 129.9 (Ar CH) 129.5 (phenyl C-4'), 128.3 (Ar CH), 125.4 (isoxazolyl C-4), 83.9 
(C-4), 61.4 (C-5), 46.8 (benzyl CH2), 45.5 (4-CH2), 38.8 (5-CH2), 10.8 (isoxazolyl 5-
CH3), 9.8 (isoxazolyl 3-CH3); m/z (ES) 425.2 (100%, [M+H]
+
); HRMS Found: 
425.1744 (C23H25ClN4O2, M+H requires 425.1738).  
171 
 
(4R*, 5S*)-1-(4-chlorobenzyl)-3-(3,5-dimethylisoxazol-4-yl)-5-((3,5-
dimethylisoxazol-4-yl) methyl)-4-(iodomethyl)imidazolidin-2-one 111
124
  
 
To a solution of the allyl urea 87 (0.1 mmol) in CH2Cl2 (0.22 M), trimethyl- 
trifluoromethanesulfonate (0.1 mL, 0.56 mmol) was added, followed by DBU
 
(90 L, 
0.6 mmol) and the resulting mixture was stirred at r.t. for 1h and half. The solvent was 
removed under reduced pressure, the crude material was dissolved in dry THF (0.16 M), 
iodine was added (2.0 eq.) and the mixture was left stirring at r.t overnight, then at 
reflux for 3 h. The reaction mixture was poured in an aqueous saturated solution of 
Na2S2SO4 (2.0 mL) and extracted with EtOAc (3 x 1.0 mL); the combined organic 
phases were dried (MgSO4) and concentrated under reduced pressure. The crude 
product was purified by mass directed chromatography (5:95, CH3CN-H2O) to give the 
imidazolidinone 111 as a yellow oil (6 mg, 12%). RF: 0.7 (10:10:80, toluene–petrol–
EtOAc); νmax/cm
-1 
(film) 2926, 2853, 1686, 1632, 1424, 1261, 1088, 614; δH (500 MHz; 
CDCl3) 7.37 (2H, d, J 8.3, phenyl 3- and 5-H), 7.26 (2H, d, J 8.3, phenyl 2- and 6-H), 
5.02 (1H, d, J 15.2, benzyl CHAHB), 4.09 (1H, d, J 15.2, benzyl CHAHB), 4.04 (1H, app. 
dt J 6.5 and 4.5, 5-H),  3.54 (1H, ddd, J 8.2, 5.4 and 4.4, 4-H), 3.02-2.99 (2H, m, 5-
CHAHB and 5-CHAHB), 2.71 (1H, dd, J 14.7 and 5.4, 4-CHAHB) 2.50 (1H, dd, J 14.7 and 
8.2, 4-CHAHB), 2.28 (3H, s, isoxazolyl 5-CH3), 2.27 (3H, s, isoxazolyl 5′-CH3), 2.17 
(3H, s, isoxazolyl 3-CH3), 2.12 (3H, s, isoxazolyl 3′-CH3); δC (75 MHz; CDCl3) 166.4 
(isoxazolyl C-5), 159.1 (isoxazolyl C-3), 156.6 (isoxazolyl C-5′), 156.4 (CO), 152.4 
(isoxazolyl C-3'), 134.3 (phenyl C-4), 129.6 (phenyl C-2 and C-6), 129.2 (phenyl C-3 
and C-5), 120.3 (phenyl C-1), 108.1 (isoxazolyl C-4), 105.0 (isoxazolyl C-4'), 79.6 (C-
5), 60.2 (C-4), 46.8 (benzyl CH2), 25.8 (5-CH2), 11.3 (isoxazolyl 5-CH3), 11.3 
(isoxazolyl 5′-CH3), 10.4 (isoxazolyl 3-CH3), 10.2 (isoxazolyl 3′-CH3), 5.2 (4-CH2); m/z 
(ES) 555.0 (100%, [M+H]
+
); HRMS Found: 555.0664 (C22H24ClIN4O3, M+H requires 
555.0670).  
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1-Benzyl-4-(hydroxymethyl)-3-phenylimidazolidin-2-one, 112
155
 
 
AgOAc (70 mg, 0.4 mmol) was added to a solution of the iodide 73 (70 mg, 0.17 
mmol) in AcOH (1.7 mL) and the resulting mixture was stirred at 70 °C for three days. 
The mixture was allowed to reach r.t., then CH2Cl2 (15 mL) and an aqueous saturated 
solution of NaHCO3 (15 mL) were added portion wise. The phases were separated and 
the organic phase was washed with H2O (2 x 8.0 mL) and brine (2 x 8.0 mL), dried 
(MgSO4) and concentrated under reduced pressure to give a crude product 116 which 
was used without further purification. 
K2CO3 (30 mg, 0.22 mmol) was added to a solution of 116 (35 mg, 0.1 mmol) in 
MeOH (2.0 mL) and the resulting mixture was stirred at r.t. for 36 hours. The solvent 
was removed and the crude material was partitioned between CH2Cl2 (5.0 mL) and H2O 
(5.0 mL); the phases were separated and the organic phase was washed with brine (2 x 
2.0 mL), dried (MgSO4) and concentrated under reduced pressure. The crude product 
was purified by flash chromatography (50:50, hexane–EtOAc) to give the title 
imidazolidione 112 as a yellow oil (13.6 mg, 28% over two steps). RF: 0.35 (40:60, 
petrol–EtOAc); νmax/cm
-1
 (film) 3369, 2961, 2927, 1681, 1446, 1260, 1088, 800; δH 
(500 MHz; CDCl3) 7.50 (2H, d J 8.3, Ar CH), 7.42-7.27 (7H, m, Ar CH), 7.11 (1H, t, J 
7.5, Ar CH), 4.54 (1H, d, J 15.0, benzyl CHAHB), 4.42 (1H, d, J 15.0, benzyl CHAHB), 
4.35 (1H, app. dtd, J 9.2, 5.1 and 3.0, 4-H), 3.77 (1H, dd, J 11.3 and 5.2, 4-CHAHB), 
3.64 (1H,.dd, J 11.3 and 3.0, 4-CHAHB), 3.47 (1H, app. t, J 9.2, 5-HA), 3.36 (1H, dd, J 
8.9 and 5.1, 5-HB), OH not observed; δC (75 MHz; CDCl3) 158.0 (CO), 129.1, 128.7, 
128.2 (Ar 3 x CH), 127.6, 124.0 (Ar 2 x C), 121.1 (Ar CH), 61.3 (4-CH2), 54.3 (C-4), 
48.0 (benzyl CH2), 44.4 (C-5); m/z (ES) 305.0 (100%, [M+Na]
+
); HRMS Found: 
305.1262 (C17H18N2O2 M+Na requires 305.1260).  
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4-(Azidomethyl)-1-methyl-3-phenylimidazolidin-2-one, compound 119
100, 124,137
 
 
The urea 117 was prepared from methyl allyl amine (70 L, 0.7 mmol) and 
phenylisocyanate (0.15 mL, 1.4 mmol) with stirring overnight according to general 
procedure B.
100
 The reaction mixture was filtered and concentrated under reduced 
pressure to give a crude product which was used without further purification for the 
preparation of the azide 119 according to general procedure F
124,137
. The crude product 
was purified by flash chromatography (70:30, hexane–EtOAc) to give the title azide 119 
as a white solid (22 mg, 14% over three steps). RF: 0.2 (50:50, petrol–EtOAc); m.p. 62-
65 
oC; νmax/cm
-1
 (film) 2933, 2868, 2094, 1687, 1494, 1427, 1377, 1248, 1160, 747; δH 
(500 MHz; CDCl3) 7.44 (2H, m, phenyl 2- and 6-H), 7.36 (2H, m, phenyl 4-H), 7.12 
(1H, tt, J 7.4 and 1.1, phenyl 3- and 5-H), 4.39 (1H, dddd, J 9.9, 6.6, 4.6 and 3.2, 4-H), 
3.59 (1H, app. t, J 9.1, 5-HA), 3.50 (1H, dd, J 12.6 and 6.6, 4-CHAHB), 3.44 (1H, dd, J 
12.6 and 3.2, 4-CHAHB), 3.36 (1H, dd, J 9.1 and 4.6, 5-HB), 2.9 (3H, s, CH3); δC (75 
MHz; CDCl3) 157.9 (CO), 138.1 (phenyl C-1), 129.2 (phenyl C-2 and C-6), 124.2 
(phenyl C-4), 121.1 (phenyl C-3 and C-5), 51.3 (C-4), 47.9 (4-CH2), (C-5), 31.0 (CH3); 
m/z (ES) 254.0 (100%, [M+Na]
+
); HRMS Found: 232.1202 (C11H13N5O M+H requires 
232.1193).  
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(4R*, 5S*)-1-Ethyl-4-(hydroxymethyl)-5-(naphthalen-2-ylmethyl)-3-phenyl 
imidazolidin-2-one, 114
156
 
 
A few drops of hydrochloric acid (12 M) were added to a solution of the 
imidazolidinone 60 (40 mol) in MeOH (0.6 mL) and the resulting mixture was stirred 
at r.t. for 2 days. Water (1.0 mL) was added and the mixture was extracted with EtOAc; 
the organic phase was washed with brine (2 x 1.0 mL), dried (MgSO4) and concentrated 
under reduced pressure to give a crude product which was purified by flash 
chromatography to give the title imidazolidinone 114 as an amorphous solid (6 mg, 
42%). RF: 0.25 (40:60, petrol–EtOAc); νmax/cm
-1
 (film) 3385, 2931, 1677, 1501, 1431, 
1261, 1060, 909, 750; δH (500 MHz; CDCl3) 7.85-7.79 (3H, m, naphthalenyl 3-, 4- and 
5- or 8-H), 7.65 (1H, s, naphthalenyl 1-H), 7.51-7.45 (2H, m, naphthalenyl 6- and 7-H), 
7.39-7.34 (3H, m, naphthalenyl 5- or 8-H and phenyl 2- and 6-H), 7.28-7.28 (2H, m, 
phenyl 3- and 5-H),
a
 7.03 (1H, app.t, J 7.5, phenyl 4-H), 4.09 (1H, app. dt, J 8.8 and 4.5, 
5-H), 3.99 (1H, app. dt, J 7.1 and 4.5, 4-H), 3.73 (1H, dq, J 14.7 and 7.3, ethyl 1-HA), 
3.57 (1H, dd, J 11.7 and 4.7, 4-CHAHB), 3.34 (1H, dd, J 13.7 and 4.7, 5-CHAHB), 3.25-
3.09 (2H, m, ethyl 1-HB and 4-CHAHB), 2.88 (1H, dd, J 13.7 and 8.8, 5-CHAHB), 1.24 
(3H, t, J 7.1, ethyl 2-H3); δC (75 MHz; CDCl3) 157.1 (CO), 138.8 (phenyl C-1), 133.7 
(naphthalenyl C-2), 133.5, 132.4, (naphthalene C-1a and C-8a), 128.9 (phenyl C-3 and 
C-5), 128.6, 128.1, 127.7, 127.5, 127.2, 126.4, 125.8 (naphthalene 7 x CH), 123.6 
(phenyl C-4), 120.5 (phenyl C-2 and C-6), 61.2 (4-CH2), 59.6 (C-4), 55.2 (C-5), 39.5 
(5-CH2), 36.5 (ethyl C-1), 13.1 (ethyl C-2); m/z (ES) 383.2 (100%, [M+Na]
+
); HRMS 
Found: 383.1736 (C23H24N2O2 M+Na requires 383.1729).  
                                                 
a
 Signal
 
masked by the solvent peak
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1-(Naphthalen -2-yl)but-3-en-2-amine, 120
126
 
 
The title compound 120 was prepared from diphenyl methylene propenamine 78 
(4.1 g, 18.4 mmol) and 2-chloromethylnaphthalenyl (3.2 mL, 18.4 mmol) in the 
presence of n-Butyl lithium (7.4 mL, 18.4 mmol) according to general procedure D.
126
 
A yellow oil was obtained and used without further purification (0.3 g, 20%). RF: 0.1 
(90:10, petrol–EtOAc); νmax/cm
-1
 (film) 3054, 2922, 1598, 1506, 1435, 1367, 994, 918, 
814, 748; δH (500 MHz; CDCl3) 7.83-7.78 (3H, m, naphthalenyl 3-, 4- and 5- or 8-H), 
7.66 (1H, s, naphthalenyl 1-H), 7.48-7.43 (2H, m, naphthalenyl 6- and 7-H), 7.35 (1H, 
dd, J 8.4 and 1.6, naphthalenyl 5- or 8-H), 5.94 (1H, ddd, J 17.1, 10.3 and 6.26, 3-H), 
5.17 (1H, dd, J 17.1 and 1.4, 4-HA), 5.06 (1H, dd, J 10.3 and 1.4, 4-HB), 3.74-3.69 (1H, 
m, 2-H), 3.00 (1H, dd, J 13.3 and 5.6, 1-HA), 2.79 (1H, dd, J 13.3 and 8.3, 1-HB), 1.5 
(2H, br. s, NH2); δC (75 MHz; CDCl3) 142.4 (C-3), 136.2 (naphthalenyl C-4a), 133.4 
(naphthalenyl C-2), 132.1 (naphthalenyl C-8a), 127.9, 127.8, 127.7, 127.6 127.5, 125.9, 
125.3 (naphthalene 7 x CH), 113.6 (C-4), 55.3 (C-2), 44.5 (C-1); HRMS Found: 
198.1277 (C14H15N M+H requires 198.1275).  
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N-(1-(Naphthalen-2-yl)but-3-en-2-yl)acetamide, 121
157 
 
Triethylamine (0.8 ml, 6.2 mmol) and acetylchloride (0.5 mL, 7.3 mmol) were 
added at 0 
o
C to a solution of the amine 120 (0.70 g, 3.7 mmol) in CH2Cl2 and the 
resulting mixture was stirred at r.t. overnight. The mixture was filtered and concentrated 
under reduced pressure; the crude material was dissolved in the minimum amount of 
CH2Cl2, acetone was added until precipitation was completed and the precipitate was 
removed by filtration. The filtrate was concentrated under reduced pressure to give a 
crude product which was purified by flash chromatography (50:50, petrol–EtOAc) to 
yield the title acetamide 121 as yellow oil (0.48 g, 54%). RF: 0.2 (40:60, petrol–EtOAc); 
νmax/cm
-1
 (film) 3282, 3052, 1655, 1542, 1432, 1369, 1278, 990, 816; δH (500 MHz; 
CDCl3) 7.83-7.77 (3H, m, naphthalenyl 3-, 4- and 5- or 8-H), 7.62 (1H, s, naphthalenyl 
1-H), 7.49-7.42 (2H, m, naphthalenyl 6- and 7-H), 7.33 (1H, dd, J 8.3 and 1.0, 
naphthalenyl 5- or 8-H), 5.86 (1H, ddd, J 16.2, 10.2 and 5.4, 3-H), 5.38 (1H, d, J 6.8, 
NH), 5.11 (1H, d, J 16.2, 4-HA), 5.10 (1H, d, J 10.2, 4-HB), 4.89 (1H, app. dq, J 6.8 and 
5.4, 2-H), 3.04 (1H, d, J 6.8, 1-HA), 3.03 (1H, d, J 6.1, 1-HB), 1.95 (3H, s, CH3); δC (75 
MHz; CDCl3) 169.3 (CO), 137.5 (C-3), 134.7 (naphthalenyl C-4a), 133.4 (naphthalenyl 
C-2), 132.3 (naphthalenyl C-8a), 128.8, 128.0, 127.8, 127.6, 127.5, 126.1, 125.6 
(naphthalene 7 x CH), 115.3 (C-4), 52.0 (C-2), 41.1 (C-1), 23.4 (CH3); m/z (ES) 262.1 
(100%, [M+Na]
+
); HRMS Found: 262.1205 (C16H17NO M+Na requires 262.1202).  
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N-Ethyl-1-(naphthalen-2-yl)but-3-en-2-amine, 122
157
 
 
LiAlH4 (0.45 g, 12.0 mmol) was added at 0 
o
C to a solution of the amide 121 (0.48 
g, 2.0 mmol) in THF, and the resulting mixture was allowed to warm to r.t. and stirred 
for 5 h, then at reflux overnight. An aqueous solution of NaOH (15% w/v) was added at 
0 
o
C dropwise, then the mixture was filtered through Celite
®
, washed with THF and the 
filtrate concentrated under reduced pressure to give the title amine 122 as a yellow oil 
(0.4 g, 88%). RF: 0.2 (92:8, CH2Cl2–MeOH); νmax/cm
-1
 (film) 3059, 2968, 1685, 1494, 
1284, 1119, 747; δH (500 MHz; CDCl3) 7.85-7.74 (3H, m, naphthalenyl 3-, 4-, and 5- or 
8-H), 7.65 (1H, s, naphthalenyl 1-H), 7.49-7.41 (2H, m, naphthalenyl 6- and 7-H), 7.34 
(1H, dd, J 8.4 and 1.5, naphthalenyl 5- or 8-H), 5.75 (1H, ddd, J 16.8, 10.5 and 8.1, 3-
H), 5.09 (1H, d, J 16.8, 4-HA), 5.08 (1H, d, J 10.5, 4-HB), 3.44 (1H, app. q, J 7.4, 2-H), 
3.02 (1H, dd, J 13.4 and 7.3, 1-HA), 2.97 (1H, dd, J 13.4 and 6.6, 1-HB), 2.73 (1H, dq, J 
11.8 and 7.1, ethyl 1-HA), 2.52 (1H, dq, J 11.8 and 7.1, ethyl 1-HB), 1.06 (3H, t, J 7.1, 
ethyl 2-H3), NH not observed; δC (75 MHz; CDCl3) 140.0 (C-3), 135.8 (naphthalenyl C-
4a), 133.5 (naphthalenyl C-2), 132.3 (naphthalenyl C-8a), 128.0, 127.9, 127.7, 127.6, 
127.5, 126.0, 125.4, (naphthalene 7 x CH), 116.8 (C-4), 62.9 (C-2), 42.3 (C-1), 41.6 
(ethyl C-1), 14.8 (ethyl C-2); m/z (ES) 226.1 (100%, [M+H]
+
). HRMS Found: 226.1598 
(C16H19N M+H requires 262.1590).  
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1-Ethyl-1-(1-(naphthalen-2-yl)but-3-en-2-yl)-3-phenylurea, 123
100
 
 
The title compound 123 was prepared from the amine 122 (0.14 g, 0.6 mmol) and 
phenylisocyanate (0.15 mL, 1.3 mmol) in CH2Cl2 stirring at 35 °C for 3 hours, 
according to general procedure B.
100
 The crude product was purified by flash 
chromatography (70:30, petrol–EtOAc) to give a yellow oil (80 mg, 47%). RF: 0.7 
(40:60, petrol–EtOAc); νmax/cm
-1
 (film) 2933, 2870, 1686, 1586, 1494, 1428, 1255, 
1016, 696; δH (500 MHz; CDCl3) 7.85-7.76 (3H, m, naphthalenyl 3-, 4- and 5- or 8-H), 
7.68 (1H, s, naphthalenyl 1-H), 7.49-7.41 (2H, m, naphthalenyl 6- and 7-H), 7.39 (1H, 
dd, J 8.4 and 1.5, naphthalenyl 5- or 8-H), 7.23 (2H, d, J 7.2, phenyl 2- and 6-H), 7.21 
(2H, d, J 7.2, phenyl 3- and 5-H), 7.00 (1H, dd, J 7.2 and 1.8, phenyl 4-H), 6.20 (1H, s, 
NH), 6.08 (1H, ddd, J 17.4, 10.5 and 5.2, 3-H), 5.31 (1H, d, J 17.4, 4-HA), 5.29 (1H, d, 
J 10.5, 4-HB), 4.79 (1H, app. q, J 6.8, 2-H), 3.35 (1H, dq, J 14.3 and 7.1, ethyl 1-HA), 
3.29 (1H, dd, J 13.6 and 7.0, 1-HA), 3.19 (1H, dd, J 13.6 and 6.9, 1-HB), 3.09 (1H, dq, J 
14.3 and 7.1, ethyl 1-HB), 1.13 (3H, t, J 7.1, ethyl 2-H3); δC (75 MHz; CDCl3) 155.0 
(CO), 139.1 (phenyl C-1), 137.6 (C-3), 135.8 (naphthalenyl C-4a), 133.6 (naphthalenyl 
C-2), 132.3 (naphthalenyl C-8a), 128.8 (phenyl C-2 and C-6), 128.2, 127.8, 127.7, 
127.6, 126.5, 126.1, 125.5 (naphthalene 7 x CH), 122.9 (phenyl C-4), 119.8 (phenyl C-3 
and C-5), 117.0 (C-4), 60.5 (C-2), 40.5 (ethyl C-1), 38.5 (C-1), 15.0 (ethyl C-2); m/z 
(ES) 711.4 (100%, [2M+Na]
+
); HRMS Found: 367.1793 (C23H24N2O M+Na requires 
367.1780).  
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 (4S*, 5S*)-4-(aminomethyl)-1-ethyl-5-(naphthalen-2-ylmethyl)-3-phenyl 
imidazolidin-2-one, compound 115
124,137, 138
 
 
The azide 125 was prepared from the allyl urea 123 (1.0 mmol), according to 
general procedure F.
124,137
 After elution through a silica plug (40:60, petrol–EtOAc) 
and evaporation under reduced pressure, the azide 125 was mixed triphenylphosphine 
(30 mg, 0.13 mmol) and stirred for 3 days according to general procedure G.
138
 The 
crude product was purified by flash chromatography (50:50 → 100:0, petrol–EtOAc) to 
give the title amine 115, as a yellow oil (22 mg, 25% over three steps). RF: 0.1 (96:4, 
CH2Cl2–MeOH); νmax/cm
-1
 (film) 3053, 2929, 1666, 1590, 1243, 1020, 754; δH (500 
MHz; CDCl3) 7.85-7.76 (3H, m, naphthalenyl 3-, 4-, and 5- or 8-H), 7.65 (1H, s, 
naphthalenyl 1-H), 7.52-7.44 (2H, m, naphthalenyl 6- and 7-H), 7.31 (1H, dd, J 8.4 and 
1.2, naphthalenyl 5- or 8-H), 7.22-7.19 (2H, m, phenyl 2- and 6-H), 7.03-7.01 (2H, m, 
phenyl 3- and 5-H), 6.94-6.91 (1H m, phenyl 4-H), 4.22 (1H, app. dt, J 6.3 and 4.7, 4-
H), 3.86 (1H, app. dt, J 9.1 and 4.7, 5-H), 3.79 (1H, dq, J 14.5 and 7.2, ethyl 1-HA), 3.33 
(1H, dd, J 13.6 and 4.4, 5-CHAHB), 3.28 (1H, dq, J 14.5 and 7.2, ethyl 1-HB), 2.87 (1H, 
dd, J 13.6 and 9.1, 5-CHAHB), 2.54 (1H, dd, J 13.6 and 4.2, 4-CHAHB), 2.47 (1H, dd, J 
13.6 and 6.3, 4-CHAHB), 1.28 (3H, t, J 7.1, ethyl 2-H3); δC (75 MHz; CDCl3) 151.9 
(CO), 147.9 (phenyl C-1), 133.6 (naphthalenyl C-4a), 133.5 (naphthalenyl C-2), 132.4 
(naphthalenyl C-8a), 128.7 (naphthalene CH), 128.5 (phenyl C-2 and C-6), 128.0, 
127.7, 127.5, 127.1, 126.4, 125.9 (naphthalene 6 x CH), 123.5 (phenyl C-3 and C-5), 
121.7 (phenyl C-4), 82.0 (C-5), 58.9 (C-4), 44.8 (5-CH2), 39.0 (4-CH2), 37.6 (ethyl C-
1), 12.3 (ethyl C-2); m/z (ES) 360.2 (100%, [M+H]
+
); HRMS Found: 360.2082 
(C23H25N3O M+H requires 360.2070).  
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5.4 General procedure for biological fluorimetric assay 
Invidual compounds were assayed using a BACE fluorimetric assay,
158
 performed 
in 96 well plates. The following materials were employed. Quenched fluorescent 
peptide substrate: Swedish mutant APP sequence (SEVNLDAEFK) tagged with FAM 
and TAMRA (FAM-SEVNLDAEFK-TAMRA). Enzymes: recombinant BACE-1 (R&D 
System),
159
 or recombinant BACE-2 (R&D System).
159
 Inhibitor: secretase Inhibitor 
IV (Merck Chemicals).
160
 
The assay protocol was adapted from Hussain et al.
158
 Recombinant BACE-1 (26.0 
nM) or recombinant BACE-2 (3.0 nM) were diluted in enzyme buffer [100.0 mM 
sodium acetate, pH 4.5, 40.0 mM sodium chloride, 10% (v/v) glycerol, 0.2% (w/v) 
CHAPS]. The enzyme was incubated in the presence or absence of -secretase Inhibitor 
IV (for positive control, at 0.01 mM for assaying BACE-1 and at 0.1 mM for assay 
BACE-2), DMSO (for negative control, 5% or 10%) or compounds (for assay 
compound activity) with shaking for 10 min at 25 
o
C. For detection of enzyme activity, 
the quenched fluorescent peptide substrate (5.0 M) was diluted in substrate buffer 
[100.0 mM sodium acetate, pH 4.5, 0.06% Triton x-100]. Enzyme buffer and substrate 
buffer were used at 1:1 ratio in each well to a total volume of 100 L. The fluorescence 
was measured using a Synergy HT Bio-Tek fluorimeter using KC4 software, with 
excitation and emission wavelengths set to 485 nm and 585 nm, respectively. Kinetic 
measurements over 20 minutes at 2 minutes intervals were performed, 2 duplicate 
readings were obtained and the results of each measurement were averaged during data 
processing. Each assay was performed at least three times. A representative 96-well 
plate layout is shown below (Figure 65).   
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Figure 65. 96 well plate layout of assessing BACE-1 and BACE-2 inhibition. 
The compounds were configured as follow for the assay: for single concentration 
tests, a solution of 100 M of compound in enzyme buffer containing 5% or 10% 
DMSO (depending on compound solubility) was used, for dose response of selected 
compounds, an initial compound solution of 2000 M or 1000 M solution in DMSO 
(depending on compound solubility) was used and then serial diluted in DMSO in 5-9 
steps, as low as 2.0 M.  
The data were processed as follows: the average value of fluorescence unit (FU) of 
wells A1 and A2 was deducted from the average value of fluorescent unit obtained from 
each measurement corresponding to either the individual compound, the negative or the 
positive control. The overall kinetic measurements for each well were plotted in a graph 
FU vs time. A linear fit was applied to the measurement points and slops corresponding 
to individual compounds, negative or positive control were derived. The compound 
inhibition % was calculated as: 
                                       
                                               
       
The results were reported as mean ± SEM. Dose response data, expressed as 
percentage inhibition vs log[M], were fitted with a sigmoidal dose response model by 
using Origin Pro 8.6.  
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5.4.1 Protocol to assess the optimal concentration of BACE-2 to use in a 
fluorimetric assay 
In order to optimise the recombinant BACE-2 for the assay, four different 
concentrations were assayed. The assay was performed according to the protocol 
described in Section 1.4, with the following exceptions. Recombinant BACE-2 was 
used in 30.0 nM, 17.2 nM, 8.6 nM and 3.0 nM diluted in an enzyme buffer, and the 
samples were incubated in the absence or in the presence of -secretase Inhibitor IV (at 
0.01 mM for BACE-1 and at 0.1 mM for BACE-2). A layout of the 96 well plate 
prepared is shown below (Figure 66). 
 
Figure 66. 96 well plate prepared to assess the optimal concentration of BACE-2.  
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Appendix 1.Virtual library generation supplementary information 
1.1 Virtual reactants employed in the virtual synthesis protocol to 
enumerate virtual library A (Section 2.3) 
1.1.1 Nucleophile building blocks 
Amine (trimethyl silyl and tert-Butoxycarbonyl are virtual protecting groups) 
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Sulfonamides (methylsulfonyl is a virtual protecting group) 
 
 
Amino acids derivatives (trimethyl silyl and methylsulfonyl are virtual protecting 
groups) 
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1.1.2 Electrophile building blocks 
Allyl carbonates (tert-Butoxylcarbonyl is a virtual protecting group) 
 
 
Cyclic sulfamidates (tert-Butoxylcarbonyl is a virtual protecting group) 
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1.1.3 Derivatisation reagents  
Acyl chlorides 
 
 
Aryl bromides 
 
 
Isocyanates and aryl aldehyde 
 
 
Sulfonyl chlorides 
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1.2 Virtual reactants employed in the virtual synthesis protocol to 
enumerate virtual library B (Section 2.3.2) 
Aryl bromides 
 
 
Isocyanates  
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Secondary amines  
 
Other derivatisation reagents employed were the acyl chlorides, aryl aldehyde and 
sulfonyl chlorides included in Appendix 1.1.3. 
1.3 Virtual reactions employed in the virtual synthesis protocol for the 
enumeration of libraries A and B (Section 2.3 and 2.3.2) 
Table 19. Virtual coupling reactions between initial nucleophiles and electrophiles 
  
Entry Virtual reaction Scheme 
1 
Iridium-catalysed 
asymmetric allylic 
amination
98
 with primary 
or secondary amines
 
 
2 
Amide formation from 
primary or secondary 
amines
161 
 
3 
Nucleophilic opening of 
cyclic sulfamidates
97
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Table 20.Virtual cyclisation reactions.  
  
Entry Virtual reaction Scheme 
1 
Formation of cyclic 
urea     
(5-
162,163
 , 6-
162, 164
,  7-
4  
membered  ring)
 
 
2 
Formation of keto-
piperidine
165
 
(6- and 7- membered 
ring) 
 
3 
Formation of cyclic 
secondary amine
166
 
(5-, 6- and 7- 
membered ring) 
 
4 
Ring-closing 
metathesis
99
              
(5- and 6- membered 
ring)
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Table 21.Virtual Pd-catalysed cyclisation reactions.  
  
Entry Virtual reaction Scheme 
1 
Pd-catalysed urea 
intramolecular amino 
arylation
100
     
 
2 
Pd-catalysed 
intramolecular 
oxyarylation
167
 
 
3 
Pd-catalysed 
intramolecular 
aminoarylation
168
 
from primary or 
secondary amines         
(5- and 6- membered 
ring) 
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Table 22. Derivatisation reactions.  
 
 
 
 
 
 
Entry Virtual reaction Scheme 
1 
Acylation of primary 
or secondary 
amines
161, 157
 
 
2 
Reductive amination 
of primary or 
secondary amines
136
 
 
3 
Arylation of primary 
or secondary 
amines
169, 170
 
 
4 
Urea formation from 
secondary amines and 
isocyanates
100
 or N-
acyl chlorides
171
 
 
5 
Thiourea formation 
from secondary 
amines
172
 
 
6 
Sulfonamide 
formation from 
secondary amines
173
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Table 23. Protecting group removal reactions  
 
 
 
 
 
 
Entry Virtual reaction Scheme 
1 
Removal of Boc 
group
174, 175
  
 
2 
Removal of Dmob 
group
176
 
 
3 
Removal of 
sulfonamide
177
  
 
4 
Removal of TMS 
group
178, 179, 180
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Appendix 2.Virtual screening supplementary information 
2.1 Predicted binding pose of representative ligands in the BACE-1 
catalytic site, free from water molecules (Section 2.4) 
Predicted binding poses of representative putative inhibitors of the imidazolidinone 
and amino tetrahydropyridine families are illustrated herein (Figure 67). The predicted 
binding poses were obtained by docking library B against the BACE-1 structure which 
did not contain water molecules in the catalytic site. The ligands chosen in the following 
illustrations are the same as the one represented in Figures 40, Section 2.4. The binding 
poses show that H-bond interactions were predicted to be formed with the catalytic 
aspartate residues, Asp32 and Asp228, even without the intermediary involvement of 
water molecules. The primary amine of the ligands was predicted to be protonated in the 
catalytic site of BACE-1 (pH 4.5).  
194 
 
 
 
 
Figure 67. Predicted binding pose of representative members of the identified 
families of BACE-1 putative inhibitors. A) and C) 2D structure of the 
imidazolidinone putative inhibitor 31 (A) and of the amino tetrahydropiridine putative 
inhibitor 32 (C) in their protonated state. B) and D) 3D image of the predicted binding 
pose of the putative inhibitors 31 (B) and 32 (D) in the catalytic site of BACE-1. The 
predicted H-bond interactions are shown with green dotted lines. Asp32 and Asp228 
form H-bonds with the protonated primary amine, NH3
+
, of the putative inhibitor 31 
(B). Asp32 and Asp228 form H-bonds with the protonated primary amine, NH3
+
, of the 
putative inhibitor 32 (D), while Lys107, located in the flap region (Section 1.3.2), forms 
H-bond with the other protonated primary amine, NH3
+
, of the putative inhibitor.  
eHiTS score = 7.04 
cLE′ = 0.28 
 
A B 
eHiTS score = 8.10 
cLE′ = 0.37 
 
C D 
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2.2 H-bond length evaluation (Section 2.4.1) 
The length of the predicted H-bonds formed between the identified putative 
inhibitors and the BACE-1 catalytic site were measured and compared to the ones 
reported in X-ray crystal structures of BACE-1 complexes available in the literature. 
The lenght range was of 2.4-2.9 Å
 
for H-bonds formed with Asp32 and Asp228, and 
2.2-2.5 Å for the H-bonds formed with Wat1 and the other water molecules located in 
the catalytic site. These values were in agreement with the length range reported in the 
literature.
 82, 86
 Examples are illustrated in Figure 68and Figure 69. 
 
 
Figure 68. Length of H-bonds formed amongst putative inhibitors and aminoacidic 
residues in the catalytic site of BACE-1. Two-dimensional representation of the 
predicted H-bonds formed by the imidazolidinone putative inhibitors 31 (A) and the 
amino tetrahydropyridine putative inhibitors 32 (B). The H-bond lengths of the 
predicted H-bonds of the putative inhibitors is in the range of 2.4-2.8 Å. 
 
 
 
 
Predicted binding poses BACE-1 putative inhibitors 
inhibitors 
imidazolidinone putative inhibitor  amino tetrahydropyridine putative inhibitor  
A B 
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Figure 69. Length of H-bonds formed amongst known inhibitors and aminoacidic 
residues in the catalytic site of BACE-1. Two-dimensional representation of the 
predicted H-bonds formed by the known inhibitors 23
28
 (C) and 27
86
 (D) (Section 1.44 
and 1.4.5). The H-bond lengths in the known X-ray crystal structures are in the range of 
2.5-3.1 Å; of 2.4-2.8 Å. 
X-ray crystal structures of known BACE-1 
inhibitors  D C 
spirocyclic sulfamide known inhibitor  aminohydantoin known inhibitor 
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Appendix 3. Stereochemical assignment of the synthesised 
imidazolidinones (Section 3.2.2.1 and 3.3.2.3) 
Table 24. Summary of the J values of the signals of the diagnostic protons of the 
urea ring system in the synthesised imidazolidinones. 
 
 
Entry Compound
a
 
J (4-H/5-H) 
Relative 
Configuration 
syn anti 
1
b 
 
8.9 6.0 - 
2
b
 
      
ca. 9.0 5.1 - 
3 
      
7.7 4.0 - 
4 
       
8.5 6.3  
5 
       
9.2 4.6 - 
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Entry Compound
a
 
J (4-H/5-H) 
Relative 
Configuration 
syn anti 
6 
 
8.9 4.7 - 
7 
 
9.2 5.2 - 
8 
       
9.1 4.6 - 
9 
    
- 3.0 trans 
10 
     
- 3.0 trans 
11 
    
- 4.5 trans 
12 
     
- ca. 4.7 trans 
13 
       
- ca. 5.2 trans 
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Entry Compound
a
 
J (4-H/5-H) 
Relative 
Configuration 
syn anti 
14 
 
- 4.3 trans 
15 
 
- ca. 3.8 trans 
16 
 
- 4.1 trans 
17 
 
- ca. 3.7 trans 
18 
 
- 4.4 trans 
19 
 
- ca. 5.0 trans 
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Entry Compound
a
 
J (4-H/5-H) 
Relative 
Configuration 
syn anti 
20 
      
- ca. 4.6 trans 
21 
         
- ca. 4.7 trans 
22 
      
- ca. 5.1 trans 
23 
       
- 3.2 trans 
24 
        
- 4.7 trans 
25 
         
- 3.0 trans 
a
The synthesised compounds were racemic, therefore the relative configuration is shown; 
b
The 
relative syn and  anti relationship was confirmed by NOE experiment. 
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Appendix 4. Biological data supplementary information 
4.1 Dose responses curves of active imidazolidinones (Section 4.2) 
 
 
Figure 70. Dose response curves of the imidazolidinone 106 and 103. Compounds 
106 and 103 were introduced in Section 4.2, Table 15, entry 2 and 9.   
IC50 = 720 ± 20 M 
IC50 = 590 ± 20 M 
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Figure 71. Dose response curves of the imidazolidinone 115. Compound 115 was 
introduced in Section 4.3.3, Table 17, entry 4. 
4.2 Assessing the optimal concentration of BACE-2 for biological 
fluorimetric assay 
In order to assay selected compounds against BACE-2 (Section 4.4.1), a homolog 
of BACE-1, the optimal concentration of BACE-2 to use in the fluorimetric assay was 
evaluated. The fluorescence resulting from BACE-2 cleavage of the peptide substrate 
was compared to that emitted by BACE-1 (26.0 nM). The signal was recorded over 20 
minutes, at intervals of 2 minutes; the results are shown below (Figure 72).  
IC50 = 724 ± 12 M 
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Figure 72. Fluorescence signal emitted by the fluorescent quenched peptide 
substrate, cleaved by BACE-2 enzyme. The most similar fluorescence emission trend, 
in comparison to BACE-1 at 26.0 nM (green line), was obtained using 3.0 nM of 
BACE-2 (pink line). 
As shown in the graph, the relative fluorescence emission using ca. 10 times less 
BACE-2, 3.0 mM, (pink line) was similar to that seen with BACE-n (green 
line). A higher quantity of BACE-2 (8.6, 17.2 and 30.0 nM) gave a much higher value 
of fluorescent emission. Inhibition of BACE-2 by -secretase inhibitor IV was also 
assessed. -secretase inhibitor IV was used at 0.01 nM to assay BACE-1 and at 0.1 mM 
to assay BACE-2
a. 
The signal was recorder over 20 minutes, at intervals of 2 minutes; 
the results are shown below (Figure 73). 
                                                 
a 
 Details of assay preparation are described in Section 5.4.1 
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Figure 73. Inhibition of BACE-2 by secretase inhibitor IV. Yellow and purple 
lines show inhibition of BACE-1 (yellow line) and BACE-2 (purple line) by -secretase 
inhibitor IV, compared to non–inhibited BACE-1 (green line) and BACE-2 (pink line) 
activity. 
The reduced fluorescence signals obtained when BACE-1 or BACE-2 cleaves the 
substrate, in the presence of the -secretase inhibitor IV, showed a similar linear trend 
(yellow and purple line). For BACE-2 assays a concentration of 3.0 nM was used to 
assay selected compounds (Section 4.4 and 5.4). 
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